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Abstract 
This thesis focuses on sporadic parkinsonian syndromes that are associated with 
neurofibrillary degeneration and the accumulation of abnormal tau protein in the brain.  
The classic clinical presentation of corticobasal degeneration is a specific constellation 
of cortical and extrapyramidal signs, collectively termed corticobasal syndrome. The 
evaluation of all the archival cases with corticobasal degeneration in the Queen Square 
Brain Bank for Neurological Disorders reveals the high frequency of other phenotypic 
presentations. The result indicates that corticobasal degeneration commonly presents 
with a clinical picture, closely resembling progressive supranuclear palsy (PSP) or 
Richardson’s syndrome. On the other hand, cases with typical PSP pathology may 
occasionally present with a corticobasal syndrome. A quantitative assessment of the 
severity of tau pathology in different brain regions of the two phenotypic presentations 
of PSP reveals topographical differences that are closely linked with their respective 
clinical features.  
The features of repetitive finger tapping and handwriting in patients with PSP and 
Parkinson’s disease are compared and a distinct abnormality is identified in PSP which 
may be useful in differentiating PSP-parkinsonism from Parkinson’s disease. 
Twelve cases clinically presenting with a levodopa-responsive parkinsonian syndrome 
and post-mortem findings of nigral degeneration and predominant tau inclusions, 
which could not be readily classified into any recognised clinicopathological entity are 
also studied. 
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Chapter 1:  Introduction to tau 
pathology and neurodegeneration 
Tau aggregation, phosphorylation and 
propagation 
Neurofibrillary tangles (NFTs) formed within the neurons are made up of filamentous 
materials, of which the major structural component is hyperphosphorylated tau 
(Goedert et al., 1992). Ultrastructurally, they contain either paired helical (Kidd, 1963) 
or straight filaments (Goedert et al., 2001). 
Tau is the most abundant microtubule-associated protein (MAP) in the brain. 
Microtubules in neurons are important for intracellular transport. Tau promotes tubule 
formation through assembly of the tubulin subunits and, once formed, it stabilizes the 
microtubules. In adult human brain, there are six tau isoforms, differing from one 
another by the presence or absence of 29 or 58 amino acid inserts located in the amino-
terminal half and an additional 31-amino acid repeat in the carboxy-terminal half 
(Figure 1). Inclusion of the latter, which is encoded by exon 10, the spliced products 
give rise to three tau isoforms with four repeats (4R) each, while the remaining three 
isoforms have three repeats (3R) each. 3R and 4R-tau isoforms are expressed in 
roughly equal amounts in the normal adult human brain, but this ratio may be altered 
in some neurodegenerative diseases.  
As a result of abnormal hyperphosphorylation, tau is unable to bind to microtubules in 
axons (Bramblett et al., 1993) and, instead, is redistributed to the cell body, where it 
accumulates to form insoluble filamentous inclusions and leads to neurodegenerative 
disease. Filamentous tau tends to aggregate in a stereotypic manner as the disease 
progresses. It is proposed that once tau aggregates are formed in discrete brain regions, 
intercellular transfer of aggregated tau occurs and, via the mechanism of ‘permissive 
templating’ (Hardy, 2005), triggers a self-propagating process and prion-like spread of 
the abnormal tau throughout the central nervous system (Clavaguera et al., 2009). 
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Figure 1. Human MAPT gene and the six tau isoforms expressed in the brain. 
The six tau isoforms are expressed in the adult human brain by alternative pre-mRNA 
splicing of exons 2 (red), 3 (green) and 10 (yellow) of the MAPT gene located on 
chromosome 17. They differ from each other by the presence or absence of 29 or 58 
amino acid inserts (red & green) located in the amino-terminal half and an additional 
31-amino acid repeat (yellow) in the carboxy-terminal half. Inclusion of the latter 
produces the three isoforms with four repeats each, whereas the other three isoforms 
have three repeats each. 
MAPT consists of 16 exons; exon 0 is part of the promoter, exon 14 is non-coding, 
exon 6 and 8 are not transcribed in human brain and exon 4a is only expressed in the 
peripheral nervous system. Blue bars indicate the microtubule-binding repeats of tau. 
The diagram is kindly provided by Dr Rohan de Silva. 
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Tauopathies and isoform compositions 
Diseases associated with insoluble tau aggregates in the brain are known as 
tauopathies, which comprise of more than 20 different conditions (Table 1)(Spillantini 
et al., 2013). Tau is one of the two most common misfolded proteins that form 
intracellular inclusions in human neurodegenerative diseases, with the other being α-
synuclein, the main component of Lewy bodies in Parkinson’s disease. Most 
tauopathies either cause dementia or parkinsonism, and in some conditions, a 
combination of both. Tauopathies are commonly categorized by their predominant tau 
isoforms. Tau pathologies in PSP and CBD contain predominantly 4R-tau and are 
referred as 4R tauopathies, whereas Pick’s disease contains predominant 3R-tau and is 
known as a 3R tauopathy. In conditions such as PSP, CBD, Pick’s disease and 
frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), tau 
inclusions are the predominantly pathology. Unlike, PSP and CBD, which are primary 
tauopathies, Alzheimer’s disease is a tauopathy that is characterised by another 
predominant type of pathology, namely amyloid-β plaques.    
Differences in tau isoform composition in these conditions are reflected by the 
different electrophoretic migration patterns on tau immunoblotting. Western blots of 
filamentous tau extracted from PSP and CBD brains shows a doublet pattern with 
64kDa and 68kDa band, whereas filamentous tau from Pick’s disease demonstrates a 
major 60 and 64kDa bands. Alzheimer’s disease, postencephalitic parkinsonism, 
parkinsonism-dementia complex of Guam (PDC) and chronic traumatic 
encephalopathy (CTE) are characterised by a major triplet with 60, 64 and 68kDa 
bands (Buee-Scherrer et al., 1997).   
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 Parkinsonism Predominant 
tau isoforms 
Predominant tau pathology 
Progressive supranuclear palsy 
Corticobasal degeneration 
Argyrophilic grain disease 
Pick’s disease 
FTDP-17 
Postencephalitic parkinsonism 
Parkinsonism dementia complex of Guam  
Guadeloupean parkinsonism 
Tangle-only dementia 
Globubar glial tauopathy 
 
+ 
+ 
- 
+/- 
+ 
+ 
+ 
+ 
- 
+ 
 
4R 
4R 
4R 
3R 
variable 
mixed 3R & 4R 
mixed 3R & 4R 
4R 
mixed 3R & 4R 
4R 
Associated with other pathologies 
Alzheimer’s disease 
Down’s syndrome 
Chronic traumatic encephalopathy 
Familial British dementia 
Familial Danish dementia 
PKAN 
Myotonic dystrophy 
Niemann Pick type C 
Subacute sclerosing panencephalitis 
 
+/- 
- 
+ 
- 
- 
+ 
- 
+ 
+ 
 
mixed 3R & 4R 
mixed 3R & 4R 
mixed 3R & 4R 
mixed 3R & 4R 
mixed 3R & 4R 
nk 
3R 
nk 
nk 
Table 1. Common tauopathies with or without parkinsonism 
+: yes, +/-: rare, -: no; 3R=3-repeat tau; 4R=4-repeat tau; FTDP-17=frontotemporal 
dementia with parkinsonism linked to chromosome 17; nk=not known; 
PKAN=pantothenate kinase-associated neurodegeneration, 
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Progressive supranuclear palsy 
In 1963, a distinct syndrome of postural instability, supranuclear gaze palsy, mild 
dementia, progressive axial rigidity and bulbar palsy was described in nine patients 
(Richardson et al., 1963). The consistent pathological findings in these cases led to the 
identification of progressive supranuclear palsy (PSP) as a distinct clinicopathological 
entity (Steele et al., 1964). The neuropathological diagnosis of PSP is defined by the 
accumulation of NFTs and neuropil threads (NTs) mainly in the globus pallidus, 
subthalamic nucleus and substantia nigra (Dickson et al., 2011, Hauw et al., 1994, Ince 
et al., 2008)(Figure 2). Other affected regions are the red nucleus, striatum, oculomotor 
nucleus, locus coeruleus, pontine tegmentum, medulla and dentate nucleus. Globose 
NFT is a typical but non-specific feature observed in the brainstem nuclei and nucleus 
basalis of Meynert, while in other regions, the NFTs are more frequently flame-shaped. 
Diffuse or granular neuronal tau cytoplasmic immunoreactive lesions, labelled 
pretangles (PreTs) are frequently encountered. Tufted astrocytes, a characteristic 
feature in PSP, are star-like tufts of tau-immunoreactive filaments located mostly in 
proximal astrocytic processes. They are frequently found in the motor cortex and 
striatum. Oligodendroglial lesions, called coiled bodies (CBs), are observed in the 
white matter. Neuronal loss in PSP is most severe in the substantia nigra and 
subthalamic nucleus, and less consistently, in the globus pallidus. 
The original description of the clinical picture of PSP is now referred as the classic 
presentation of PSP or Richardson’s syndrome (RS), which is seen in at least half of all 
pathologically confirmed cases, with a mean disease duration of five to eight years 
(Williams et al., 2009). In 2005, a variant of PSP known as PSP-parkinsonism (PSP-
P), with a longer disease duration and predominant parkinsonism in the early stage, 
was characterised and is observed in up to a third of all PSP cases (Williams et al., 
2005). PSP-P is frequently misdiagnosed as Parkinson’s disease in the early stage due 
to the presence of asymmetrical limb bradykinesia, rigidity and, in some cases, tremor 
and transient response to levodopa (Williams et al., 2005, Williams et al., 2010). The 
pathologies of PSP-P are less severe and more restricted in distribution than in PSP-RS 
(Williams et al., 2007). Another group of patients present with early gait disturbance, 
micrographia and hypophonia, followed by gait freezing are collectively termed PSP-
pure akinesia with gait freezing (PSP-PAGF)(Williams et al., 2007). The disease 
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progression in PSP-PAGF can be insidious and may have a prolonged disease course 
of more than 10 years in some cases. Neuronal loss in PSP-PAGF is restricted to the 
globus pallidus, substantia nigra and subthalamic nucleus (Ahmed et al., 2008). PSP-P 
and PSP-PAGF subtypes are sometimes referred as the brainstem variants of PSP in 
view of the milder tau pathology and restriction of tau pathology in the basal ganglia 
and brainstem (Dickson et al., 2010).  
Another PSP subtype, with clinical presentation of progressive asymmetric limb 
dystonia, rigidity, ideomotor apraxia and cortical sensory loss, are collectively referred 
as PSP-corticobasal syndrome (PSP-CBS)(Tsuboi et al., 2005). The subgroups with 
predominant features of apraxia of speech or behavioural disturbance and 
frontotemporal dementia, are known as PSP-progressive non-fluent aphasia (PSP-
PNFA)(Josephs et al., 2006) and PSP-frontotemporal dementia behavioural variant 
(PSP-FTDbv)(Hassan et al., 2011), respectively. The subgroups of PSP-CBS, PSP-
PNFA and PSP-FTDbv have been shown to have more severe cortical tau pathology 
than PSP-P and PSP-PAGF and are labeled as the cortical variants of PSP (Dickson et 
al., 2010). The clinical features of all phenotypes are most distinct in the early disease 
stages, however, as the disease progresses, the symptoms evolve and after several 
years, most patients develop a clinical picture compatible with RS with supranuclear 
gaze palsy, especially on downward gaze, severe axial rigidity, postural instability, 
executive dysfunction and pseudobulbar palsy (Williams et al., 2009).  
Despite the heterogeneous phenotypic presentation, the classic RS and the variants are 
linked under the generic term of PSP by their rapid progressive course leading to death 
within a decade and post-mortem findings of NFT accumulation, predominantly in the 
globus pallidus, subthalamic nucleus and substantia nigra, atrophy of the subthalamic 
nucleus and presence of tufted astrocytes, fulfilling the established neuropathological 
diagnostic criteria of PSP (Dickson et al., 2011, Hauw et al., 1994, Ince et al., 2008). 
The regional differences in the severity of tau pathology are linked with the distinct 
clinical features in the subtypes (Dickson et al., 2010). 
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Figure 2. Tau-immunohistochemistry of PSP. 
A: Tau-positive neurofibrillary tangle and fine neuropil threads in the caudate; B: 
Tufted astrocytes and neuropil threads; C: Tau-positive tufted astrocyte containing 
4R-tau isoform; A & B: AT8 immunohistochemistry, C: 4R-tau immunohistochemistry 
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Corticobasal degeneration 
In 1967, Rebeiz and colleagues reported a clinicopathological entity termed 
‘corticodentatonigral degeneration with neuronal achromasia’ (Rebeiz et al., 1967, 
Rebeiz et al., 1968). Since the description, several other terms were used in the case 
reports of the same entity. In 1989, Gibb and colleagues coined the abbreviated term of 
corticobasal degeneration (CBD) and proposed it as a distinct clinicopathological 
entity that had pathological similarities to Pick’s disease (Gibb et al., 1989). Molecular 
studies subsequently established the distinction by demonstrating that PSP and CBD 
are 4R tauopathies while 3R-tau predominates in Pick’s disease (Arai et al., 2001).  
The classic clinical presentation of CBD is corticobasal syndrome (CBS) with 
progressive clumsiness and loss of function of one hand due to a combination of 
frontoparietal and basal ganglia sensorimotor dysfunction. The mean disease duration 
of CBD is seven years (Kouri et al., 2011). A similar constellation of signs has also 
been linked with cerebrovascular disease, Alzheimer’s disease, PSP and other rarer 
pathologies (Wadia et al., 2007). Conversely, the pathological diagnosis of CBD can 
give a clinical picture of RS, PNFA, apraxia of speech and progressive posterior 
cortical atrophy syndrome (Kouri et al., 2011).  
The neuropathological diagnosis of CBD is based on the findings of numerous NTs in 
the frontal and parietal cortices, their adjacent white matter, striatum and midbrain 
(Dickson et al., 2002)(Figure 3). Neuronal lesions in CBD are pleomorphic, including 
small sized NFTs or Pick body-like inclusions in superficial cortical neurons, PreTs, 
globose NFTs or corticobasal bodies. Astrocytic plaques, the pathological hallmark of 
CBD, are structures formed by annular clusters of short, stubby tau-positive structures 
located in the distal segments of astrocytic processes. They are numerous in the 
affected cortices, but are also found in the caudate nucleus, putamen and, sometimes, 
thalamus and midbrain tectum. It is of considerable diagnostic help that astrocytic 
plaques in CBD are morphologically distinct from tufted astrocytes in PSP. 
Morphological studies indicate that astrocytic plaques and tufted astrocytes do not 
coexist in the same brain (Komori et al., 1998). Oligodendroglial tau accumulation and 
ballooned neurons are also characteristic features of CBD.  
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Figure 3. Tau-immunohistochemistry of CBD. 
Tau-positive inclusions (A), pretangles (arrows) and threads (B), astrocytic plaque 
(arrow) in frontal cortex (C) and CBs (arrow) in the cortical white matter (D), are 
characteristic pathological lesions in CBD. 
  
26 
 
Tau genetics 
In 1998, the first mutations in the MAPT gene on chromosome17q21-22 were reported 
in families with an autosomal dominantly inherited form of frontotemporal dementia 
with parkinsonism, which is now known as FTDP-17T (Hutton et al., 1998, Poorkaj et 
al., 1998, Spillantini et al., 1998). The finding of this gene confirms the notion that 
dysfunction of tau protein is directly linked with the pathogenesis of disease and that 
the presence of tau aggregates in the brain is not merely an epiphenomenon. To date, 
over 50 pathogenic mutations of this gene have been identified, most of which are 
located in exons 9-12 and the adjacent introns. At a functional level, mutations reduce 
the ability of tau to interact with microtubules, leading to tau aggregation. Some 
mutations also promote the assembly of tau into filaments or enable the 
hyperphosphorylation of tau. Others alter the ratio of 3R and 4R-tau isoforms, 
resulting in the overproduction of 4R-tau, which is sufficient to cause disease 
(Spillantini et al., 2013). It is now known that mutations in the progranulin gene can 
cause a tau-negative type of FTDP-17 (Baker et al., 2006, Cruts et al., 2006). On the 
other hand, mutations in the MAPT gene can be associated with phenotypic 
presentations and pathologies identical to those of PSP, CBD, argyrophilic grain 
disease and Pick’s disease (Spillantini et al., 2013). Phenotypic heterogeneity is 
associated with different MAPT mutations. Interfamilial and intrafamilial variability 
may be observed for the same mutation. 
MAPT in populations of European descent is characterised by the H1 and H2 
haplotypes, resulting from a 900-kb inversion (H1) or non-inversion (H2) 
polymorphism (Stefansson et al., 2005). The H2 lineage is found in 20% of the 
Europeans, but is rare in Africans and almost absent in east Asians. 
The H1 haplotype is a risk factor of PSP, CBD and PDC, but it does not contribute to 
risk for Alzheimer’s disease. Notably, genome-wide association studies (GWAS) also 
confirm an association between H1 haplotype and Parkinson’s disease, a disease 
characterised by α-synuclein pathology rather than tau (Simon-Sanchez et al., 2009). A 
mechanism of cross-talk between molecular pathways of different aggregating proteins 
is thought to be implicated. Conversely, the H2 haplotype, is thought to be protective 
against PSP, CBD and Parkinson’s disease (Caffrey et al., 2008). H2 is associated with 
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increased expression of exon 3 of MAPT in grey matter (Trabzuni et al., 2012), which 
has an inhibitory role in tau aggregation, unlike exons 2 and 10 which promote 
aggregation (Zhong et al., 2012). 
A GWAS study also identified three novel signals associated with risk for PSP; 
EIF2AK3, a gene that encodes for PERK, which is a component of unfolded protein 
response, STX6, that encodes syntaxin 6, which is a protein in vesicle trafficking and, 
MOBP, which encodes myelin oligodendrocyte basic protein, a structural component 
of myelin in the central nervous system (Hoglinger et al., 2011). These loci provide 
insights into the additional pathways in the pathophysiology of PSP.  
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Chapter 2:  Does corticobasal 
degeneration exist? A 
clinicopathological re-evaluation 
Introduction 
The earliest description of CBS dates back to 1925 when Jean L’Hermitte and 
colleagues reported the case of a 72-year old carpenter presenting with a clumsy 
useless arm with rigidity, ideomotor apraxia, abnormal flexed posture, ‘jerky’ 
contractions, alien limb phenomenon and cortical parietal sensory dysfunction (Ballan 
et al., 1997, Lhermitte et al., 1925). There is also speculation that the French composer 
Maurice Ravel (1875-1937) who developed aphasia, apraxia and loss of musical 
creativity had a CBS (Alajouanine, 1948). 
In 1967, the first comprehensive clinicopathological description of CBD was published 
by Rebeiz and colleagues, who described three patients with progressive clumsy, slow 
and awkward movements of one limb for which no cause could be found (Rebeiz et 
al., 1967, Rebeiz et al., 1968). Other features such as alien hand, jerky tremor, 
dystonia, parkinsonism, pyramidal features and gait difficulty were also noted. 
Cortico-dentato-nigral degeneration with neuronal achromasia and swollen cortical 
cells identical to those found in Pick’s disease led to the proposal that this was a 
hitherto unreported distinctive nosological clinicopathological entity (Rebeiz et al., 
1967, Rebeiz et al., 1968). In the 1980’s, several further small series of similar cases 
were described but the disorder received little interest and was considered to be a rare 
neurological curiosity (1985, Watts et al., 1985). In 1989, Gibb and colleagues coined 
the abbreviated term corticobasal degeneration. They highlighted the pathological 
similarities to Pick’s disease but concluded that the clinical picture and distribution of 
neuronal loss and neurofibrillary degeneration supported the view that this was a 
distinct disease (Gibb et al., 1989). Molecular pathological studies have further 
supported this distinction by demonstrating that CBD, in common with PSP is a 
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predominantly 4R isoform tauopathy; whereas 3R tau accumulation predominates in 
Pick’s disease (Arai et al., 2001). 
The classic description of CBD includes clumsiness and loss of function of one hand 
due to a combination of fronto-parietal and basal ganglia sensorimotor dysfunction.  
Ideomotor and limb-kinetic apraxia, cortical sensory loss leading to an alien limb, limb 
dystonia, focal action or stimulus-sensitive myoclonus and levodopa-unresponsive 
rigidity and bradykinesia may all be found on examination and contribute to the 
asymmetric limb dysfunction. A similar constellation of signs has been linked with 
cerebrovascular disease (Kreisler et al., 2007), Alzheimer’s disease (Imamura et al., 
2009), PSP (Tsuboi et al., 2005), Pick’s disease (Boeve et al., 1999), dementia with 
Lewy bodies (Horoupian et al., 1999), Creutzfeldt-Jakob disease (Vandenberghe et al., 
2007), neurofilament inclusion body disease (now known as FTLD-FUS)(Josephs et 
al., 2003) and argyrophilic grain disease (Rippon et al., 2005). Genes associated with 
frontotemporal dementia (FTD) including MAPT, progranulin and C9orf72 are other 
rare causes (Casseron et al., 2005, Lesage et al., 2013, Masellis et al., 2006, Snowden 
et al., 2012, Tartaglia et al., 2009). The term CBS has been used to embrace this 
distinctive collection of symptoms and signs.  
Conversely, pathologically diagnosed CBD can masquerade as PSP (Boeve, 2005), 
FTD (Josephs et al., 2006), PNFA and apraxia of speech (Josephs et al., 2006, 
McMonagle et al., 2006) and progressive posterior cortical atrophy syndrome (Renner 
et al., 2004, Tang-Wai et al., 2004). Cases carrying mutations in the MAPT (FTDP-
17T) may have a similar pathological signature as CBD and it may be reasonable to 
look on these cases as examples of monogenetic CBD. Marked early cognitive 
dysfunction which was once considered an exclusion criteria for the diagnosis of CBD, 
is now accepted as a clinical variant (Grimes et al., 1999). Kertesz and colleagues have 
suggested that the phenotypes of CBS, PSP, primary progressive aphasia (PPA) and 
FTDbv are closely related and frequently overlap leading them to propose that all of 
these different diagnoses should be lumped together and referred to as the FTD/Pick 
complex (Kertesz et al., 2005).   
Previous studies have indicated that between 25 and 56% of CBD cases are diagnosed 
correctly in life (Boeve, 2005, Grimes et al., 1999, Hughes et al., 2002, Murray et al., 
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2007). Pathological prediction of a primary tauopathy is, however, much more 
accurate (Josephs et al., 2006). Josephs et al, for example, indicated that the clinical 
presentation of CBS or a PSP-like syndrome was 100% specific for a primary 
tauopathy (Josephs et al., 2006). Of 83 cases presenting with CBS studied in four large 
clinicopathological series, 69 (83%) had a tauopathy with pathological inclusions 
made up predominantly of 4R tau in CBD, PSP and 3R tau in Pick’s disease (Wadia et 
al., 2007).  
The aim of the this study was to review the archival cases with either clinical diagnosis 
of CBS or pathological diagnosis of CBD examined at the Queen Square Brain Bank 
for Neurological Disorders (QSBB) between 1989 and 2009. 
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Materials and methods 
Patients 
Patients with either a final clinical diagnosis of CBS or pathological diagnosis of CBD 
were identified from the archive of 1440 cases referred to the QSBB over a 20-year 
period (1989 - 2009). Some cases have been included in previous QSBB series, 
previously known as the United Kingdom Parkinson’s Disease Society Brain Research 
Centre (Houlden et al., 2001, Jendroska et al., 1995, Litvan et al., 1996, O'Sullivan et 
al., 2008, Pittman et al., 2005, Williams et al., 2005). Most of the cases were 
registered as donors while under the care of physicians at the National Hospital for 
Neurology and Neurosurgery, Queen Square, London. Prospective brain donors were 
required to fill in annual assessment forms which provided clinical information related 
to their neurological condition. Consent for brain donation was obtained from the 
patients prior to death and consent for post-mortem examination was obtained from the 
next of kin after death. The protocols for the retention and access to human tissue and 
clinical records at the QSBB have been approved by the London Multi-Centre 
Research Ethics Committee. The QSBB restricted itself to the collection of abnormal 
movement disorders until five years ago when it also started to collect brains of 
patients with presumed FTD, who had presented to the Dementia Research Centre at 
the Institute of Neurology, University College London.                         
Medical record review 
A retrospective review was performed of all medical records, including the primary 
care medical notes, the correspondence between the medical specialists and general 
practitioners, medical files from the National Hospital for Neurology and 
Neurosurgery and the QSBB annual assessment data. All patients, except one who had 
incidental CBD pathology, had been assessed by hospital specialists (general 
neurologists, movement or cognitive disorders specialists) throughout the course of 
their illness. The information from the case notes was assessed by a neurologist who 
was blinded to the pathological diagnosis.  
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Symptoms were recorded as being absent if they were not reported in the case notes. 
Clinical signs were recorded as unknown if they were not specifically mentioned. The 
time of onset of selected clinical features was noted. When the onset was not 
documented, the onset was recorded as the time when the particular clinical feature 
was first mentioned in the chart. In cases with conflicting clinical features, the findings 
of the hospital specialist were used.  
The clinical research definitions used in the study were as follows: (i) age of onset, 
approximated to the specific month when the first symptom considered to be 
attributable to the neurological disorder was reported, (ii) duration of illness, time 
between the age of onset and the age at death, (iii) initial clinical diagnosis, the first 
diagnosis made by neurologist, (iv) final clinical diagnosis, the last diagnosis recorded 
before death; where more than one possible clinical diagnosis was listed in the clinical 
records, an attempt was made to ascertain which diagnosis was thought by the 
neurologist to be most likely, (v) initial presenting symptoms, first symptoms 
considered to be attributable to the neurological disorder, (vi) alien limb, defined as a 
feeling that one limb is ‘foreign’ or ‘has a will of its own’, together with observable 
‘involuntary motor activity’, including grasping of nearby objects or ‘intermanual 
conflict’; where the reported symptoms fulfilled this definition or when ‘alien limb 
phenomenon’ was documented by neurologists, this feature was recorded as present, 
and limb levitation alone was not considered as alien limb phenomenon (Joseph et al., 
2004), (vii) falls, reported as present when an unprovoked fall was mentioned, (viii) 
backward falls, more than 50% of the falls were in the backward direction, (ix) 
pyramidal signs, when there was documentation of a Babinski’s sign and 
pathologically brisk reflexes and (x) response to levodopa, a reported improvement of 
>30% coinciding with the introduction of  levodopa was recorded as being a positive 
response: a 4-point scale of improvement post-levodopa was used as follows: 1 = nil, 
or <30% improvement; 2 = moderate response (30-50% improvement); 3 = good 
response (51-70% improvement); and 4 = excellent response (71-100% improvement). 
A transient response to levodopa was defined as a reported benefit lasting less than 2 
years of commencing on levodopa.  
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Neuropathological methods  
Cases were selected from the archival collection of the QSBB where brain donation 
takes place according to ethically approved protocols and tissue is stored under a 
license from the Human Tissue Authority. In all cases the neuropathological diagnosis 
was reviewed by two neuropathologists using established pathological criteria. The 
minimal pathological features required for the diagnosis of CBD were tau-positive 
neuronal and glial lesions, including astrocytic plaques and extensive thread pathology 
in both grey and white matter of cerebral cortex and striatum along with focal neuronal 
loss in cortical regions and in the substantia nigra (Dickson et al., 2002, Ince et al., 
2008).  Other neuropathological diagnoses established for cases in the present series 
included PSP (Ince et al., 2008, Litvan et al., 1996), FTLD (Cairns et al., 2007), 
Alzheimer-type or α-synuclein pathologies (Ball et al., 1997, Ince et al., 2008) and 
Parkinson’s disease (Oppenheimer, 1984). 
Statistical methods 
Four diagnostic parameters were calculated for CBD cases in the QSBB database: (i) 
sensitivity: the percentage of pathologically diagnosed CBD cases, which had been 
diagnosed clinically as CBS in life, (ii) specificity: the percentage of cases which did 
not have CBD pathology which had been clinically diagnosed as not having that 
diagnosis in life, (iii) positive predictive value (PPV): the percentage of cases which 
had been diagnosed clinically as CBS and were pathologically confirmed as CBD and 
(iv) negative predictive value (NPV): the percentage of cases which were not clinically 
diagnosed with CBS and were confirmed post-mortem not to have CBD pathology. 
The calculations of PPV and NPV depend on the prevalence of disease in a targeted 
population, whereas sensitivity and specificity are constant measures of clinical 
diagnostic acumen. Confidence intervals at 95% for each diagnostic parameter were 
calculated by Stata 10.0 statistical programme.
 
Final clinical and neuropathological 
diagnoses were cross-tabulated using a two-by-two contingency table. Clinical features 
from patient subgroups were compared using the Student’s t test for continuous 
variables and the χ2 or Fisher exact tests for categorical variables by SPSS 17.0 
statistical programme.  
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Results 
Of the 1440 cases in the QSBB collected over the 20-year period, there were 179 cases 
with a pathological diagnosis of PSP, 117 multiple system atrophy and 608 
Parkinson’s disease. There were 35 patients (16 female, 19 male) with either a final 
clinical diagnosis of CBS or pathological diagnosis of CBD (Figure 4). Twenty-one of 
these had been followed up regularly at the National Hospital for Neurology and 
Neurosurgery (nine under the movement disorders team, six under the cognitive 
disorders team, four jointly by both teams, one followed up by a general neurologist 
and the other by a neuropsychiatrist). Of the 14 cases seen in other hospitals, nine were 
under the care of general neurologists and five followed by movement disorders 
specialists.  
 
 
 
 
 
 
 
 
 
Figure 4. Inclusion criteria of the study.  
Cases with either a clinical diagnosis of CBS or pathological diagnosis of CBD from 
the archival cases of the Queen Square Brain Bank were included in the study. 
  
Queen Square Brain Bank (1989-2009) 
Total number of cases studied = 1440 
21 cases with clinical 
diagnosis of CBS 
19 cases with CBD 
pathology 
5 CBD cases with 
clinical diagnosis 
of CBS 
14 CBD cases with 
other clinical 
diagnoses 
16 cases with CBS 
with non-CBD 
pathologies 
8-PSP, 5-AD,            
2-PD, 3-FTLD 
1-Incidental case, 8-RS, 2-PD, 1-Pick’s disease, 
1-FTD, 1-spastic quadriparesis 
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Clinical parameters All cases  
(N=19) 
CBD-CBS 
(N=5) 
CBD-RS    
(N=8) 
 
Female : Male 
 
Age of symptom onset 
 
Duration of illness 
 
Age of death 
 
Duration from final 
diagnosis till death 
 
9 : 10 
 
66.3 (56.6–77.2) 
 
6.0 (4.0–9.3) 
 
71.7 (63.8–81.6) 
 
2.3 (0.1-6.3) 
 
 
2 : 3 
 
69.0* (64.3-76.3) 
 
6.3 (4.8-8.8) 
 
75.3* (70.9-81.0) 
 
3.2* (1.0-6.3) 
 
 
4 : 4 
 
62.8* (56.6-69.5) 
 
5.6 (4.0-9.3) 
 
68.1* (65.1-73.8) 
 
1.5* (0.8-2.3) 
Cases where final 
clinical diagnosis 
was different from 
initial clinical 
diagnosis: 
Disease duration at 
final clinical diagnosis 
 
Duration from final 
diagnosis till death 
 
 
 
14 cases 
 
 
 
4.2 (1.0-8.0) 
 
 
 
1.9 (0.0-3.8) 
 
 
4 cases 
 
 
 
3.6 (0.1-5.5) 
 
 
 
2.5 (1.0-3.8) 
 
 
7 cases 
 
 
 
4.1 (2.4-8.0) 
 
 
 
1.5 (0.8-2.3) 
Table 2. Demographic parameters of 19 CBD cases. 
Data are mean in years (range); *=p < 0.05 comparing between CBD-CBS and CBD-
RS subgroups using Student’s t-test. 
CBD-CBS=corticobasal degeneration-corticobasal syndrome; CBD-RS=corticobasal 
degeneration-Richardson’s syndrome 
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Cases with pathological diagnosis of CBD 
Clinical diagnoses 
Of the 35 patients included in the present study, 19 (9 female, 10 male) had CBD 
pathology (Figure 4). Five of these had been diagnosed with CBS at the time of death. 
The diagnoses in the other 14 cases were PSP (8), Parkinson’s disease (2), FTD (1), 
Pick’s disease (1), spastic quadriparesis with myoclonus (1) and Gilles de la Tourette’s 
syndrome (1). At the time of first neurological specialist review, eight had been 
initially diagnosed with Parkinson’s disease, two with PSP and the rest with other 
movement disorders or dementia syndromes.   
Incidental finding of CBD pathology 
One patient had the incidental finding of CBD pathology at post-mortem. The patient 
developed motor tics at age eight followed by vocal tics several years later and was 
followed-up with the psychiatrists at the National Hospital for Neurology and 
Neurosurgery, during which he joined the QSBB brain donor programme. Four 
generations of his family had also had tics. At age 63, he died of metastatic carcinoma 
of the prostate. Before his death, there was no documentation of any neurological 
symptoms or signs suggestive of a progressive neurodegenerative disorder. 
Clinical features  
The demographic features of all pathologically confirmed CBD cases are summarized 
in Table 2 and are similar to those reported in previous studies (Gibb et al., 1989, 
Grimes et al., 1999, Litvan et al., 1997, Murray et al., 2007).  
Nine CBD cases (47%) had a markedly asymmetrical presentation. Seven patients 
(37%) had delayed initiation of horizontal saccadic eye movements. Majority of cases 
with features suggestive of CBS were correctly diagnosed in life. Twelve (63%) were 
noted to have a vertical supranuclear gaze palsy (VSGP). Initial clinical presentation of 
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parkinsonism was observed in nine (47%), aphasia in three (16%) and memory decline 
characterised by retrieval difficulties in seven (37%), four of whom also had executive 
dysfunction. Six of 12 patients with initial gait difficulty also had symmetrical 
bradykinesia. Sixteen patients (84%) had been prescribed levodopa, nine of whom 
(56%) had transient mild to moderate improvement and three (17%) had developed 
reversible and dose-related dystonic or choreiform movements of the limbs. Focal 
asymmetrical cortical atrophy was found in only three out of the 14 cases (21%) who 
had had a brain MRI performed. 
CBD subgroups with different clinical diagnoses 
Clinical diagnosis of CBS 
Four of the five pathologically confirmed CBD cases who had been eventually 
considered to have CBS (CBD-CBS) had received an alternative earlier diagnosis: 
Parkinson’s disease (2), PSP (1) and spastic paraparesis (1). All had presented with a 
clumsy useless limb and had subsequently developed symptoms of ideomotor apraxia 
and action myoclonus (Table 3). Focal limb dystonia (4), cortical sensory loss (4), 
alien limb (3) and stimulus-sensitive myoclonus (2) were also noted. Delayed initiation 
of horizontal saccades was observed in three cases. Of the four patients who had 
received levodopa, only one had a positive levodopa challenge test with transient 
improvement in mobility and subsequently developed a reversible levodopa induced 
foot dystonia. 
None of the three cases who had a brain MRI performed showed focal or asymmetrical 
cortical atrophy. One patient had decreased speech fluency at presentation which later 
manifested as PNFA with preserved comprehension. 
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Clinical features CBD-CBS (N=5) CBD-RS (N=8) P-values 
Classical CBS phenotype: 
Initial useless limb 
Asymmetrical features 
Alien limb 
Limb dystonia 
Cortical sensory loss 
Limb apraxia 
Action myoclonus 
Delayed initiation of saccade 
Latency from first symptom 
onset to onset of delayed 
initiation of saccade 
 
5 
5 
3 
4 
4 
5 
5 
3 (nk: 1) 
 
4.7years (2.5-7.7) 
 
0 
2 
0 
1 
0 
1 
2 
3 
 
3.7years (2.5-5.8) 
 
0.001* 
0.02* 
0.04* 
0.03* 
0.002* 
0.005* 
0.02* 
ns 
 
ns 
Classical PSP phenotype: 
Symmetrical bradykinesia 
VSGP 
Predominant downgaze 
abnormalities 
Duration from first symptom 
to onset of VSGP 
Duration from first symptom 
to onset of falls 
Early falls within 2 years  
Predominant backward falls 
Frontal release signs 
Apraxia of eyelid opening 
Frontalis hyperactivity 
 
0 
2 (nk: 1) 
0 
 
5.9years (4-7.7) 
  
2.4years (1.0-3.0) 
 
1 
2 
2 
0 
0 
 
6 
8 
3 
 
3.4years (1.2-7.3) 
 
1.0years (0.0-3.0) 
 
7 
5 
7 
5 
4 
 
0.02* 
0.04* 
ns 
 
ns 
 
0.04
†
 
 
0.03* 
ns 
ns 
ns 
ns 
Neuropsychiatric features: 
Initial behavioural change 
Initial memory decline 
Initial aphasia 
Orobuccal apraxia 
Hallucination 
 
0 
1 
1 
1 
0 
 
4 
3 (nk: 1) 
1 (nk: 1) 
0 (nk: 1) 
1 
 
ns 
ns 
ns 
ns 
ns 
Other motor disabilities: 
Initial parkinsonism 
Tremor 
Pyramidal signs 
 
2 
2 
2 
 
4 
2 
4 
 
ns 
ns 
ns 
Table 3. Clinical features of CBD-CBS and CBD-RS subgroups. 
nk=not known; ns=not statistically significant; *=p < 0.05 comparing between CBD-
CBS and CBD-RS subgroups using χ2; †=p < 0.05 comparing between CBD-CBS and 
CBD-RS subgroups using Student’s t-test. 
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Clinical diagnosis of PSP 
Among the eight CBD cases who had been diagnosed with PSP, seven were initially 
considered to have had a different disorder: Parkinson’s disease (3), unclassifiable 
akinetic rigid syndrome (1), multiple system atrophy (1), Alzheimer’s disease (1) and 
FTD (1). All of them had a VSGP (8)(Table 3). Seven had presented with gait 
difficulty and five had prominent postural instability with backward falls in the first 
year. Other symptoms and signs pointing in hindsight towards a clinical diagnosis of 
PSP were apraxia of eyelid opening (5), frontalis hyperactivity (4), frontal and 
subcortical cognitive impairment (4). All patients were prescribed levodopa, six of 
whom experienced transient mild to moderate improvement and two of whom 
developed levodopa induced dyskinesia. The MRI brain of one patient showed 
unequivocal midbrain atrophy. One patient had aphasia at presentation characterised 
by fluent phonemic paraphasia.  
Not surprisingly, the clinical features of this PSP-lookalike subgroup (CBD-RS) were 
very different from the CBD-CBS subgroup. There were more CBD-CBS patients with 
initial presentation of a useless limb, limb apraxia and dystonia, action myoclonus, 
cortical sensory loss, alien limb and asymmetrical clinical features (p < 0.05, Table 3). 
On the other hand, there were more CBD-RS patients with VSGP, early falls and 
symmetrical bradykinesia (p < 0.05, Figure 5).  
One of the two CBD-RS patients with asymmetric presentation manifested clinical 
features of CBS at late stage, whereas the other had recorded absence of these features 
(Figure 5). 
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Figure 5. Clinical features of CBD-CBS and CBD-RS subgroups.  
*=p < 0.05 comparing between CBD-CBS and CBD-RS subgroups using χ2test; 
SPG=supranuclear gaze palsy 
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Clinical diagnosis of Parkinson’s disease 
Two patients presented with strongly asymmetrical tremor-predominant parkinsonism 
and the presumptive diagnosis of Parkinson’s disease remained unchanged throughout 
the disease course. Review of the notes, however, revealed a poor levodopa response, 
short duration of disease (4.5 and 5.7 years), early onset of falls (0.1 and 2.8 years) and 
early wheelchair dependence (4 and 5 years). The hand tremor was coarse, jerky and 
more obvious on movement than at rest and neither patient had a classical pill-rolling 
resting tremor. One patient had perseveration, apraxia of eyelid opening and developed 
visual hallucinations after an increase of levodopa to 800mg/day. Ocular movements 
were not recorded at late stage of disease in one patient. 
Clinical diagnosis of Pick’s disease 
One patient presented with verbal communication and language difficulties (PNFA-
phenotype) and was initially diagnosed with depression. Three years after the onset of 
her first symptoms, she was noted to have orofacial apraxia and dysphagia, and two 
years later, she developed prominent abulia and anhedonia (FTDbv-phenotype). In 
2004, she was diagnosed with Pick’s disease. Seven years into her illness, she 
developed limb apraxia, a symmetrical akinetic rigid syndrome, gait difficulty, falls 
and a VSGP with delayed initiation of saccades in all directions. She died at age 74 
after a disease course of nine years.  
Clinical diagnosis of FTD 
This patient presented with an asymmetrical tremor-predominant parkinsonism in 
association with early striking behavioural change and memory impairment. He was 
initially diagnosed with Parkinson’s disease although there was no response to 
therapeutic doses of levodopa. Four years into his illness, disinhibition, anti-social 
behaviour and excessive spending were striking clinical features and the diagnosis was 
revised to FTD. A few months before death, he was noted to have a VSGP with 
predominant restriction of downgaze. The patient died at the age of 69 years after a 
disease course of five years. 
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Clinical diagnosis of spastic quadriparesis with myoclonus  
This patient presented with difficulty walking and recurrent falls and examination 
revealed bilateral pyramidal leg weakness with decreased vibration sense. She was first 
investigated for possible multiple sclerosis. In the following two years, the pyramidal 
weakness gradually involved her arms and she developed generalized marked action 
myoclonus and a symmetrical akinetic rigid syndrome without response to levodopa. 
She had pathological reflexes, equivocal plantar responses and normal cortical 
sensation. In 1995, despite extensive investigations, no underlying cause for her spastic 
quadriparesis was identified. Differential diagnosis shortly before death included 
spinal interneuronitis and primary lateral sclerosis. MRI brain showed symmetrical 
cerebral atrophy with focal atrophy in the peri-Rolandic area. The patient died at age 
75 years after a disease course of eight years. 
Secondary pathologies  
One of the five clinically diagnosed CBS patients, who died aged 77 years, had Lewy 
body pathology in the neocortex and brain stem and moderate cerebral amyloid 
angiopathy (CAA). Another who presented with right hand apraxia and alien limb, had 
cerebral infarction of the left middle cerebral artery territory in addition to the 
characteristic pathological changes associated with CBD. 
Two of the eight cases, who had been clinically diagnosed as PSP, had additional 
pathological findings. One patient who died at age 74, with a history of early falls, 
VSGP, apraxia of eyelid opening in association with frontal executive dysfunction and 
one recorded episode of hallucination, was found to have severe CAA and pathological 
ageing with Aβ deposition in the neocortical and medial temporal regions. Another 
patient, who initially presented with walking difficulties followed by the development 
of classical RS, was found to have small vessel cerebral vascular disease with 
Binswanger-type cerebral white matter changes.  
The patient, who was clinically diagnosed with Pick’s disease, had mild small vessel 
cerebral vascular disease with pathological ageing. 
43 
 
Cases with clinical diagnosis of CBS 
There were 16 cases with CBS which did not have associated CBD pathology. There 
were six cases with PSP, five with Alzheimer’s disease, two Parkinson’s disease, two 
with FTLD-TDP and one with FTLD-FUS. The clinical features of the cases with CBS 
are summarized in Table 4.  
Although five out of the six cases with pathological changes of PSP and CBS had 
asymmetrical clinical features, they also manifested some features which might have 
suggested PSP: VSGP was noted in three cases and early falls within two years of 
onset of first symptoms was also reported in three cases. Four had prominent frontal 
release signs including positive palmomental and grasp reflex, glabellar tap and 
utilization behaviour, and one of whom had frontal cognitive dysfunction. The mean 
onset of VSGP was 2.2 years from first symptom onset; this short duration had 
borderline statistical significance when compared to cases with CBD, Parkinson’s 
disease and FTLD pathologies (p = 0.09). There were significantly more PSP (100%) 
and CBD cases (80%) with unprovoked falls when compared to the Alzheimer’s 
disease cases (0%; p = 0.005). Apraxia of eyelid opening was noted in three PSP cases 
while none of the CBD or Alzheimer’s disease cases had this feature (p = 0.06). 
Parkinsonism at presentation was observed in both the cases with Parkinson’s disease, 
three of the PSP cases, but in none of the Alzheimer’s disease cases (p = 0.07). One 
patient with Alzheimer’s disease presented with word-finding difficulty followed by 
expressive aphasia.  
Both cases with Parkinson’s disease also had focal limb dystonia in late stage of 
disease and one had limb apraxia. The mean duration of illness of the cases with 
Parkinson’s disease (17.3 years) was much longer than the rest of the cases (p = 0.01). 
Both had moderate response to levodopa for prolonged duration of 5.3 and 19.8 years 
respectively. 
The patient with FTLD-TDP-MND presented with dyspraxia of the right hand 
followed by speech and swallowing difficulty. Nerve conduction studies revealed 
chronic partial denervation and fasciculations in the late stages of the illness. Another 
patient with FTLD-TDP subtype 2 presented with clumsiness of one arm followed by 
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behavioural changes suggestive of FTD-like syndrome. The patient had early marked 
delayed in initiation of horizontal saccades. The patient with FTLD-U presented with 
depression, limb apraxia and dystonia. Cognitive decline and behavioural changes 
followed.   
Secondary pathologies  
Of the cases with PSP pathology (N=6), one had mild CAA. Among the cases with 
Alzheimer’s disease (N=5), one had incidental Lewy body pathology, one had CAA 
and one had small vessel cerebral vascular disease. One of the cases with Parkinson’s 
disease had minor limbic cortical Lewy body involvement while the other had 
moderate neocortical Lewy bodies. The patient with FTLD-TDP with MND pathology 
also had Alzheimer pathology (Braak and Braak stage II) and small vessel cerebral 
vascular disease.  
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 Cases with CBS (N=21) 
Clinical features CBD 
pathology
(N=5) 
PSP 
pathology
(N=8) 
AD 
pathology 
(N=5) 
PD 
pathology 
(N=2) 
FTLD 
pathology 
(N=3) 
CBS phenotype: 
Initial useless limb 
Asymmetrical features 
Alien limb 
Limb dystonia 
Cortical sensory loss 
Limb apraxia 
Action myoclonus 
Latency from first 
symptom onset to onset 
of myoclonus  
Delayed initiation of 
saccade 
 
5 
5 
3 
4 
4 
5 
5 
 
2.7years 
(1.3-4) 
3 
 
2 
5 
1 
4 
2 
4 
3 
 
4.1years 
(1.5-6.8) 
3 (nk: 1) 
 
2 
2 
2 
0 
5 
5 
5 
 
4.0years 
(2.0-6.5) 
1 
 
0 
1 
0 
2 
0 
1 
0 
 
na 
 
0 (nk: 1) 
 
1 
2 
0 
2 
0 
2 
0 
 
na 
 
1 
PSP phenotype: 
VSGP 
Predominant downgaze 
abnormalities 
Duration from first 
symptom onset to VSGP 
Early falls within 2 years  
Unprovoked falls 
Frontal release signs 
Apraxia of eyelid opening 
 
2 
0 
 
5.9years 
(4-7.7) 
1 
4 
2 
0 
 
3 
2 
 
2.2years 
(1.7-3.1) 
3 
6 
4 
3 
 
1 
1 
 
2.0years 
(2.0-2.0) 
1 
0 
1 
0 
 
0 
1 
 
na 
 
0 
0 
2 
0 
 
2 
0 
 
na 
 
1 
2 
2 
2 
Neuropsychiatric 
features: 
Initial memory decline 
Initial aphasia 
Hallucination 
 
 
1 
1 
0 
 
 
1 (nk: 1) 
0 (nk: 1) 
0 
 
 
4 
1 
1 
 
 
0 (nk: 1) 
0 (nk: 1) 
1 
 
 
1 
0 
0 
Other motor 
disabilities: 
Initial parkinsonism 
Pyramidal signs 
 
 
2 
2 
 
 
3 
4 
 
 
0 
1 
 
 
2 
0 
 
 
0 
1 
Table 4. Clinical features of cases with CBS 
na=not applicable; nk=not known; VSGP=vertical supranuclear gaze palsy 
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Diagnostic accuracy of CBD  
Of the 19 pathologically diagnosed CBD cases, only five were accurately diagnosed as 
CBS in life, giving a sensitivity of 26.3% (Table 5). The positive predictive value 
(PPV) of the clinical diagnosis of CBS was 23.8%, with five cases confirmed to have 
CBD pathology out of 21 cases clinically diagnosed with CBS. The high specificity for 
CBD (98.9%) indicated that cases without CBD pathology were correctly identified in 
life as not having the condition.   
The PPV for a clinical diagnosis of Parkinson’s disease in the QSBB is 82.7% (564 out 
of 682), for PSP 69% (131 out of 190) and multiple system atrophy 70.1% (82 out of 
117), figures which contrast strikingly with those obtained for CBD in this study 
(Table 5). 
The sensitivities for other major parkinsonian disorders were also much higher than in 
CBD (Table 5). The sensitivity for Parkinson’s disease was 92.8% (564 out of 608), 
indicating the high proportion of cases with Parkinson’s disease pathology that had 
been correctly diagnosed with Parkinson’s disease in life. The sensitivity for PSP was 
73.2% (131 out of 179) and for multiple system atrophy was 70.1% (82 out of 117). In 
agreement with previous studies, the specificity for Parkinson’s disease was lower than 
other parkinsonian disorders, suggesting Parkinson’s disease was over-diagnosed 
(Litvan et al., 1998). 
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Disorder Sensitivity  
(95% CI) 
Specificity  
(95% CI) 
PPV             
(95% CI) 
NPV             
(95% CI) 
CBD 
PSP 
MSA 
PD 
26.3% (9.1-51.0) 
73.2% (66-79.5) 
70.1% (60.9-78) 
92.8% (90-94.7) 
98.9% (98-99.4) 
95.3% (94-96.4) 
97.4% (96-98.2) 
85.8% (83.3-88) 
23.8% (8.2-47.2) 
69.0% (61.8-75) 
70.1% (60.9-78) 
82.7% (80-85.5) 
99.0% (99-99.5) 
96.2% (95-97.2) 
96.2% (95-97.2) 
94.2% (92.3-96) 
Table 5. Diagnostic accuracy for CBD and other parkinsonian disorders 
Data was generated from 1440 archival cases in the QSBB over a 20-year period; 
CI=confidence interval 
 
 
Studies CBD cases Cases accurately 
diagnosed in life 
Sensitivity (%) 
Grimes et al. (1990) 
Boeve et al. (2005) 
Murray et al. (2007) 
13 
32 
15 
4 
18 
6 
31 
56 
40 
 Total = 60 Total = 28 Overall sensitivity    
= 47% 
Table 6. Summary of sensitivity in predicting CBD pathology in life 
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Discussion 
A previous study of 143 cases of parkinsonism followed by movement disorder 
specialists at the National hospital for neurology and neurosurgery reported that of four 
cases with CBD pathology, only one had been diagnosed correctly in life; whereas in 
the three cases with clinical CBS, only one had CBD pathology at post-mortem 
(Hughes et al., 2002).  Diagnostic accuracy of CBD does not appear to have improved 
in the decade since this paper was published, suggesting that the clinical spectrum of 
CBD remains poorly delineated and that the nosological entity first described by 
Rebeiz and colleagues is extremely difficult to diagnose accurately in life. The low 
sensitivity in predicting CBD reported in this study is consistent with the findings of 
other published clinicopathological series (Boeve, 2005, Grimes et al., 1999, Litvan et 
al., 1997, Murray et al., 2007). It is also evident that CBS is much more likely to be 
caused by a pathology other than that described as characteristic of CBD which is 
reflected by the low PPV of 23.8% in the present series. Five of the 11 cases with CBS 
presentation followed by movement disorder specialists were confirmed to have CBD 
pathology. The PPV for movement specialists is 45.5%, which is almost twice as high 
as the overall PPV. The remaining 10 cases diagnosed with CBS, had been followed 
by general neurologists or cognitive neurologists, none of which had CBD pathology. 
CBD cases correctly identified in previous published series manifested all the classical 
features reported in the seminal description by Rebeiz and colleagues, but together 
they constituted less than half of all cases with CBD pathology (28 out of 60, Table 6). 
Most of the cases in this series had been followed by movement disorder specialists, 
which differs from some of the other reported series where referral came primarily 
from cognitive disorder clinics (Boeve, 2005, Murray et al., 2007, Shelley et al., 
2009). The difference in referral source almost certainly accounts for the marked 
overlap between CBD and PSP identified in this series whereas in the publications 
coming from cognitive disorder clinics, confusion between CBD and FTD, PNFA and 
Alzheimer’s disease was more frequent (Alladi et al., 2007, Hodges et al., 2004, 
Josephs et al., 2008). Hodges and colleagues reported nine cases with a clinical 
diagnosis of CBS, of whom seven had been confirmed to have CBD pathology and the 
other two cases had FTLD (Hodges et al., 2004). In a series of 100 patients with 
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pathologically confirmed focal cortical syndromes 12 presented with CBS and six of 
them had CBD pathology while the other six fulfilled pathological criteria for 
Alzheimer’s disease (Alladi et al., 2007). Conversely, of the 12 cases with CBD 
pathology, on autopsy, six had presented with CBS, four with FTDbv and two with 
PNFA. 
Some previous publications have reported overlap between CBD and PSP but to a 
significantly lesser extent than found in this study (Boeve, 2005, Josephs et al., 2006, 
Murray et al., 2007). In the Mayo Clinic series, seven out of 32 CBD cases (22%) had 
been diagnosed with PSP in life and six out of 36 cases (17%) with CBS were found to 
have PSP pathological changes (Boeve, 2005). In one study, where 10 pathologically 
diagnosed CBD cases were reconstructed as case vignettes and presented to 
neurologists, 42% of CBD cases received a clinical diagnosis of PSP (Litvan et al., 
1997). In the present study, eight out of 19 CBD cases had been diagnosed with PSP 
(42%) and of the 21 cases clinically diagnosed with CBS, six were found to have PSP 
pathology (29%).   
In the present series, there are two main clinical variants which present to movement 
disorder specialists and are associated with the pathological changes considered 
characteristic of CBD. The term, CBD-CBS, has been provisionally used to refer to 
patients who present with the classical features first described by Rebeiz and 
colleagues and subsumed under the generic rubric of the CBS. The more problematical 
and more numerous group are patients who closely resemble classical PSP and which 
have been termed CBD-RS. These cases are characterised by VSGP, early falls within 
two years and symmetrical bradykinesia and, therefore, had been given a clinical 
diagnosis of PSP (Figure 5). Four of eight cases in the CBD-RS subgroup would have 
fulfilled the probable NINDS-PSP diagnostic criteria, the other four being excluded on 
the grounds of amnesia and aphasia (Litvan et al., 1996). A previous QSBB study 
identified VSGP, early falls and fronto-limbic cognitive dysfunction as the 
characteristic features of RS (Williams et al., 2005). Symmetrical motor handicap has 
been considered a helpful diagnostic pointer in distinguishing PSP from CBD, and 
represented one of the reasons why some of the CBD-RS cases had been clinically 
diagnosed with PSP. Post-mortem studies showed that aphasia and dementia can be 
presenting features in both CBD and PSP (Grimes et al., 1999, Josephs et al., 2008, 
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Masliah et al., 1991). Of interest, the age of symptom onset and age of death were 
significantly younger in the CBD-RS subgroup (62.8 years and 68.1 years) compared 
to the CBD-CBS subgroup (69 and 75.3), although considerable overlap makes this an 
unreliable distinguishing criterion in the individual case (Table 2).  
Delayed initiation of saccades may be helpful as a feature suggestive of underlying 
parietal lobe dysfunction and this ocular abnormality has been shown to correlate with 
the degree of limb apraxia in cases with CBS (Vidailhet et al., 2000), however, this 
can be a difficult clinical sign to elicit with certainty. A supranuclear gaze paresis in 
both the vertical and horizontal plane can also be observed in CBD but when present it 
is usually in the terminal phase of the illness. In PSP, vertical saccades are slow and 
hypometric and are more affected than horizontal ones (Vidailhet et al., 1994). Clinical 
diagnostic criteria for PSP have emphasised the importance of downgaze abnormalities 
(Lees, 1987, Litvan et al., 1996, Williams et al., 2005).  
The present study identified RS as the most common phenotypic presentation of CBD, 
while the classical presentation of CBS was only found in a quarter of CBD cases. The 
clinical features in CBD-RS cases closely resemble classical cases with PSP 
pathology. The findings in this study indicated that some clinical features might point 
to underlying CBD pathology but further validation of these differences will be 
required. For instance, VSGP was detected at a later stage in CBD-RS (3.4years) than 
in cases with PSP pathology and CBS (2.2years). VSGP predominantly affecting 
downgaze was infrequent in CBD-RS (3 in 8). Delayed initiation of saccades noted in 
three CBD-RS cases (38%) can be helpful when present in distinguishing CBD-RS 
from PSP-RS. This feature, however, is not specific for CBD pathology and can be 
found in cases with PSP and Alzheimer’s disease pathology presenting with CBS. Age 
of symptom onset in the CBD-RS subgroup (62.8years ±3.7) was younger than the 
archival QSBB cases with PSP pathology (66.4years ±12)(Williams et al., 2005). 
Nevertheless, until more reliable diagnostic markers become available, the division of 
CBD-CBS and CBD-RS subtypes can only be confirmed retrospectively. The classical 
PSP phenotype was accountable for over a third of all CBD cases, whereas PSP was 
the most common pathology underlying cases with CBS presentation, emphasising the 
considerable diagnostic difficulties and significant overlap between these two primary 
4R tauopathies. Conversely, among the QSBB archival collection of PSP cases, CBS is 
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a rare clinical presentation occurring in only six of the 179 pathologically diagnosed 
PSP cases (3%), and only five out of 160 PSP cases (3%) in the Mayo Clinic series 
were found to have CBS presentation (Tsuboi et al., 2005).  
Three other clinical presentations of CBD were also noted in this study: (i) a rapidly 
progressive levodopa unresponsive asymmetrical tremulous-parkinsonism with early 
postural instability, (ii) PNFA and (iii) FTDbv. The clinical presentation of PNFA and 
FTDbv are both recognised phenotypes of CBD (Geda et al., 2007, Josephs et al., 
2006, Murray et al., 2007). CBD can also present as an amnestic syndrome or posterior 
cortical atrophy, and is sometimes misdiagnosed as Alzheimer’s disease (Boeve, 2005, 
Grimes et al., 1999).   
As few as one in four cases with clinical CBS who come to autopsy are associated with 
CBD pathology, suggesting that previous studies based on clinical diagnostic criteria 
and neuroimaging studies alone could be considered as unreliable. Post-mortem series 
prior to the publication of validated neuropathological criteria (Dickson et al., 2002) 
may also have introduced error due to the overlapping pathological findings of CBD 
with other tauopathies such as PSP and Pick’s disease. Secondary pathologies 
observed in 12 out of the 35 cases may in some cases have influenced the phenotype. 
Specific topographic distribution of tau pathology has been reported to correlate with 
clinical phenotypes in a small study which reported an increased tau burden in mid-
frontal and inferior-parietal cortices in three PSP cases who presented with CBS 
(Tsuboi et al., 2005).  
Clinical presentation of CBS can be associated with a variety of underlying 
pathologies. If the disease course is very malignant with rapid clinical progression, the 
differential diagnoses of FTLD-TDP with progranulin mutation, FTLD-FUS and prion 
disease should be considered. If the symptom onset is acute followed by a static 
course, cerebrovascular disease is more likely whereas slow symptom progression with 
long disease duration along with sustained levodopa response are more suggestive of 
Parkinson’s disease. MAPT or progranulin mutation should be considered in cases with 
at least one first degree relative with CBS, dementia or primary progressive aphasia 
(Cairns et al., 2007, Le Ber et al., 2008, Tartaglia et al., 2009). A previous study 
identified initial episodic memory complaints as a specific predictor for Alzheimer’s 
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disease with CBS presentation (Shelley et al., 2009). In the present series, initial 
memory decline was also more common in Alzheimer’s disease with CBS while none 
of the CBD-CBS cases had this feature. On the other hand, cortical sensory loss and 
action myoclonus were equally common in both Alzheimer’s disease presenting with 
CBS and CBD-CBS subgroups, and it is interesting to note that action myoclonus was 
an early feature (within first 3 years of illness) in three of five cases of Alzheimer’s 
disease presenting with CBS. 
This study has identified three features which are likely to be helpful in excluding 
CBD in cases presenting with CBS, namely, a sustained initial levodopa response for 
over 2 years, early VSGP within 2 years of first symptom onset, and finally, a disease 
duration of over 10 years. By applying these criteria retrospectively, two cases with 
Parkinson’s disease and two cases with PSP could be excluded, along with another 
case diagnosed with FTLD-TDP with MND supported by electrophysiological 
features. These more stringent criteria allow the exclusion of five false positive cases; 
accuracy in predicting CBD pathology in patients with CBS is improved from 23.8% 
to 31.3% (5 of 16 cases) and accuracy in predicting tau pathology in CBS reaches 69% 
(5 CBD, 6 PSP out of 16 cases). CBS is much more sensitive in predicting tau 
pathology than CBD pathology. Other post-mortem series had an overall 83% of CBS 
cases with tauopathy (Wadia et al., 2007). PSP-like syndrome and PNFA are other 
clinical presentations that were identified to accurately predict underlying tau 
pathology (Hodges et al., 2004, Josephs et al., 2006). In the present series, 14 out of 19 
CBD cases (73%) had a clinical presentation of either CBS, PSP or PNFA.  
CBD and PSP are sporadic diseases sharing important biological and morphological 
features. In both conditions, the possession of H1 allele of the MAPT gene, and in 
particular, the H1/H1 genotype is a risk factor and the accumulation of 4R-tau in both 
neuronal and glial inclusions is characteristic (Baker et al., 1999, Houlden et al., 
2001). These similarities have led some authors to propose that CBD and PSP are 
actually the same disorder with a wide spectrum of pathological and clinical 
manifestations (Scaravilli et al., 2005). Nevertheless, their classical clinical 
presentations are strikingly different and the neuropathological diagnostic criteria of 
CBD and PSP were validated with high sensitivity and specificity (Dickson et al., 
2002, Litvan et al., 1996). Although both conditions share extensive neuronal tau 
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pathology, astrocytic plaques of CBD are characteristic while in PSP tufted astrocytes 
are the hallmark glial lesion (Dickson, 1999). Furthermore Ishizawa et al have also 
demonstrated distinct patterns of microglial activation and tau distribution in 
pathologically diagnosed CBD and PSP cases (Ishizawa et al., 2001). These findings 
support the notion that CBD and PSP are distinct if closely related clinicopathological 
entities which have a tendency to occur in patients sharing a similar genetic 
predisposition.   
The greatest strength of this study is its size and the use of modern 
immunohistochemistry techniques to characterise the underlying pathology. All 
patients were reviewed by hospital specialists and the majority (60%) was followed-up 
at the National Hospital for Neurology and Neurosurgery, a tertiary referral centre, 
where atypical presentations, overlap syndromes and diagnostic conundrums are seen 
frequently. An over-inclusion of diagnostically more challenging cases occurs in any 
brain bank post-mortem series and the retrospective review of medical records has 
inherent limitations. The predominant referral from movement disorder clinics can also 
potentially lead to referral bias. Cognitive and language functions were not until 
recently consistently tested and recorded in those patients presenting with predominant 
motor handicap and could have resulted in underestimation of neuropsychiatric 
features. Six of 35 cases did not receive full neuropsychological evaluations. 
Nevertheless, the findings of this study are likely to be of relevance in neurological 
practice. 
Conclusion 
This study has identified a number of pathologically confirmed CBD cases whose 
clinical picture more closely resembled PSP than a CBS. CBD cases with PSP-like 
presentation often have delayed onset of VSGP after 3 years and infrequent 
observation of downgaze predominant abnormalities. Despite the clinical heterogeneity 
of CBD and the increasingly wide differential diagnosis of CBS, CBD should continue 
to be considered a distinct clinicopathological entity with an abnormality of tau 
aggregation which closely links it with PSP.  
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Chapter 3:  Progressive supranuclear 
palsy presenting with corticobasal 
syndrome: a cortical variant 
Introduction 
The classic presentation of PSP, now known as PSP-RS, is characterised by early onset 
of postural instability with falls backwards, VSGP and frontal subcortical cognitive 
impairment (Steele et al., 1964, Williams et al., 2005, Williams et al., 2008). Other 
well recognised clinical variants of PSP are PSP-P (Williams et al., 2005, Williams et 
al., 2010), PSP-PAGF (Ahmed et al., 2008, Williams et al., 2007), PSP-PNFA 
(Hodges et al., 2004, Hu et al., 2007, Josephs et al., 2006, Kertesz et al., 2005), PSP-
FTDbv (Hassan et al., 2011) and PSP-CBS (Tsuboi et al., 2005).  Clinicopathological 
studies have since demonstrated a close correlation between topographical severity of 
tau pathology and clinical phenotypes of PSP. For instance, severe tau pathology was 
identified in the inferior frontal gyrus in PSP-PNFA (Josephs et al., 2006) and frontal 
and temporal cortices in PSP-FTDbv (Bigio et al., 2001). Conversely, very mild 
cortical tau burden was observed in the PSP-PAGF subtype (Ahmed et al., 2008, 
Williams et al., 2007). Similar clinicopathological correlation was also identified in 
another closely related 4R tauopathy, CBD and its clinical phenotypes (Kouri et al., 
2011)  
CBS commonly presents as progressive clumsiness and loss of function of one hand 
due to apraxia, an alien limb, cortical sensory loss, dystonia or levodopa-unresponsive 
rigidity, and it was initially described as the distinctive clinical presentation of CBD 
(Gibb et al., 1989, Rebeiz et al., 1967). Since its original description, multifarious 
other pathologies have been linked to a CBS presentation (Alladi et al., 2007, Hodges 
et al., 2004). From the QSBB archival cases, the most common underlying pathology 
for CBS is PSP (8 of 21) rather than CBD (5 of 21), however, only 4% of all 
pathologically diagnosed PSP cases (N=227) had a CBS presentation (PSP-CBS, 
Chapter 2). Previously, Tsuboi and colleagues quantified tau load in four selected 
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cortical regions, including cingulate gyrus, mid-frontal cortex, motor cortex and 
inferior parietal cortex in three PSP-CBS cases and eight randomly chosen PSP-RS 
cases (Tsuboi et al., 2005). They reported an increased tau pathology in the mid-frontal 
and inferior-parietal cortices in PSP-CBS when compared to PSP-RS and concluded 
that the CBS presentation of PSP was either caused by a concurrent cortical pathology 
from a secondary process such as Alzheimer’s disease or by the primary PSP-tau 
pathology involving the cortical regions (Tsuboi et al., 2005). Nevertheless, it is 
uncertain if differences exist in the distribution of tau pathology in other brain regions 
or if the overall tau load is increased in the brains of PSP-CBS. It is noteworthy that 
imaging studies have identified predominant focal grey matter loss on voxel-based 
morphometry in the premotor cortex, posterior superior frontal lobe and supplementary 
motor area and relatively preserved brain stem grey matter in cases with PSP-CBS 
(Whitwell et al., 2010). Therefore, this study was performed with the hypothesis that 
the distribution of tau pathology in PSP-CBS would resemble the distribution of grey 
matter loss identified by in vivo imaging in voxel-based morphometry.  
The aims of this study were: (i) To validate the findings reported by Tsuboi and 
colleagues in a significantly larger cohort of PSP-CBS cases and to quantitatively 
assess tau distribution in more brain regions, (ii) To determine the cellular lesions 
which contribute to the tau pathology were characteristic of PSP pathology rather than 
Alzheimer-type NFT pathology and (iii) To assess the severity of neuronal loss in the 
substantia nigra and subthalamic nuclei and the extent of pathological involvement of 
the corticospinal tract.  
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Materials and methods 
Case selection 
Of the 227 PSP cases available in the QSBB archives between 1988 and 2010, nine 
had received a final clinical diagnosis of CBS during life (PSP-CBS, 3.9% of all PSP 
cases). An additional case, seen and diagnosed pathologically at the University of 
Nottingham, was also included. These ten PSP-CBS cases were matched with ten PSP-
RS control cases for disease duration and age at death. The brain donor program of the 
QSBB was approved by a London Multi-Centre Research Ethics Committee and tissue 
is stored for research under a license from the Human Tissue Authority.  
Medical record review 
Systematic retrospective review of the medical records was carried out. All patients 
were assessed by at least one neurologist during life. Symptoms and clinical signs were 
recorded as being absent if they were not reported in the case notes. When the onset 
was not recorded, the onset was taken as the time when the particular clinical feature 
was first mentioned in the notes. If there were conflicting clinical features, the findings 
of the neurologist took precedence. The deﬁnitions for each selected clinical feature 
were described in Chapter 2.  
Pathological material 
The neuropathological diagnosis of PSP was confirmed in all 20 included cases. 
Immediately after post-mortem the brains were divided in the mid-sagittal plane. One 
half, chosen randomly, was sliced and tissue blocks were frozen and stored at -80ºC, 
while the other half was immersed and fixed in 10% neutral formalin for three weeks 
before neuropathological examination. Tissue blocks were taken using standard 
protocols. Established pathological diagnostic criteria for PSP were used, requiring the 
presence of NFTs, NTs and glial tau pathology in different brain regions including the 
cerebral cortex, striatum, globus pallidus, subthalamic nucleus, midbrain, pons and 
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cerebellum together with neuronal loss and gliosis in basal ganglia and brainstem and 
cerebellar nuclei (Dickson et al., 2011, Hauw et al., 1994, Ince et al., 2008, Litvan et 
al., 1996). In each case, 8µm-thick tissue sections cut from the paraffin blocks and 
stained with haematoxylin and eosin (H&E) were used to assess neuronal loss and 
gliosis in the basal ganglia and substantia nigra. Immunohistochemistry with 
antibodies to phosphorylated tau (AT8; BioScience Life Sciences; 1:600), 3R and 4R 
tau (3R tau: RD3; 1:2000; 4R tau: RD4; 1:200)(de Silva et al., 2003), microglia 
(CD68; Dako; PG-M1; 1:75), αB-crystallin (Novocastra; G2JF; 1:300), amyloid-β 
(Aβ) peptide (Dako; 6F/3D; 1:100) and α-synuclein (Vector Laboratories; KM51; 
1:50) was performed using a standard avidin-biotin method. Endogenous peroxidase 
activity was blocked with 0.3% H2O2 in methanol, followed by pressure cooker pre-
treatment in citrate buffer pH 6.0. Sections were treated with 10% dried milk solution 
to block non-specific binding. Tissue sections were incubated with the primary 
antibody for one hour at room temperature, followed by biotinylated anti-mouse 
(Vector Laboratories, Burlingame, CA; 1:200) and ABC complex (Dako). Colour was 
developed with di-aminobenzidine/H2O2. 
Additional pathologies were documented. Argyrophilic grains were identified by AT8 
and αB-crystallin immunohistochemistry (Togo et al., 2002) while Aβ cortical plaque 
pathology was characterised using the modified Consortium to Establish a Registry for 
Alzheimer’s disease (CERAD) criteria (Mirra et al., 1991). Alzheimer’s type NFT 
pathology was determined using AT8 immunohistochemistry for Braak and Braak 
staging (Braak et al., 2006). The presence of incidental Lewy body disease, 
cerebrovascular disease and CAA was documented. Only cases with limited 
Alzheimer-type NFT pathology of Braak and Braak stage III or less were recruited to 
avoid confounding the analysis of PSP-related tau pathology.  
Regional tau quantitation with image analysis 
Using coded slides, quantitative assessment of tau pathology, comprising of all tau-
positive lesions including NFTs, PreTs, NTs, tufted astrocytes (TAs) and CBs was 
performed. Fifteen brain regions, which are known to be affected in PSP and whose 
involvement is predicted to contribute to the clinical features, were selected: the 
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posterior frontal cortex including the motor strip, cerebral cortex and subcortical white 
matter of the middle frontal gyrus (level: 1 cm behind the temporal pole), middle 
temporal gyrus (level: mammillary body) and parietal region (level: 1cm behind the 
splenium), caudate nucleus, putamen, globus pallidus, subthalamic nucleus, substantia 
nigra (level: emergence of the third cranial nerve), pontine base (including the pontine 
nuclei), cerebellar dentate nucleus and cerebellar white matter. The posterior frontal 
white matter was omitted from the analysis as the quantity was very small in some 
cases due to variability of routine sampling.  
In each region, the images of ten random microscopic fields using a x20 objective were 
captured by a colour digital camera connected to the microscope (Nikon Microphot-
FXA and Digit sight DS-L1) and processed with an image analysis software (Image 
Pro; MediaCybernetics®), converted to grey-scale images and labelling was measured 
in pixels. Threshold was adjusted to capture the two-dimensional area of all tau-
positive lesions and the same threshold setting was used throughout the study. ‘Areal 
fraction’, defined by a ratio of the tau-positive immunoreactive pixels to the total 
number of pixels of the whole field was computed by Image Pro and tau load for each 
region, i.e. ‘regional’ tau load was expressed as percentage (areal fraction x 
100%)(Gundersen et al., 1988). ‘Total’ tau load was the sum of tau load in all fifteen 
brain regions. ‘Cortical’ tau load was the sum of tau load in seven regions, comprised 
of both grey and subcortical white matter in the anterior frontal, temporal and parietal 
regions and grey matter in the posterior frontal region. ‘Basal ganglia’ tau load was the 
sum of tau load in four structures: caudate nucleus, putamen, globus pallidus and 
subthalamic nucleus.  
Quantitation of tau lesions 
The different tau-positive lesions were quantified individually in ten random fields of 
three selected regions, posterior frontal cortex, anterior frontal cortex and caudate, 
where differences in regional tau load were found to be the most robust between PSP-
RS and PSP-CBS. NFTs, PreTs, TAs and CBs were individually counted. NT 
pathology was quantified using a four-tiered semi-quantitative grading scale (0–3, with 
grade 0=no NT to grade 3=most severe NT).  
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Neuronal loss  
Neuronal loss in the subthalamic nucleus and substantia nigra was determined using a 
four-tiered semi-quantitative grading system, while the case identity was blinded (0–3, 
with grade 0=no neuronal loss to grade 3=most severe neuronal loss). The substantia 
nigra was divided into five regions (medial, dorsomedial, dorsolateral, ventrolateral 
and lateral) for subregional assessment. 
Corticospinal tract involvement 
Microglial pathology of the corticospinal tract identified in the midbrain cerebral 
peduncles was assessed using CD68 immunohistochemistry, while the case identity 
was blinded. A semi-quantitative grade was used: grade 0=baseline microglial 
population to grade 3=most severe microglial pathology.  
Tau biochemistry 
Frontal cerebral cortex was used for tau biochemistry in two PSP-CBS, two PSP-RS 
cases and two pathologically diagnosed CBD cases with classic CBS presentation 
(CBD-CBS). Regional variation of phosphorylated tau species in PSP brains was 
previously reported (Puig et al., 2005). However, tau protein extraction was limited to 
the frontal cortex in the present study.  
Sarkosyl-Insoluble tau isolation 
Isolation of sarkosyl-insoluble tau was carried out (Goedert et al., 1992, Greenberg et 
al., 1990). Brain tissue was homogenised in 10x volume (v/w) homogenisation buffer 
(10mM Tris–HCl pH 7.4, 0.8 M NaCl, 1 mM EGTA and 10% sucrose containing 
Complete protease inhibitor cocktail (Roche, Burgess Hill, UK). The suspension was 
then spun at 20,000 x g for 20 min at 4 ºC and the supernatant set aside. The pellet was 
re-suspended in 5x volumes of homogenisation buffer and re-centrifuged as above. 
The supernatants were combined and N-lauryl sarcosinate added to a concentration of 
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1% (w/v), and incubated at room temperature for one hour with shaking. The mixture 
was then centrifuged at 100,000 × g for 1 h at 4ºC. The sarkosyl-insoluble pellet was 
re-suspended in 50 mM Tris–HCL pH7.5 at 0.2 ml/g of starting material. 
SDS-PAGE 
Sarkosyl-insoluble tau was separated on 10% SDS-polyacrylamide gels and blotted 
onto nitrocellulose membranes using standard procedures. The blots were probed with 
a pan-tau rabbit polyclonal TP70 antibody that recognises the carboxy-terminus of tau 
(Brion et al., 1993, Cairns et al., 1997)(1/15,000; kind gift from Dr Diane Hanger, 
King’s College, London) and IRDye 800CW Donkey Anti-Rabbit secondary antibody 
(Li-Cor Biosciences) followed by imaging on a Li-Cor Odyssey Infrared Scanner. 
Haplotype analysis of the MAPT gene 
Haplotype was determined by PCR typing of the 238 bp MAPT H2 deletion in intron 9 
in seventeen cases (8 PSP-CBS, 9 PSP-RS) where frozen tissue was available for DNA 
extraction (Baker et al., 1999, Hoglinger et al., 2011). 
Statistical analysis 
The Mann-Whitney U test was used to compare tau load between PSP-CBS and PSP-
RS. The null hypothesis (H0) was rejected if the p-value was <0.05 when ‘total’, 
‘cortical’ and ‘basal ganglia’ tau load was assessed. For ‘regional’ tau load assessment, 
p-value of 0.0033 (0.05/15) was used to adjust for multiple comparisons; for tau-
positive cellular lesion load, p-value of 0.01 (five different types of tau lesions: 0.05/5) 
was used. χ2 / Fisher’s exact test or the Student’s t test was used to compare semi-
quantitative grading or clinical data using p-value of 0.05. The intra-rater repeatability 
was assessed by repeating tau quantitation in four randomly selected cases (20%). The 
intraclass correlation coefficient was 0.80 (p < 0.001), indicating that the ‘regional’ tau 
load results were highly repeatable. The SPSS 17.0 programme was used for statistical 
analysis. 
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Results 
Clinical features  
PSP-CBS  
All patients had been diagnosed with CBS/CBD by neurologists during life (Tables 7-
8). Mean duration of first symptom onset to the final clinical diagnosis was 3.4 years. 
All cases had strikingly asymmetrical clinical features throughout the entire disease 
course; ten had ideomotor limb apraxia, eight had focal hand dystonia, five had distal 
myoclonus, three had an alien limb phenomenon, three had non-fluent aphasia, three 
had cortical sensory loss and two had hemisensory neglect. Delayed initiation of 
horizontal saccades was observed in three patients, two of whom also had head thrust 
at saccadic initiation (cases 2 and 5).  
Seven patients developed ocular features suggestive of PSP including slow vertical 
saccades or VSGP but in most cases these occurred in the advanced stage of the 
illness. Two exceptions were cases 8 and 9, who developed VSGP within 4 years from 
symptom onset and an initial clinical diagnosis of PSP was considered, but was later 
revised to CBS, after the onset of asymmetrical cortical symptoms. Six patients 
developed postural instability or falls within the first year of symptom onset.  
Nevertheless, VSGP (χ2, p = 0.016) and postural instability or early falls were still 
more frequent in PSP-RS than in PSP-CBS. Pyramidal signs were more frequent in 
PSP-CBS (N=5) than in PSP-RS (N=0)(χ2, p = 0.016). Extensor plantars and hyper-
reflexia were noted in five PSP-CBS patients, three of whom also had spasticity and 
one had pyramidal weakness, but none of these features was observed in PSP-RS. 
62 
 
PSP-RS  
All PSP-RS patients had a final clinical diagnosis of probable PSP and had VSGP 
including downgaze abnormalities and early postural instability or falls (Tables 9-11). 
Three patients had cognitive decline and five had frontal type personality change 
characterised by apathy and abulia.  
 
Features PSP-CBS 
Case no. 1 2 3 4 5 
Gender M F M M M 
Age at onset, years 
Age at death, years 
Disease duration, years 
55 
64.3 
9.3 
63.8 
70.2 
6.4 
60.4 
66.3 
5.9 
60.5 
68.8 
8.3 
79.3 
82.8 
3.5 
Initial clinical diagnosis 
Final clinical diagnosis 
Duration from onset to 
final diagnosis, years 
PD 
CBS 
6.3 
CBS 
CBS 
3.5 
C-Spond 
CBS 
5.2 
CVD 
CBS 
2.1 
PD 
CBS 
1.5 
Presenting symptom(s) Balance 
difficulty 
Useless 
arm 
Useless 
arm 
Jerky arm Falls 
Asymmetrical features 
Limb apraxia 
Alien limb 
Cortical sensory loss 
Hemi-neglect 
Aphasia 
+ 
+ 
- 
- 
- 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
- 
- 
+ 
+ 
- 
- 
- 
- 
+ 
+ 
- 
- 
- 
- 
Hand dystonia 
Clenched fist 
Myoclonus 
Tremor 
+ 
+ 
- 
- 
+ 
+ 
- 
- 
+ 
+ 
+ 
- 
+ 
+ 
+ 
- 
- 
- 
+ 
+ 
Delayed initiation of 
saccades 
Slow vertical saccades 
VSGP 
Postural instability within 
first years 
nk 
 
nk 
+ 
- 
+ 
 
- 
- 
+ 
nk 
 
nk 
nk 
- 
+ 
 
+ 
- 
- 
+ 
 
+ 
+ 
+ 
Cognitive decline 
Personality change  
- 
- 
+ 
- 
- 
- 
+ 
+ 
+ 
- 
Pyramidal signs 
Akinetic rigidity in first two 
years 
Dysarthria in first 2 years 
Dysphagia in first 2 years 
+ 
+ 
 
+ 
- 
+ 
- 
 
- 
- 
- 
- 
 
- 
- 
+ 
- 
 
+ 
nk 
+ 
+ 
 
- 
- 
Levodopa response - - - - mild 
MAPT genotype H1/H1 H1/H1 H1/H1 nk H1/H1 
Table 7. Features of PSP-CBS (cases 1 - 5). 
C-Spond=cervical spondylosis; CVD=cerebrovascular disease 
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Features PSP-CBS 
Case no. 6 7 8 9 10 
Gender F F F M F 
Age at onset, years 
Age at death, years 
Disease duration, years 
66.3 
77.9 
11.6 
60 
70.8 
10.8 
64 
72.5 
8.5 
77 
81 
4 
73 
79.2 
6.2 
Initial clinical diagnosis 
Final clinical diagnosis 
Duration from onset to 
final diagnosis, years 
Depressed 
CBS 
2.6 
CBS 
CBS 
7 
PSP 
CBS 
6 
PSP 
CBS 
4 
CBS 
CBS 
3 
Presenting symptom(s) Gait 
difficulty & 
cognitive 
slowing 
Useless 
arm & 
balance 
difficulty 
Falls Balance 
difficulty & 
slurred 
speech 
Useless 
arm & falls 
Asymmetrical features 
Limb apraxia 
Alien limb 
Cortical sensory loss 
Hemi-neglect 
Aphasia 
+ 
+ 
- 
- 
- 
+ 
+ 
+ 
- 
- 
- 
- 
+ 
+ 
- 
- 
+ 
- 
+ 
+ 
+ 
- 
- 
+ 
+ 
+ 
+ 
- 
- 
- 
Hand dystonia 
Clenched fist 
Myoclonus 
Tremor 
- 
- 
- 
- 
+ 
+ 
+ 
- 
+ 
- 
- 
- 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
Delayed initiation of 
saccades 
Slow vertical saccades 
VSGP 
Postural instability  
within first years 
nk 
 
+ 
+ 
+ 
nk 
 
nk 
nk 
- 
- 
 
+ 
+ 
+ 
- 
 
nk 
+ 
+ 
nk 
 
+ 
- 
+ 
Cognitive decline 
Personality change  
+ 
+ 
- 
- 
+ 
- 
- 
- 
+ 
- 
Pyramidal signs 
Akinetic rigidity in first 
two years 
Dysarthria in first two 
years 
Dysphagia in first two 
years 
- 
+ 
 
- 
 
- 
+ 
- 
 
- 
 
nk 
- 
+ 
 
- 
 
nk 
- 
+ 
 
+ 
 
+ 
- 
+ 
 
- 
 
- 
Levodopa response - - - - Mild 
MAPT genotype H1/H2 H1/H1 H1/H1 nk H1/H2 
Table 8. Features of PSP-CBS (cases 6 - 10). 
VSGP=vertical supranuclear gaze palsy  
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Features PSP-RS 
Case no. 1 2 3 4 5 
Gender F F M M F 
Age at onset, years 
Age at death, years 
Disease duration, years 
62 
69.8 
7.8 
65.2 
71.3 
6.1 
63 
69.5 
6.5 
74.3 
79.5 
5.2 
66 
81.7 
15.7 
Initial clinical diagnosis 
Final clinical diagnosis 
Duration from onset to 
final diagnosis, years 
Depressed 
PSP 
4 
PD 
PSP 
4 
Depressed 
PSP 
2.5 
PD 
PSP 
3 
PD 
PSP 
7 
Presenting symptom(s) Falls & 
cognitive 
slowing 
Falls Falls & 
cognitive 
slowing 
Falls Slow up 
Asymmetrical features 
Limb apraxia 
Alien limb 
Cortical sensory loss 
Hemi-neglect 
Aphasia 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Hand dystonia 
Clenched fist 
Myoclonus 
Tremor 
- 
- 
- 
+ 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Delayed initiation of 
saccades 
Slow vertical saccades 
VSGP 
Postural instability 
within first years 
nk 
 
+ 
+ 
+ 
- 
 
nk 
+ 
+ 
- 
 
+ 
+ 
+ 
nk 
 
nk 
+ 
+ 
- 
 
+ 
+ 
+ 
Cognitive decline 
Personality change 
+ 
+ 
- 
- 
+ 
+ 
- 
+ 
- 
- 
Pyramidal signs 
Akinetic rigidity in first 
two years 
Dysarthria in first two 
years 
Dysphagia in first two 
years 
- 
+ 
 
+ 
 
+ 
- 
+ 
 
nk 
 
- 
- 
+ 
 
- 
 
- 
- 
+ 
 
- 
 
- 
- 
+ 
 
- 
 
- 
Levodopa response - - - - - 
MAPT genotype H1/H1 H1/H1 nk H1/H1 H1/H1 
Table 9. Features of PSP-RS (cases 1 - 5). 
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Features PSP-RS 
Case no. 6 7 8 9 10 
Gender M M F F M 
Age at onset, years 
Age at death, years 
Disease duration, years 
61 
78.3 
17.3 
52.1 
61.3 
9.2 
67 
73 
6 
72 
79.1 
7.1 
76 
80.7 
4.7 
Initial clinical diagnosis 
Final clinical diagnosis 
Duration from onset to 
final diagnosis, years 
CVD 
PSP 
2.2 
PSP 
PSP 
3 
PSP 
PSP 
3 
PSP 
PSP 
3 
PSP 
PSP 
2 
Presenting symptom(s) Slurred 
speech 
Balance 
difficulty 
Falls Falls Falls 
Asymmetrical features 
Limb apraxia 
Alien limb 
Cortical sensory loss 
Hemi-neglect 
Aphasia 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Hand dystonia 
Clenched fist 
Myoclonus 
Tremor 
- 
- 
- 
- 
+ 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
+ 
Delayed initiation of 
saccades 
Slow vertical saccades 
VSGP 
Postural instability 
within first years 
- 
 
+ 
+ 
+ 
- 
 
nk 
+ 
+ 
- 
 
+ 
+ 
+ 
- 
 
+ 
+ 
+ 
nk 
 
nk 
+ 
+ 
Cognitive decline 
Personality change  
- 
- 
- 
+ 
+ 
+ 
- 
- 
- 
- 
Pyramidal signs 
Akinetic rigidity in first 
two years 
Dysarthria in first two 
years 
Dysphagia in first two 
years 
- 
+ 
 
+ 
 
- 
- 
+ 
 
+ 
 
+ 
- 
+ 
 
nk 
 
nk 
- 
+ 
 
+ 
 
+ 
- 
+ 
 
- 
 
- 
Levodopa response - - - - - 
MAPT genotype H1/H1 H1/H1 H1/H1 H1/H1 H1/H1 
Table 10. Features of PSP-RS (cases 6 - 10). 
VSGP=vertical supranuclear gaze palsy  
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 PSP-CBS PSP-RS P-values 
(Student’s      
t test) 
Mean age of symptom 
onset (mean years ± S.D.) 
65.9 ± 8.0 65.9 ± 7.1 0.98 
Mean age of death            
(mean years ± S.D.) 
73.4 ± 6.4 74.4 ± 6.5 0.72 
Mean disease duration      
(mean years ± S.D.) 
7.5 ± 2.7 8.6 ± 4.4 0.51 
Table 11. Comparison of features between PSP-CBS and PSP-RS groups. 
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Neuropathological findings  
Both PSP-CBS and PSP-RS groups met established pathological criteria of PSP 
(Dickson et al., 2011, Hauw et al., 1994, Ince et al., 2008). All inclusion types were 
immunoreactive for 4R tau by differential immunohistochemistry but negative for 3R 
tau in all cases, which was characteristic for PSP. 
Regional tau load  
The median ‘regional’ tau load in the posterior frontal cortical grey matter (PSP-CBS: 
0.59; PSP-RS: 0.05), anterior frontal cortical grey matter (PSP-CBS: 0.06; PSP-RS: 
0.03) and parietal subcortical white matter (PSP-CBS: 0.06; PSP-RS: 0.01) was 
significantly greater in PSP-CBS than in PSP-RS (p < 0.0033 in all). The median 
‘regional’ tau load in the caudate (PSP-CBS: 0.14; PSP-RS: 0.49; p < 0.001), 
subthalamic nucleus (PSP-CBS: 0.21; PSP-RS: 0.40; p < 0.001) and cerebellar white 
matter (PSP-CBS: 0.02; PSP-RS: 0.06; p = 0.007 with borderline significance) was 
greater in the PSP-RS than in PSP-CBS (Figures 6-7).  
The presence of delayed initiation of horizontal saccades in PSP-CBS had a moderate 
correlation with an increased total parietal tau load (Spearman’s correlation 
coefficient=0.59; p < 0.001). However, other cortical features such as cortical sensory 
loss, alien limb phenomenon or hemisensory neglect did not correlate with the parietal 
tau load (p > 0.05) or other regional tau load.  
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Figure 6. Median regional tau load in PSP-CBS and PSP-RS. 
Quantitative data illustrating median regional tau load in PSP-RS (black) and PSP-
CBS (yellow) in fifteen selected brain regions. *= statistical significance adjusted for 
multiple comparisons, p < 0.0033 using the Mann-Whitney U test.  
PFG=posterior frontal grey matter; AFG=anterior frontal grey matter; 
AFWM=anterior frontal white matter; TG=temporal grey matter; TWM=temporal 
white matter; PG=parietal grey matter; PWM=parietal white matter; SN=substantia 
nigra; PONS=pons; CAUD=caudate; PUT=putamen; GP=globus pallidus; 
STN=subthalamic nucleus; DENT=dentate nucleus; CWM=cerebellar white matter.  
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Figure 7. Tau immunohistochemistry in selected brain regions. 
PSP-CBS has greater tau load in the posterior frontal and anterior frontal grey matter 
(GM) when compared with PSP-RS; whereas PSP-RS has greater tau load in the 
caudate and subthalamic nuclei than PSP-CBS. AT8 immunohistochemistry; scale bar 
in panel B=225microns in all the panels. 
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Total, cortical and basal ganglia tau load  
There was no difference in ‘total’ tau load between the PSP-CBS and PSP-RS groups 
(p = 0.176, Figure 8). However, PSP-CBS had an increased ‘cortical’ tau load when 
compared with PSP-RS (p < 0.001), and the ‘basal ganglia’ tau load was greater in 
PSP-RS than in PSP-CBS (p = 0.003; Figure 8).  
In five PSP-CBS cases, the half brains examined were contralateral to the side with the 
more predominant clinical symptoms and signs. The median ‘total’ and ‘cortical’ tau 
load were numerically, but not statistically, greater in these five cases (total tau load = 
5.3; cortical tau load = 1.4) compared to the remaining PSP-CBS cases (total tau 
load=4.0; cortical tau load=1.0). 
 
 
 
Figure 8. Total, cortical and basal ganglia tau load in PSP-CBS and PSP-RS. 
Total tau load is the same between the two groups, but PSP-CBS has greater cortical 
tau load and less basal ganglia tau load than PSP-RS. 
Mann-Whitney U test; Error bars represent 95% confidence interval. 
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Tau-positive cellular lesions 
In the posterior frontal cortical grey matter, all types of tau lesions were more 
numerous in PSP-CBS than in PSP-RS (NFTs, TAs, CBs and NTs: p < 0.001; PreTs: p 
= 0.005). In the anterior frontal grey matter, there were numerically, but not 
statistically, more NFTs, CBs and NTs in PSP-CBS than in PSP-RS (p > 0.01 in all). 
In the caudate, there were more TAs, NTs and NFTs in PSP-RS than in PSP-CBS 
(TAs and NTs: p < 0.001, NFTs: p = 0.01).  
Neuronal loss  
In the subthalamic nucleus, the median semi-quantitative rating score for neuronal loss 
was moderate (grade 2) and there was no difference between the two groups (χ2; p ≥ 
0.05). In the substantia nigra, neuronal loss was more severe in the dorsolateral (χ2; p = 
0.033) and ventrolateral (χ2; p = 0.018) subregions in PSP-RS than in PSP-CBS 
(Figure 9).  
 
 
Figure 9. Neuronal loss of substantia nigra in PSP-CBS and PSP-RS. 
Ventrolateral and dorsolateral subregions of the substantia nigra are relatively 
preserved from cell loss in PSP-CBS when compared with PSP-RS.  
Haematoxylin and eosin method; scale bar in panel B=1135microns in both panels. 
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Corticospinal tract involvement 
There was a more severe microglial response in the corticospinal tract in PSP-CBS, 
ranged from mild to severe, than in PSP-RS (χ2; p = 0.035, Figure 10). 
 
 
Figure 10. Microglial pathology in the corticospinal tract of PSP-CBS and PSP-RS. 
More severe microglial pathology in the corticospinal tract of the PSP-CBS group is 
identified when compared with the PSP-RS group. A semi-quantitative grading scale 
was used to characterise the severity of microglial pathology; grade 0=baseline 
microglial population; grade 1=mild microglial pathology; grade 2=moderate 
microglial pathology; grade 3=severe microglial pathology.  
73 
 
Additional pathologies 
The CERAD A plaque score ranged from ‘absent’ to ‘sparse’, except for two PSP-
CBS and one PSP-RS cases, which had a ‘moderate’ score (Mirra et al., 1991). Small 
vessel cerebrovascular disease was noted in 1 PSP-CBS and 1 PSP-RS case. Other 
additional pathological findings are summarised in Table 12.  
 
 
 PSP-CBS PSP-RS 
CERAD: Negative 
CERAD: Infrequent 
CERAD: Moderate   
CERAD: Frequent 
1 
7 
2 (cases 5, 7) 
0 
1 
8 
1 (case 15) 
0 
Argyrophilic grain disease 4 (cases 3, 5, 8, 9) 4 (cases 11, 14, 16, 18) 
Incidental Lewy body disease 1 (Braak stage 3) 0 
Cerebrovascular pathology 1 (mild) 1 (severe, case 19) 
Cerebral amyloid angiopathy 1 (mild) 0 
Table 12. Additional pathological findings of PSP-CBS and PSP-RS. 
CERAD=Consortium to Establish a Registry for Alzheimer’s disease   
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Tau biochemistry and haplotype analysis 
Western blots of the sarkosyl-insoluble tau fractions from the frontal cortical 
homogenates showed the characteristic doublet at 64 and 68 kDa, indicating 
predominant 4R tau in PSP-CBS, PSP-RS and CBD-CBS cases (Figure 11). PSP-CBS 
and PSP-RS showed a single band at ~33kDa, whereas CBD-CBS had a doublet at ~ 
37kDa, consistent with previous findings of the molecular differences in the low 
molecular weight proteolytic fragments between CBD and PSP (Arai et al., 2001). No 
association was identified between H1/H1 genotype and either of the two PSP 
subgroup (χ2 test; p = 0.21, Tables 7-10).   
 
 
Figure 11. Tau immunoblotting of CBD-CBS, PSP-CBS and PSP-RS. 
Western blot analysis of sarkosyl-insoluble tau from frontal cortex homogenates. The 
characteristic doublet of predominant 4R-tau in both CBD and PSP cases 
(arrowheads). CBD-CBS has a lower molecular weight doublet consisting of 
proteolytic fragments at ~37kDa (**). PSP-RS and PSP-CBS have a single band at 
~33kDa (*). Numbers on the left indicate positions of molecular weight markers (kDa). 
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Discussion 
The present study compared the morphological, biochemical and genetic 
characteristics of ten clinically well-characterised PSP-CBS cases and ten PSP-RS 
controls, matched for age and disease duration. Irrespective of the clinical presentation, 
all 20 included cases met established neuropathological diagnostic criteria of PSP, with 
the presence of 4R tau-positive neuronal and glial inclusions, including TAs in a 
characteristic distribution (Dickson et al., 2011, Hauw et al., 1994, Ince et al., 2008). 
Biochemical studies of sarkosyl insoluble tau confirmed 4R tau as the main protein 
species in both PSP-RS and PSP-CBS groups and the presence of a smaller, faster 
migrating carboxy-terminal fragment, which has been previously reported in PSP (Arai 
et al., 2001, Wray et al., 2008). No difference in the distribution of the H1/H1 and 
H1/H2 genotypes was identified between the two PSP groups.  
Morphometry was used to compare tau load, defined as the sum of all tau-positive 
lesions in the brain regions studied, between the two PSP groups and to determine the 
contribution of different neuronal and glial lesions to the overall tau pathology. A 
previous study at the Mayo Clinic established that PSP-CBS was associated with a 
greater tau burden in the mid-frontal and inferior-parietal cortices than in PSP-RS 
(Tsuboi et al., 2005). By including a larger number of cases and evaluating more brain 
regions, this study found increased tau load in the cortical regions predominantly in the 
posterior frontal grey matter, anterior frontal grey matter and parietal white matter in 
PSP-CBS, validating the findings reported by Tsuboi and colleagues. The inclusion of 
other non-cortical regions in the quantitative assessment of tau load enabled the 
identification of a lower tau load in the caudate, subthalamic nucleus and cerebellar 
white matter in the PSP-CBS variant. It is noteworthy that the increased cortical tau 
load in PSP-CBS is compensated by the lower basal ganglia tau load, resulting in the 
total tau load, determined as the sum of the all regional tau load, being similar in the 
two PSP groups.  
Increased cortical tau pathology has also been reported in PSP variants with clinical 
presentation of cortical symptoms, including PSP-PNFA (Josephs et al., 2005) and 
PSP-FTDbv (Hassan et al., 2012). Together with PSP-CBS, these clinical phenotypes 
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are collectively referred as the ‘cortical’ PSP variants (Dickson et al., 2010). On the 
other hand, PSP-P and PSP-PAGF, which are considered as the ‘brainstem’ variants of 
PSP, have less severe overall tau pathology when compared to PSP-RS (Ahmed et al., 
2008, Williams et al., 2007). Interestingly, these ‘brainstem’ variants are associated 
with a more benign disease course and a longer disease duration when compared to the 
classic PSP-RS (Ahmed et al., 2008, Williams et al., 2007, Williams et al., 2007). The 
mean disease duration of the PSP-CBS in this series was similar to that of PSP-RS as 
previously reported (Williams et al., 2005). It is plausible that the total tau pathology is 
inversely correlated with the disease duration in PSP variants. While the ‘brainstem’ 
PSP variant appears to be a more ‘benign’ form of PSP, the ‘cortical’ PSP variant 
represents a deviation from the classic presentation determined by a shift of tau 
pathology from the basal ganglia to the cerebral cortex. By selecting only cases with 
limited Alzheimer-type NFT pathology and assessing co-existing secondary 
pathologies, it is clear that the clinical presentation in the PSP-CBS cases was closely 
associated with the topographical severity of tau pathology which could not otherwise 
be explained by secondary pathologies. This study also showed that the regional 
differences in tau load between the two PSP groups were contributed by neuronal and 
glial lesions characteristic of PSP pathology rather than Alzheimer-related tau 
pathology (Oshima et al., 2009).  
A clinicopathological study from the Mayo Clinic compared the characteristics of CBS 
and RS clinical phenotypes in pathologically confirmed CBD cases (Kouri et al., 
2011). Their study on CBD also demonstrated significant differences in the 
topographical severity of tau pathology between the two CBD subtypes, which 
correlated with the different clinical presentations. Similar to the findings in the PSP-
CBS cases in the present series, their study showed that CBD-CBS had more severe 
tau deposition in the cortical regions and less severe tau pathology in the lower 
brainstem and cerebellum when compared to the CBD-RS cases. However, total tau 
load and the contribution by different neuronal and glial lesions to the tau pathology 
were not assessed (Kouri et al., 2011).  
The subthalamic nucleus is one of the regions characteristically targeted by the PSP 
disease process (Hardman et al., 1997, Hauw et al., 1994), while this nucleus is better 
preserved in cases with pathologically confirmed CBD. The extent of neuronal loss in 
77 
 
the subthalamic nucleus was similar in both PSP-CBS and PSP-RS groups. However, 
there was less tau pathology in the subthalamic nucleus in PSP-CBS than in PSP-RS, 
indicating that it was probably glial rather than neuronal tau lesions that have 
significantly contributed to the differences in regional tau load. The tau pathology in 
the subthalamic nucleus has also been reported to be less severe in other PSP variants 
such as PSP-PNFA (Josephs et al., 2005).  
In PSP, cell loss in the substantia nigra affects both the pigmented neurons of the pars 
compacta and non-pigmented neurons in the pars reticulata and neurons in the medial 
nigra are relatively preserved (Oyanagi et al., 2001). In the present study, neuronal loss 
was less severe in the ventrolateral and dorsolateral subregions in PSP-CBS when 
compared to PSP-RS (Figure 9). This regional difference may, in part, influence the 
clinical features due to the resulting selective damage to the dopaminergic and 
GABAergic neuronal nigral projections (Oyanagi et al., 2001).  
Pyramidal signs were documented in half of the PSP-CBS cases in the present series, 
but they were absent in the ten PSP-RS cases. Pyramidal signs are relatively 
uncommon in PSP and in one series they were present in only one fifth of all 
pathologically confirmed PSP cases (Williams et al., 2005). On the other hand, 60% of 
pathologically confirmed CBD cases had pyramidal signs (Tsuchiya et al., 2005). In 
CBD, the pathological involvement of the primary motor cortex including loss of Betz 
cells is a common finding, explaining the presence of pyramidal signs (Dickson et al., 
2010, Tsuchiya et al., 2005). The common occurrence of pyramidal signs in the 
present PSP-CBS series can be explained by the abundant tau pathology in the primary 
motor cortex, which was 12-fold greater in PSP-CBS than in PSP-RS. There was also 
more severe microglial pathology in the corticospinal tract in PSP-CBS than in PSP-
RS. Corticospinal tract degeneration and significant tau pathology in the motor cortex 
are prominent in globular glial tauopathy, previously referred as atypical PSP, which 
occasionally presents with a clinical picture of CBS (Ahmed et al., 2013). 
All PSP-CBS cases had received a final clinical diagnosis of CBS and they all had 
markedly asymmetrical cortical and extrapyramidal features, including unilateral limb 
clumsiness with a progressively maladroit and functionally useless hand. In the past, 
the presence of marked asymmetrical clinical signs would exclude the clinical 
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diagnosis of PSP, but this concept has been challenged in recent years with the 
findings of clinicopathological series confirming asymmetrical presentations in some 
PSP variants (Williams et al., 2005). A post-mortem report of a Japanese patient who 
had focal limb dystonia and levitation has identified significantly more tau pathologies 
in the frontal cortices, basal ganglia and brain stem in the contralateral half brain than 
the ipsilateral half brain (Oide et al., 2002). In the present PSP-CBS series, there was a 
numerically greater total tau load and cortical tau load in five cases where the 
contralateral half brain was available for evaluation when compared to the other five 
cases where the ipsilateral half brain was examined. However, this finding cannot 
confirm if tau load is greater in the clinically more manifested hemisphere within an 
individual as only half brains were used.  
Asymmetrical limb apraxia and delayed initiation of horizontal saccades are clinical 
features suggestive of underlying parietal lobe dysfunction and are characteristic signs 
in CBS (Vidailhet et al., 2000). The present data showed that regional tau load in the 
parietal white matter was five-fold greater in PSP-CBS than in PSP-RS and that PSP-
CBS patients who had delayed initiation of horizontal saccades also had greater 
regional tau load in the parietal cortex and white matter. 
Three patients had delayed initiation of horizontal saccades and, interestingly, half of 
them also had VSGP in the later stage of the illness, with involvement of downgaze, a 
diagnostic prerequisite for the diagnosis of PSP-RS (Lees, 1987, Rivaud-Pechoux et 
al., 2000). VSGP is rare in CBD with classic CBS presentation (CBD-CBS), and was 
noted in only 18% of cases in the Mayo Clinic series (Kouri et al., 2011) and was not 
observed in the QSBB series (Chapter 2). Six PSP-CBS patients had recurrent falls in 
the first year of their illness, whereas early falls were less frequent in CBD-CBS cases 
and were recorded in only 20% and 18% in the QSBB (Chapter 2) and Mayo Clinic 
series, respectively (Kouri et al., 2011). The findings of the present study support the 
postulation that early postural instability, falls and supranuclear downgaze palsy in 
patients with CBS are clinical clues which, when present, suggest an underlying PSP 
pathology even in the presence of clinical signs of CBS. Notably, three cases in the 
PSP-CBS group (cases 2, 7, 10) had a pure CBS presentation throughout the disease 
course and did not have any tell-tale signs of PSP. This is in concordance with 
clinicopathological evaluation of cases in the QSBB that some pathologically 
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confirmed PSP and CBD cases present with a pure clinical syndrome such as CBS or 
RS irrespective of the underlying pathology, whereas some cases manifest overlap 
clinical features such as RS or CBS at the same time and occasionally, the clinical 
syndromes temporally evolve from one to another throughout the disease course as 
previously described (Kertesz et al., 2005).   
Conclusion 
Data from transgenic animal studies indicate that soluble rather than fully aggregated 
tau species may ultimately be responsible for neuronal degeneration and cell death. 
However, the findings in this study support the notion that neuronal and glial 
inclusions composed of fibrillar pathological tau are useful and clinically valid 
pathological markers of the underlying neurodegenerative process. This study has 
provided comprehensive evidence that the topographical severity of tau pathology in 
PSP is closely associated with its clinical manifestation (Ahmed et al., 2008, Hassan et 
al., 2012, Josephs et al., 2005, Williams et al., 2007, Williams et al., 2007). This is 
comparable to the findings in Alzheimer’s disease where cognitive deficit shows a far 
better correlation with tau lesions than with A plaques (Bennett et al., 2004). A better 
understanding of the factors that influence the selective pathological vulnerability in 
different PSP variants will provide further insights into the underlying mechanistic 
pathways.  
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Chapter 4:  Hypokinesia without 
decrement distinguishes progressive 
supranuclear palsy from Parkinson’s 
disease 
Introduction 
Bradykinesia is a sine qua non for the diagnosis of Parkinson’s disease. In clinical 
practice, the term bradykinesia is often used interchangeably with the terms akinesia 
and hypokinesia. Nevertheless, bradykinesia literally describes slowness in 
movements, akinesia means absence or poverty of expected spontaneous voluntary 
movement including slow reaction time (Golbe et al., 2007), and hypokinesia refers to 
small amplitude movements. Bradykinesia, akinesia and hypokinesia are closely 
related but not necessarily well correlated in individual patients and each component of 
motor abnormality probably has a different underlying mechanism (Berardelli et al., 
2001). Both bradykinesia and hypokinesia in Parkinson’s disease improve with 
levodopa therapy whereas reaction time is thought to be related to non-dopaminergic 
deficit (Berardelli et al., 1986, Jahanshahi et al., 1992, Velasco et al., 1973). 
Bradykinesia is explicitly defined in the QSBB criteria for the diagnosis of Parkinson’s 
disease as ‘slowness of initiation of voluntary movement with progressive reduction in 
speed and amplitude of repetitive action’ (Gibb et al., 1988). The term sequence effect 
is used to describe the progressive reduction in amplitude and speed of sequential 
movements which is a key feature of Parkinson’s disease. If the amplitude and speed 
of sequential movements progressively decline until the movement ceases, this is 
known as motor arrest (Iansek et al., 2006, Kim et al., 1998, Marsden, 1989). The 
pathophysiology and levodopa response of the sequence effect are unclear. 
This study investigates whether bradykinesia, as defined above, is also a feature of 
PSP. PSP is characterised by VSGP, early gait instability with falls characteristically in 
a backwards direction, axial rigidity and bulbar dysfunction. In the seminal paper with 
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descriptions of the nine original PSP cases, Richardson and his colleagues provided 
brief accounts of elements of bradykinesia in only two cases, one of whom had 
slowness in walking and the other had awkwardness in performing rapid repetitive 
movements (Steele et al., 1964). As a consequence of their findings, the authors 
concluded that PSP was a distinct clinicopathological entity which was unlikely to be 
confused with Parkinson’s disease. However, much of the more recent literature 
closely links bradykinesia and parkinsonism with PSP and many movement disorder 
specialists consider PSP to be an example of atypical parkinsonism. In two large post-
mortem series, early bradykinesia was reported in 88% and 75% of patients with 
pathologically confirmed PSP (Litvan et al., 1996, Williams et al., 2005). In line with 
this view, about 6% of cases with a clinical diagnosis of Parkinson’s disease turn out to 
have tau pathology compatible with PSP at post-mortem examination (Hughes et al., 
2002). These and other findings (Morris et al., 2002) have led to the delineation of two 
common clinical phenotypes: classical PSP-RS and PSP-P (Williams et al., 2005). 
PSP-P closely resembles Parkinson’s disease and is characterised by asymmetric 
symptoms at onset, tremor and a moderate initial therapeutic levodopa response.  
Nevertheless, it is unclear whether the movement disorder described in the above 
literature adheres to the QSBB definition of bradykinesia. Clinical observations 
suggest that most PSP patients do not exhibit slowness or progressive reduction in 
amplitude and speed during finger tapping or handwriting.  
Micrographia or small handwriting was first noted by Pick in 1903 (Pick, 1903) and 
has been associated with focal cerebral lesions (Derkinderen et al., 2002, Kim et al., 
2005, Kuoppamaki et al., 2005, Pick, 1903, Scolding et al., 1994), postencephalitic 
parkinsonism (Snowden et al., 2012), Parkinson’s disease (McLennan et al., 1972) and 
Huntington’s disease (Iwasaki et al., 1999). Micrographia characterised by small 
handwriting with further progressive reduction in size can be observed in 15% of 
patients with Parkinson’s disease (McLennan et al., 1972). The relationship between 
micrographia and bradykinesia remains controversial (McLennan et al., 1972). It is 
also not known if the handwriting in Parkinson’s disease differs from PSP.   
This study investigated differences in the form of bradykinesia and handwriting 
between Parkinson’s disease and PSP. Importantly, repetitive finger tap movements 
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were objectively studied. Repetitive finger tapping was selected as it is more severely 
impaired in patients with Parkinson’s disease than hand opening and closing and hand 
pronation and supination elements of the motor section of Part III of the Unified 
Parkinson’s Disease Rating Scale (UPDRS)(Agostino et al., 1998, Agostino et al., 
2003). Both finger tapping and writing are simple and commonly used bedside 
assessments and any distinctive features identified for each condition would provide 
helpful diagnostic clinical clues.  
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Materials and methods 
Participants 
Fifteen patients with Parkinson’s disease, nine with PSP and 16 healthy controls, 
matched for age range and gender, participated in this study (Table 13). Patients were 
recruited from the movement disorder clinic in the National Hospital for Neurology 
and Neurosurgery, Queen Square, London, United Kingdom. All patients with 
Parkinson’s disease fulfilled the United Kingdom QSBB diagnostic criteria (Hughes et 
al., 1992). All patients with PSP fulfilled the National Institutes of Neurological 
Disorders and Stroke (NINDS) Society for PSP diagnostic criteria (Litvan et al., 
1996). Parkinson’s disease patients were included in the study if they were taking 
levodopa treatment with predictable motor fluctuations but were excluded if they had 
hand dystonia or if their tremor or dyskinesia were severe enough to interfere with 
their motor performance in the experiments. Exclusion criteria which applied to all 
subjects included significant medical co-morbidity, cognitive impairment (Mini 
Mental State Examination score < 28), depression (Beck depression score ≥ 21)(Beck 
et al., 1961) and disabilities that might restrict finger movements. All participants were 
assessed by the Edinburgh Handedness Inventory (Oldfield, 1971). The UPDRS was 
performed in all patients (Fahn et al., 1987). The PSP Rating Scale (Golbe et al., 2007) 
and the Frontal Assessment Battery (FAB)(Dubois et al., 2000) were performed in 
patients with PSP. Patients’ daily intake of anti-parkinsonian medications including 
levodopa, dopamine agonist, monoamine oxidase type B inhibitor, catechol-O-methyl 
transferase inhibitor and amantadine was recorded. Total daily levodopa equivalent 
dose (LED) was calculated for each patient according to published conversion 
formulae (Tomlinson et al., 2010). The study was conducted with the understanding 
and written consent of all participants and was approved by the Camden and Islington 
Community Research Ethics Committee of the National Research Ethics Service.  
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 Controls 
(N=16) 
PSP      
(N=9) 
PD      
(N=15) 
P-value 
Age, years 
Gender 
 
Handedness 
 
Edinburgh handedness 
inventory 
 
Disease duration, years 
 
Total daily levodopa 
equivalent dose 
(mg/day) 
68.9±4.5  
9M : 7F 
13R : 3L 
61.9±56.4 
NA 
NA 
70.9±8.3  
5M : 4F 
7R : 2L 
55.6±77.3 
4.5±3.3  
255.6±194.4  
65.0±9.2  
9M : 6F 
14R : 1L 
78.0±50.9 
10.8±7.4 
  874.8±323.9 
0.14** 
0.97
$
 
0.51
$
 
0.62** 
0.01* 
<0.001* 
UPDRS NA I=NA 
II-ON=NA 
II-OFF=NA 
III-ON=NA 
III-OFF= 
41.6±14 
IV=NA 
I=3.1±2.5 
II-ON=7.7±3.9 
II-OFF=17.2±9 
III-ON=24.4±9 
III-OFF= 
36.3±9.7 
IV=6.7±4.3 
NA 
H&Y-ON 
H&Y-OFF 
NA NA 2.1±0.4 
2.8±0.6 
NA 
PSP rating scale 
NA 39.4±2.4 NA NA 
Frontal assessment 
battery 
NA 14.4±2.4 NA NA 
Table 13. Features of control, PSP and PD groups. 
*=Student t-test; **=ANOVA; $= χ2 test; NA=not applicable; UPDRS=Unified 
Parkinson’s Disease Rating Scale 
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Finger tapping task 
Participants were instructed to repeatedly tap their index finger and thumb as rapidly 
and as widely as possible for 15 seconds. The participants were instructed to relax the 
3
rd
, 4
th
 and 5
th
 digits in a semi-extended position so that the index finger-thumb 
movements were not restricted. The beginning and the end of the 15-second finger-
tapping trial were signalled by a buzzer. Infrared-emitting diodes were fixed to eight 
designated regions on digits and the back of the hand, and motion was recorded in 3D 
(Coda Cx1, Charnwood Dynamics, Rothley, UK; Figure 12). Three 15-second trials 
were performed consecutively by each hand with 60 seconds rest in-between. Hand 
order was pseudo-randomised across participants. Parkinson’s disease patients were 
tested during ‘OFF’ in the morning after 12 hours of overnight withdrawal of levodopa 
therapy, followed by a second experiment during ‘ON’ in the afternoon one hour after 
taking levodopa. Only two PSP patients were receiving levodopa treatment and both 
underwent overnight withdrawal of medication for 12 hours prior to testing.  
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Figure 12. Key parameters measured and infrared-emitting diodes. 
Motion was recorded in 3D (Coda) and key parameters were measured for each cycle 
of finger tap. Infrared-emitting diodes fixed to eight designated regions. 
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Handwriting task 
Handwriting task was performed after the tapping experiments by all participants and 
was repeated during ‘ON’ by Parkinson’s disease patients. The participant was asked 
to copy three times a standardized print of Times New Roman, 34 font size, eleven-
word sentence on unlined A4 paper (Figure 13). No instructions were provided to the 
participants regarding the required size or speed of their script. The letters ‘a’ in the 
third (W3) and tenth words (W10) were selected and measurements were obtained 
using Microsoft Paint® programme. The script size (cm
2
) of the selected letter was 
determined by the product of height and width outlined by the upper, lower, left and 
right margins of the loop in the letter. The size of W3 and W10 were plotted separately 
against successive sentence trials (1 to 3). Progressive reduction in size was 
represented by two slopes of the fitted linear regression line across the scatter-plots: 
script slope 1 from W3 and script slope 2 from W10. 
 
 
 
Figure 13. Example of handwriting task. 
Handwriting performed by a healthy 65-year-old female. Mean script size=0.86cm
2
, 
slope 1=0.28, slope 2=-0.06.  
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Kinematic parameters 
Amplitude (mm), cycle duration (ms) and mean speed (mm/s) were measured for each 
cycle of finger tap from one finger-thumb separation to the next (Figure 12) using 
custom scripts written in Matlab. Mean speed, designed to be sensitive to both 
amplitude and cycle duration, was the mean rate of change in aperture regardless of 
whether the aperture was opening or closing. Thus, mean speed decreased when the 
cycle duration increased independently of amplitude, when amplitude decreased 
independently of duration, and when both occurred simultaneously. If amplitude 
increased at the expense of cycle duration, or vice versa, the mean speed tended to stay 
constant. Close and open velocities (mm/s) were the peak velocities of aperture closure 
and opening within a cycle. To eliminate potential confounding factors of different 
hand size and finger length across participants, distance (mm) measured was converted 
into the degree (deg) of angle separation between index finger and thumb. The 
conversion was obtained by the product of distance (mm) and k-value (deg/mm), 
calculated by the linear regression slope of maximum finger-thumb separation angle 
against maximum finger-thumb separation distance of each hand of the participant. 
The separation angle was calculated as the angle between the straight line segments 
joining the index fingertip marker and the thumb marker to the marker placed at 
marker 3.  
Progressive changes in amplitude, duration and speed across a 15-second finger tap 
trial were represented by the slope of the fitted linear regression line across the scatter-
plot of the kinematic parameter against the tap cycle. The slope of change in amplitude 
was used to assess progressive hypokinesia or ‘decrement’. The slope of change in 
speed which encompassed both amplitude and duration was used to assess progressive 
slowing of movement or ‘fatigue’ (Figure 15). Measurement of regularity of amplitude 
and speed across a tap trial was represented by the coefficient of variation (CV) which 
was computed by the residual standard deviation about the linear regression line 
divided by the mean value. High amplitude or speed CV values represent irregularities 
of these kinematic parameters.  
Group parameters including amplitude, cycle duration, maximum close velocity, 
maximum open velocity, mean speed, slopes and CVs were summarized by computing 
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the mean parameter value for all tap cycles across three finger tap trials of both hands 
for all subjects.  
Statistical analysis 
Comparisons of continuous variables were carried out by univariate Analysis of 
Variance (ANOVA) with gender, age and disease duration as covariates. Student t-test 
was used to compare disease duration and total daily levodopa equivalent dose 
between the two patient groups. Tukey HSD post-hoc analysis was used to determine 
differences between groups (controls, PD-OFF and PSP). Paired t-tests were used to 
compare variables of Parkinson’s disease patients in ON vs. OFF states. χ2 test was 
used for discreet variables. Spearman’s correlation was used to study correlation 
between group parameters and clinimetric scores. Statistical significance was 
determined when p ≤ 0.05. SPSS version 17.0 was used for statistical analysis.  
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Figure 14. Kinemetric parameters during 15-s finger tap trials. 
Kinematic parameters during the first 15-second right finger tap trial in a patient with 
Parkinson’s disease during ‘OFF’, represented by red and circle plots (UPDRS-III-
OFF=32), and a patient with PSP, represented by blue and triangle plots (UPDRS-III 
=69; Frontal assessment battery=14).  
The slopes (S) for amplitude, duration and speed, and coefficient of variation (CV) for 
speed are shown. Lack of decrement and fatigue in PSP is reflected by the positive 
amplitude slope and speed slope. The speed CV in Parkinson’s disease is three times 
greater than PSP, suggesting high irregularity in speed. 
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Results 
The demographic features and clinimetric scores are listed in Table 13. Age was 
closely matched between groups. There were slightly more male participants compared 
to female in each group and the majority of participants were right-handed. All the 
patients with Parkinson’s disease were receiving dopamine replacement therapies and 
all of them had derived good or excellent sustained therapeutic benefit. There were 
significant improvements in the Parkinson’s disease patients’ UPDRS-II, UPDRS-III, 
Hoehn and Yahr (H&Y) scores one hour after taking levodopa (OFF Vs. ON; p < 
0.001 in all). The mean total daily levodopa equivalent dose in Parkinson’s disease 
was greater than that of PSP (t-test, p < 0.001). Eight PSP patients were taking 
amantadine but only two were receiving levodopa therapy. The PSP patients who were 
not receiving levodopa had failed to respond to levodopa and had a negative 
therapeutic response to an acute levodopa challenge (Steiger et al., 1992).  
Five of nine PSP patients had had evidence of midbrain atrophy on their most recent 
MRI. One PSP patient died six months after participating in this study and his 
pathological diagnosis was confirmed to be PSP at post-mortem. The mean disease 
duration in Parkinson’s disease was longer than in PSP (t-test, p = 0.01).   
The mean bradykinesia subscore, which included the sum of UPDRS motor scores for 
finger tap, hand opening and pronation/supination movements, also improved after 
levodopa therapy (OFF: 2.06 ± 0.54; ON: 1.76 ± 0.66; paired t-test, p = 0.009).  
Repetitive finger tap movements 
Spatial and temporal variables (amplitude, duration, peak velocities and mean speed) 
were measured for each tap cycle and used to characterise different aspects of motor 
performance (Figure 14). The analyses focused on mean performance, progressive 
changes in performance (slope of linear regression line of variable against cycle 
number), and regularity of performance (coefficient of variation; CV) achieved over a 
15-s trial. As shown in Table 14, one-way ANOVA revealed significant differences 
between the three groups for all measures apart from slope of cycle duration. In the 
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following sub-sections, post-hoc analyses are used to study these group differences in 
order to describe the important performance characteristics of each group in turn. 
Healthy subjects 
Linear regression analysis did not show a significant correlation of any performance 
variables with age or gender. There was a modest effect of hand dominance in that 
mean cycle duration was longer for the non-dominant hand (dominant hand: 289.38 ± 
64.6ms; non-dominant hand: 302.23 ± 67.5ms; p = 0.003) but no other performance 
parameters differed between the two hands.  
The slope of the dominant hand’s mean speed was significantly more negative in the 
third trial compared to the first (trial 1 speed slope = -1.03deg/s/cycle; trial 3 speed 
slope=-1.46deg/s/cycle; p = 0.043), indicating an increase in physiological fatigue. All 
other parameters showed a similar, but non-significant, slight decline in performance 
in progressive trials.  
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 Controls 
(N=16) 
PSP     
(N=9) 
PD-OFF 
(N=15) 
F(1,19) P-value 
Average no. of 
tap cycles / 15s 
50.0(10.7) 52.2(10.3) 41.5(9.7) 8.5 0.009* 
Average 
parameters 
 
Amplitude (º) 
Duration (ms) 
Close velocity (º/s) 
Open velocity (º/s) 
Speed (º/s) 
45.9(8.7) 
295.8(65.6) 
928.2(215.2) 
788.9(167.9) 
330.1(64.6) 
18.7(6.3) 
288.3(67.7) 
386.3(134.4) 
327.7(106.1) 
142.9(49.8) 
37.8(916.0) 
356.5(80.6) 
737.5(385.0) 
584.4(297.0) 
224.1(93.1) 
18.5 
7.8 
11.4 
10.3 
8.3 
< 0.001* 
0.012* 
0.003* 
0.005* 
0.009* 
Average 
coefficients of 
variations 
 
 
Amplitude 
Duration 
Speed 
0.09(0.03) 
0.09(0.03) 
0.09(0.02) 
0.27(0.13) 
0.28(0.18) 
0.236(0.9) 
0.41(0.08) 
0.17(0.10) 
0.167(0.06) 
9.69 
4.26 
6.88 
0.006* 
< 0.001* 
0.017* 
Average slopes 
values 
 
Amplitude slope 
(º/cycle) 
Duration slope 
(s/cycle) 
Speed slope 
(º/s/cycle) 
-0.12(0.12) 
0.77(0.75) 
-1.52(0.81) 
0.01(0.17) 
1.86(2.58) 
-0.39(0.79) 
-0.20(0.21) 
1.49(2.39) 
-1.71(1.59) 
4.45 
0.16 
7.81 
0.048* 
0.70 
0.012* 
Table 14. Comparison of parameter measurements. 
Mean parameter measurements (SD) of control, PD-OFF and PSP subgroups and p-
values from one-way ANOVA adjusting for age, gender and duration. Covariates 
appearing in the model above are evaluated at the following values: gender=0.58 (0-
female; 1-male), age=67.87 years, disease duration=8.43 years; F(degrees of 
freedom)=f value from one-way ANOVA; *=p < 0.05 by one-way ANOVA 
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Figure 15. Comparison of key parameters between groups. 
a. Mean amplitude, duration and speed of controls, PSP and PD-OFF and p values by 
post-hoc analysis. Error bars represent 95% confidence intervals. *=p < 0.05 
indicates statistical significance and #=p: 0.05-0.10 indicates borderline significance 
by Tukey HSD post-hoc analysis.  
b. Mean slope values for amplitude, duration and speed of controls, PSP and PD-OFF 
and p values by post-hoc analysis. Error bars represent 95% confidence intervals. 
Dotted reference lines represent zero, values below which represent progressive 
downward negative slope across the 15-second finger tap trial. *=p < 0.05 indicates 
statistical significance and #=p = 0.05-0.10 indicates borderline significance by Tukey 
HSD post-hoc analysis. 
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Patients with PSP 
The performance of patients with PSP was characterised by strikingly small 
amplitudes of finger-thumb separation distance with a lack of performance decrement 
during a trial and with excessive variability of performance between cycles. 
The small mean amplitude in PSP (mean = 18.65deg) was less than half that of healthy 
subjects (mean = 45.91deg) and PD-OFF (mean = 37.82deg; p < 0.001 in both cases; 
Table 14 & Figure 15a). The amplitude slope in PSP had a positive value of 
0.01deg/cycle, indicating a lack of amplitude decrement throughout the 15-second 
finger tap trial. This value differed significantly from the negative slope in PD-OFF (p 
= 0.002; Table 14 & Figure 15b). The possibility that the very small tapping amplitude 
in PSP as a group might have masked the detection of small degree of decrement was 
further explored. After adjusting for mean amplitude, there was no difference in 
amplitude slope between PSP and controls, indicating an absence of decrement in PSP 
(p = 0.36, Table 15).  
A greater number of tap cycles were achieved by patients with PSP during a 15s trial 
(mean=52.22 cycles) when compared to PD-OFF (mean = 41.54 cycles; p = 0.046), 
but not controls (50.03 cycles; Table 14).  
Although PSP cycle duration was normal, the markedly reduced amplitude led to an 
overall reduction in close and open velocities and mean speed in PSP when compared 
to PD-OFF (close velocity: p = 0.01; open velocity: p = 0.02; mean speed: p = 0.04) 
and controls (p < 0.001 in all; Table 14 & Figure 15a). This probably does not indicate 
an intrinsic slowing of movement as such, but simply stems from the digits moving 
through a smaller amplitude with approximately the same cycle duration. 
In PSP, there was greater variability of performance from one cycle to the next as 
reflected in the highest CV values. They were greater than control for amplitude CV, 
cycle duration CV and mean speed CV (p < 0.001 in all cases) and were also greater 
than PD-OFF for amplitude CV (p = 0.001) and mean speed CV (p = 0.009). 
Among the PSP group, there was no correlation between mean amplitude and clinical 
markers of disease severity including disease duration (p = 0.40), total daily levodopa 
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equivalent dose (p = 0.72), UPDRS motor score (p = 0.64), H&Y (p = 0.57), PSP 
staging (p = 0.40) or Frontal Assessment Battery scores (p = 0.15). There was a 
positive correlation between the number of tap cycles/15-second and the FAB score in 
PSP (Spearman’s coefficients: 0.64; p = 0.04). 
 PD-OFF vs. Control PSP vs. Control PSP vs. PD-OFF 
 F (1, 26) P values F (1, 20) P values F (1, 18) P values 
Amplitude slope 
(adjusted for 
mean amplitude)  
4.41 0.046* 0.88 0.36 4.45 0.048* 
Duration slope 
(adjusted for 
mean duration) 
0.47 0.501 3.75 0.067# 3.20 0.09# 
Speed slope 
(adjusted for 
mean speed) 
2.89 0.070# 1.70 0.208 3.33 0.085# 
Table 15. Comparison of slope values between groups. 
Comparison of slope values between PD-OFF, PSP and controls after adjusting for 
mean amplitude, duration and speed respectively. General linear model univariate 
analysis (*=significant, p < 0.05, #=borderline significant, p = 0.05-0.10); F (degrees 
of freedom) = f value from univariate analysis of variance. 
Covariates appearing in the model PD-OFF vs. controls are evaluated at the following 
values: gender=0.58 (0=female; 1=male), age=66.99 years, mean amplitude for 
amplitude slope model=42.34 deg, mean duration for duration slope model=325.18s, 
mean speed for speed slope model=278.81deg/s. 
Covariates appearing in the model PSP vs. controls are evaluated at the following 
values: gender=0.56 (0=female; 1=male), age=69.6 years, mean amplitude for 
amplitude slope model=36.09 deg, mean duration for duration slope model=293.12s, 
mean speed for speed slope model=262.73deg/s. 
Covariates appearing in the model PSP vs. PD-OFF are evaluated at the following 
values: gender=0.58 (0=female; 1=male), age=67.19 years, disease duration = 8.43 
years, mean amplitude for amplitude slope model=31.08 deg, mean duration for 
duration slope model=330.95s, mean speed for speed slope model=193.64deg/s.   
97 
 
Patients with Parkinson’s disease 
When compared with controls, the main finding in PD-OFF was slowness of 
movement coupled with greater variability of speed between tap cycles. When 
compared with PSP, PD-OFF exhibited larger amplitude movements, a smaller number 
of tap cycles and greater decrement of performance during a trial. 
PD-OFF amplitude (p = 0.10) tended to be smaller than that in healthy subjects while 
cycle duration (p = 0.06) tended to be more prolonged, but only with borderline 
significance. However, the combination of both these trends led to a highly significant 
lower mean speed of PD-OFF compared with controls (p = 0.001; Figure 15). 
Similarly, peak open velocity of PD-OFF was less than controls (p = 0.033), although 
there was no difference in peak close velocity between the two groups. In addition, CV 
of mean speed in PD-OFF was significantly greater than that of controls (p = 0.004), 
suggesting proportionally greater irregularities between cycles.  
Both amplitude and speed slopes in PD-OFF, reflecting the progressive decrement in 
performance, were more strongly negative when compared to those of PSP (amplitude: 
p = 0.002; mean speed: p = 0.028). However, the negative amplitude and speed slopes 
of PD-OFF, were numerically, but not significantly, greater than healthy subjects. In 
Parkinson’s disease patients with severe parkinsonism, slope measurements may be 
underestimated due to poor performance during the tap trial, rendering their slope 
values lower than patients with milder disease severity who do not exhibit a ‘floor’ 
effect. After adjusting for differences in mean amplitude, the amplitude slope in PD-
OFF became significantly more strongly negative than PSP and healthy controls (PD-
OFF vs. PSP, p = 0.048; PD-OFF vs. controls, p = 0.046, Table 15). There was a trend 
for a more negative speed slope in PD-OFF when compared to controls after adjusting 
for mean speed (p = 0.07, Table 15). These findings demonstrate progressive 
decrement in performance in PD-OFF and represents sequence effect in Parkinson’s 
disease. 
The UPDRS-III-OFF score was correlated with small amplitude (Spearman’s 
coefficient: -0.79, p < 0.001), slow mean speed (Spearman’s coefficient: -0.68, p = 
0.005) and high irregularities in speed (Spearman’s coefficient: 0.75, p = 0.001; Figure 
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16). There was no correlation between performance decrement, i.e. slopes for 
amplitude and speed, and disease duration, total daily levodopa equivalent dose, 
UPDRS motor scores or H&Y (p > 0.05 in all cases). 
Levodopa therapy improved the total number of tap cycles (OFF = 41.5cycles/15s ± 
9.7; ON = 45.9cycles/15s ± 9.5, p = 0.04), peak open velocity (OFF = 584.4deg/s ± 
297.0; ON = 639.9deg/s ± 269.0; p = 0.04), mean speed (OFF = 224.1deg/s ± 93.1; ON 
= 255.6deg/s ± 86.4; p = 0.006) and speed CV (OFF = 0.167 ± 0.07; ON = 0.150 ± 
0.08; p = 0.014). However, levodopa therapy did not significantly improve 
performance decrement (amplitude slope: OFF = -0.20deg/cycle ± 2.1; ON = -
0.17deg/cycle ± 2.1; speed slope: OFF = -1.71deg/s/cycle ± 1.6; ON = -
1.78deg/s/cycle ± 1.4).  
When analysis of the effect of levodopa was limited to the Parkinson’s disease 
patients’ more affected hand, more robust ON vs. OFF differences were observed. In 
addition to the improvements described above, improvement was also observed in 
mean cycle duration (OFF = 370.8ms ± 103.6; ON = 321.1ms ± 93.2; p = 0.005) and 
there was a trend towards improvement in performance decrement (amplitude slope: 
OFF = -0.20deg/cycle; ON = -0.15deg/cycle; p = 0.07).  
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Figure 16. Correlations between UPDRS motor scores and finger tap parameters. 
Among PD-OFF subgroup, a more severe UPDRS-III-OFF score was correlated with 
smaller mean amplitude, slower mean speed and greater variability in speed. 
Deg=degree; CoV=coefficient of variation; UPDRS=Unified Parkinson’s Disease 
Rating Scale. 
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Hypokinesia without decrement 
Each 15-second finger tap trials in the PSP and PD-OFF groups were analysed. 
Hypokinesia was defined as a mean amplitude of <23deg, i.e. 50% of the control 
group’s mean amplitude. Hypokinesia was observed in 70% of the finger tap trials in 
the PSP group, 24% in the PD-OFF group and 2% of the control group. The remaining 
30% of the PSP finger tap trials had a small mean amplitude of 27.8deg ±3.7 and a 
positive mean amplitude slope of 0.05deg/cycle. The 24% of PD-OFF finger tap trials 
with hypokinesia were performed by a small group of four Parkinson’s disease patients 
who had severe parkinsonism with a mean UPDRS-III-OFF score of 46.4 and a long 
mean disease duration of 17.5 years. All four patients had good levodopa response and 
an average improvement in UPDRS motor score by 14.3 one hour after intake of 
levodopa therapy. Despite severe hypokinesia with a mean amplitude of 11.4deg ± 5.6, 
decrement was still evident with a negative mean amplitude slope of -0.037deg/cycle ± 
0.1 (vs. control, p = 0.05). When lack of decrement, defined as a positive amplitude 
slope, was combined with hypokinesia, 87% of finger tap trials in the PSP group, 12% 
in the PD-OFF group and none in the control group were noted to exhibit both 
features.  
Handwriting in Parkinson’s disease and PSP 
The scripts from one PSP and two Parkinson’s disease patients were discarded from 
the analysis as they were written in capital letters. The mean script size of PSP 
(0.50cm
2 
± 0.46) was numerically, but not statistically, smaller than PD-OFF (0.78cm
2 
± 0.38; p = 0.29) and controls (0.79cm
2 
± 0.20; p = 0.07). Progressive changes in script 
size were assessed from the slopes of the linear regression lines separately fitted for 
W3 (script slope 1) and W11 (script slope 2) across the three successive sentences. 
There was less of a decrement over successive sentences for W11 in PSP (mean script 
slope 2; 0.06 ± 0.09) than in PD-OFF (-0.08 ± 0.30) after adjusting for age, gender, 
disease duration and mean script size (p = 0.02). A similar trend was found in mean 
script slope 1 (PSP: -0.004 ± 0.21; PD-OFF: -0.103 ± 0.21; p = 0.16). After levodopa 
therapy, six Parkinson’s disease patients exhibited a mean increase of 0.26cm2 in script 
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size, however, the overall script size did not achieve statistical significance between 
PD-OFF and PD-ON (p = 0.28, Figure 17). Decrements in script size persisted in 
Parkinson’s disease patients despite levodopa therapy as shown by the negative script 
slope 1 (OFF: -0.10, ON: -0.05; p = 0.48) and script slope 2 (OFF: -0.08, ON: -0.09; p 
= 0.82).  
Micrographia was determined as present when the mean script size was less than 
0.40cm
2
, i.e. half the mean script size of the control group, and the lack of progressive 
micrographia was defined by a positive mean script slope. Micrographia was more 
frequent in PSP (N=6, 75%) than in PD-OFF (N=2, 15.4%, p = 0.01) and control 
(N=1, 6.3%; p = 0.001) subjects. The script size numerically improved in the two 
Parkinson’s disease patients with micrographia but their ON script size still did not 
exceed 0.40cm
2
. A positive script slope 2 was more frequent in PSP (N=5, 62.5%) than 
in control (N=1, 6.3%; p = 0.007) and, possibly, in PD-OFF (N=3, 23.1%; p = 0.09) 
subjects. A positive script slope 1 was more frequent in PSP (N=6, 75%) than in PD-
OFF patients (N=3, 23.1%; p = 0.03), but it did not differ from control subjects (N = 8, 
50%; p = 0.23).  The patients with the smallest script size in the PSP and PD-OFF 
were also noted to have the most severe UPDRS-III score in their group (smallest 
script size in PSP = 0.14cm
2
, UPDRS-III = 69, Figure 17; smallest script size in PD-
OFF = 0.11 cm
2
, UPDRS-II I= 50).  
There were more PSP patients (N=5, 62.5%) who had both hypokinesia (< 23deg) and 
micrographia (< 0.40cm
2
) than controls (0; p = 0.001) and PD-OFF (N=1, 7.7%, p = 
0.014). In PSP, the finger tap amplitude slope was strongly correlated with script slope 
2 (Spearman’s coefficient = 0.88, p = 0.004). No correlation was found between script 
findings and markers of disease severity in either Parkinson’s disease or PSP groups.  
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Figure 17. Handwriting in PD and PSP. 
PD: Handwriting performed by a 58-year-old right-handed patient with PD during 
‘OFF’ (UPDRS=18, mean script size=0.66cm2, slope 1=-0.01, slope 2=-0.16) and 
‘ON’ (UPDRS=13, mean script size=1.14cm2, slope 1=-0.08, slope 2=-0.46). 
PSP: Example of microscopic micrographia by a patient with advanced PSP who had 
the smallest script size in the PSP group (UPDRS-III=69, mean script size=0.14cm
2
, 
slope 1=0.23, slope 2=-0.01). UPDRS=Unified Parkinson’s Disease Rating Scale. 
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Discussion 
Bradykinesia in Parkinson’s disease 
This study captured objective recordings of the sequence effect during repetitive finger 
tap movements and found that a progressive decrement in amplitude was present in 
Parkinson’s disease but not in PSP. This study confirmed that the characteristic finger 
tap pattern in Parkinson’s disease consists of slowness with variability in speed and 
progressive decrement in performance (Agostino et al., 1998, Agostino et al., 1994). 
Although levodopa improved most tapping parameters in Parkinson’s disease, it did 
not improve the sequence effect of progressive deterioration in cycle duration and 
speed. However, there was a borderline improvement in decrement in treated 
Parkinson’s disease when only the more affected hand was studied. The findings 
indicated that the sequence effect in Parkinson’s disease may be relatively independent 
of dopaminergic regulation. A recent study using a Modified Purdue Pegboard Test 
showed that sequence effect in Parkinson’s disease did not respond to levodopa 
medication (Kang et al., 2010). In another study, reduced stride length (hypokinesia) 
improved with either levodopa or visual cues, but the progressive reduction of stride 
length (sequence effect) only improved with cueing (Iansek et al., 2006). The present 
study showed that the variability of speed was significantly greater in PD-OFF when 
compared to controls, and that it improved with levodopa therapy, suggesting that the 
mechanisms underlying the temporal regularity of movements and the sequence effect 
are likely to be different. 
Hypokinesia without decrement in PSP 
The most striking finding in the present study was the very small index finger-to-
thumb separation amplitude during repetitive finger tapping in PSP. The average 
amplitude of finger separation in PSP was less than half of that in controls and PD-
OFF. PSP patients also had a greater number of tap cycles and higher variability in 
amplitude and speed when compared to PD-OFF. The greater number of tap cycles 
was most probably related to the small amplitude as the digits moved through a smaller 
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distance allowing more cycles to be performed within a given time. While small 
amplitude in PD-OFF was correlated with more severe UPDRS motor score, there was 
no correlation between amplitude and markers for disease severity in the PSP group. 
Thus, the differences in disease duration between Parkinson’s disease and PSP could 
not account for the reduced mean amplitude in PSP. Furthermore, it could not be 
explained by medication status because all patients were tested after 12 hour-
withdrawal of anti-parkinsonian medications. 
The second key finding was the lack of progressive reduction in amplitude. This is 
compatible with general clinical observation that most PSP patients do not exhibit 
progressive reduction in performance during repetitive finger tapping. The positive 
amplitude slope of 0.01deg/cycle in PSP was similar to controls but differed 
significantly from the negative slope of -0.2deg/cycle in PD-OFF. It is possible that a 
lack of decrement in PSP might be due to a floor effect caused by severe hypokinesia. 
However, even among the subgroup of Parkinson’s disease patients with severe 
hypokinesia (amplitude < 23deg), a mean negative amplitude slope of -0.037deg/cycle 
was found. Furthermore, when comparisons were performed after adjustment for any 
differences in mean amplitudes between groups, the mean amplitude slope in PD-OFF 
was shown to be more negative than PSP and controls, while there was no difference 
between PSP and controls (table 15). These findings support a minimal or lack of 
performance decrement and sequence effect in PSP that is incompatible with the 
QSBB definition of bradykinesia for the clinical diagnosis of parkinsonism. 
Pathophysiological mechanisms 
Severe neuronal loss in the substantia nigra pars compacta is observed in both 
Parkinson’s disease and PSP with greater involvement in the ventromedial and dorsal 
tiers in PSP (Fearnley et al., 1990, Hardman et al., 1997). In PSP, substantial damage 
also occurs in the zona reticulata of the nigra (Hardman et al., 1996), the internal 
segment of the globus pallidus (GPi), the subthalamic nucleus of Luys (STN), the 
dentate nucleus, superior cerebellar peduncle and, to a lesser degree, the striatum and 
thalamus (Bryant et al., 2010, Demirci et al., 1997).  
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In Parkinson’s disease, the STN and GPi are affected functionally with increased 
neuronal discharges as a result of disruption of the basal ganglia circuit (Wichmann et 
al., 2003). Functional compensatory change in the putamen has also been reported in 
Parkinson’s disease, which has been proposed to contribute to the diminished levodopa 
response later in the disease course (Halliday, 2007). The cerebellum may play a role 
in motor sequencing (Garraux et al., 2005). Greater activity of both cerebellar 
hemispheres was found in functional imaging in Parkinson’s disease patients during 
automated movements when compared with healthy controls, suggesting that the 
cerebellum might contribute to the compensatory pathway in Parkinson’s disease (Wu 
et al., 2005). 
It has been postulated that movement size is regulated by phasic signals from GPi to 
the supplementary motor area (SMA) and premotor cortex (Alexander et al., 1990). 
Severe hypokinesia in PSP, therefore, might be due to the extensive pathological 
damage to the GPi and STN (Hauw et al., 1994, Litvan et al., 1996). There is also loss 
of cholinergic neurons in the putamen and loss of pyramidal neurons in the premotor 
cortex (Halliday, 2007) that may also influence the nature of the motor deficit. Finally, 
potential compensatory mechanisms via the cerebellar outflow pathway are cut off in 
PSP due to damage of the superior cerebellar peduncle (Tsuboi et al., 2003, Whitwell 
et al., 2011). The putamen appears to have a role in movement timing which may 
contribute to the variability in performance in PSP and Parkinson’s disease (Garraux et 
al., 2005). 
Sequence effect is reflected by the impairment of scaling of motor sequences and 
contributes to prolonged movement time in Parkinson’s disease (Agostino et al., 1994, 
Benecke et al., 1987). Its pathophysiology in Parkinson’s disease is still poorly 
understood but it is likely to be independent of dopaminergic pathways. It appears that 
the sensorimotor apparatus in patients with Parkinson’s disease is set smaller but the 
capacity to achieve the correct amplitude is intact and can be overcome by visual 
guidance (Hallett, 2003). These findings may not be relevant in PSP where the 
pathological lesion is more extensive and where visual cueing is an ineffective strategy 
to improve gait. The lack of levodopa response in sequence effect in Parkinson’s 
disease was also supported by the findings in this study. 
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In Parkinson’s disease, rigidity and tremor are thought to contribute to slowness in 
limb movements (Berardelli et al., 2001, Quencer et al., 2007). On the other hand, PSP 
patients who have more axial symptoms and sometimes no detectable rigidity of the 
limbs on examination might arguably manifest less degree of slowness on repetitive 
finger tapping.  
Finger tapping assessments 
‘Hypokinesia without decrement’ was identified in 87% of finger tap trials in the PSP 
group and only 12% in the PD-OFF group. This finding might be particularly useful in 
patients with PSP-P, where the physical signs can mimic Parkinson’s disease. Other 
PSP finger tap trials also had a small mean amplitude of 27.8deg, not quite making the 
cut off value of 23deg for hypokinesia. Small finger tap amplitudes can be easily 
recognised by careful bedside examination. Small degrees of decrement may, however, 
be difficult to detect in Parkinson’s disease patients with severe motor impairment who 
have small amplitude finger movements on initiation of finger movements. These 
patients are readily differentiated from PSP by their sustained levodopa response and 
relatively long disease duration. The Parkinson’s disease patients with severe 
hypokinesia in the present study had a mean disease duration of 17.5 years, whereas 
the mean duration from diagnosis to death in PSP is 7 years (Williams et al., 2005). In 
addition to decrement, delayed initiation of voluntary movements and motor arrests 
during repetitive finger tapping in Parkinson’s disease may also have clinical 
usefulness (Fahn et al., 1987, Marsden, 1989).   
The average number of tap cycles performed in 15 seconds was 50 in controls, 52 in 
PSP, 42 in PD-OFF and 46 in PD-ON. Therefore, to detect the differences reported 
above would require a tap trial of approximately 50 finger-thumb tap cycles. The 
modified MDS-UPDRS (Goetz et al., 2008) proposed a 10-tap trial, which would take 
an average of 3.8 seconds (15s/42taps x 10taps) for PD-OFF subjects to perform. It is 
likely that a tap trial consisting of only 10 taps would be too brief for the sequence 
effect to emerge in either treated or untreated Parkinson’s disease. To investigate this, 
an additional analysis on the collected data was performed by arbitrarily assessing only 
the first 20 taps of the first trials performed by both hands after adjusting for disease 
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duration, age and gender. With a 20-tap trial, PSP can still be differentiated from both 
PD-OFF and controls by having amplitudes of less than half the expected size. Mean 
speed in PD-OFF was slower than controls (p = 0.007). However, after 20 taps, the 
amplitude slope (mean = +0.04) and speed slope (mean = +0.21) in PD-OFF group 
were both positive, indicating the lack of decrement and fatigue at that time point and 
the slope values did not differ between PD-OFF, PSP and control groups. This analysis 
indicated that 20-tap trials were not adequate to detect either decrement or fatigue in 
Parkinson’s disease. Based on these findings, it is proposed that repetitive finger 
tapping with 50-tap cycles is required to detect criteria-defined bradykinesia in treated 
and untreated patients with Parkinson’s disease.  
Handwriting in Parkinson’s disease and PSP 
Micrographia was more common in PSP (75%) than in Parkinson’s disease (15%).  
Decrement in script size was less common in PSP than in PD-OFF. These findings 
were similar to the ‘hypokinesia without decrement’ in repetitive finger tapping 
observed in PSP. Five of the six PSP patients with micrographia, also manifested 
hypokinesia on repetitive finger tapping. Despite the similarities in the findings of 
finger tapping and handwriting in PSP, the correlations between the parameters of 
these two kinematic tasks are inexact. ‘Fast micrographia’ characterised by 
microscopically small letters performed at a normal or slightly faster than normal 
speed may be a physical sign related to pallidal damage (Kuoppamaki et al., 2005) and 
has been associated with some cases of PSP. General clinical impression suggests an 
increase in writing speed in some PSP patients. Nevertheless, it is uncertain if the ‘fast’ 
speed represents a shorter performance time due to the reduced stroke size or an 
intrinsic increase in writing speed. This cannot be verified as the handwriting task was 
not timed in the present study.  
McLennan and colleagues reported micrographia in 15% of Parkinson’s disease 
patients and, in 16 out of 30 cases, a significant and sustained improvement in script 
size was noted after levodopa therapy (McLennan et al., 1972). The findings of this 
study also showed the same percentage of micrographia in Parkinson’s disease and 
after levodopa therapy, six patients exhibited marked improvement in script size but 
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decrements in script size persisted. Copying scripts, as in the present study, writing on 
parallel lines and verbal reminders to write ‘big’ can serve as external cues to correct a 
reduction in script size (Bryant et al., 2010, Kim et al., 2005, Oliveira et al., 1997). 
Abnormally increased dependence on external visual feedback has been noted in 
patients with Parkinson’s disease (Demirci et al., 1997). The mechanism of 
micrographia is poorly understood but the hypothesis of a ‘tuned-down’ sensorimotor 
apparatus might explain the reduction in motor scaling during sequential motor tasks 
such as finger tapping and handwriting (Demirci et al., 1997).  
Strengths and limitations 
The three-dimensional motion assessment used in this study proved particularly useful 
in tremulous patients who would have had difficulties maintaining their finger 
separation in a two-dimensional plane. This method captures accurate and diverse 
measurements of the finger tap trials. Pilot studies were conducted on healthy 
volunteers and it was determined that healthy elderly participants become tired after 
prolonged tap sequences of more than 15 to 20 seconds. In order to minimise the 
confounding factor of physiological fatigue, the trial duration was, therefore, limited to 
15 seconds. The study was specifically designed to study motor execution, not 
processing or reaction time. Certain aspects of the quantitative measurements made 
here may not be applicable to subjective bedside observation. Further studies are 
warranted to apply the findings of this study in a clinical context. However, very small 
finger tapping amplitudes can be easily identified during neurological examination. 
The relative persistence of the sequence effect despite levodopa therapy in Parkinson’s 
disease makes it an especially useful physical sign to help distinguish Parkinson’s 
disease and PSP. Future prospective studies on patients with early PSP or PSP-P 
subtype will determine if this specific finger tap pattern can be used as a reliable early 
diagnostic sign to distinguish between Parkinson’s disease and PSP and if the specific 
patterns in PSP applies to all PSP subtypes. Kinematic studies in PSP may also help 
our understanding of the mechanisms underlying the findings in this study.  
An inherent limitation of clinical studies of this kind is the lack of pathological 
confirmation of diagnosis given that about 20% of suspected PSP cases and 10% of 
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suspected Parkinson’s disease cases are found at post-mortem to have a different 
pathology (Snowden et al., 2012). Finally, it should be noted that patients with 
prominent tremor were excluded from this study. In tremor-predominant Parkinson’s 
disease, motor flurries can potentially interrupt normal self-paced movements, 
confounding  clinical interpretation (Bajaj et al., 2010). 
Conclusion 
Patients with PSP have small finger separation amplitude without progressive 
decrement on repetitive finger tapping and do not have criteria-defined limb 
bradykinesia. The severe hypokinesia irrespective of disease severity and the lack of a 
sequence effect help distinguish PSP patients from those with Parkinson’s disease. 
Similarly, ‘micrographia’ and ‘lack of decrement’ in script size is also more common 
in PSP than in Parkinson’s disease. 
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Chapter 5:  Parkinson’s syndrome 
associated with neurofibrillary tangle 
pathology 
5.1:  Parkinsonism with neurofibrillary 
degeneration: a new clinicopathological 
entity? 
Introduction 
Parkinson’s disease is a progressive levodopa-responsive bradykinetic syndrome, 
which, in specialist centres, can be accurately diagnosed in life in the great majority of 
cases (Hughes et al., 1992, Lees et al., 2009). The salient histopathological findings 
are nigral cell loss and the accumulation of α-synuclein-positive Lewy bodies (Gibb et 
al., 1988). A QSBB series identified 24 out of 100 cases, that were misdiagnosed as 
Parkinson’s disease by United  Kingdom hospital specialists and did not have Lewy 
body pathology at post-mortem (Hughes et al., 1992). The pathological diagnoses in 
the misdiagnosed cases were PSP (6), multiple system atrophy (5), Alzheimer’s 
disease (3), vascular parkinsonism (3) and essential tremor with normal 
neuropathological findings (1). Another five cases, which were considered 
unclassifiable had Alzheimer-type neurofibrillary tangle pathology (NFT) with striatal 
involvement (3), postencephalitic parkinsonism (PEP)-type pathology (1) and pure 
nigral degeneration (1).  
The epidemic of encephalitis lethargica (EL) occurred  between 1917 and 1928 and 
was first fully described by Constantin von Economo in Vienna (Von Economo, 1917, 
Von Economo, 1931). At least half of all EL survivors developed progressive 
parkinsonism after a latent interval that ranged from a few months to several decades 
(Duvoisin et al., 1965, Geddes et al., 1993, Howard et al., 1987, Rail et al., 1981). Von 
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Economo suspected the extensive neuronal loss in the substantia nigra in PEP brains 
was the pathological substrate for akinesia and rigidity in these patients (Ransmayr, 
2007). The predominant pathological aggregates in PEP are Alzheimer-type NFTs 
(Geddes et al., 1993, Jellinger, 2011, Torvik et al., 1966, Wenning et al., 1997). In the 
1920’s and 1930’s, PEP accounted for half of all parkinsonism in Europe and up until 
the mid-nineteen sixties, it was common for all young onset cases of slowly 
progressive parkinsonism to be labeled as PEP even in the absence of a history of 
encephalitis or the presence of oculogyric crises. In some patients, trivial flu-like 
illnesses were over-interpreted as indicative of an antecedent mesencephalitis (Burr, 
1925, Duvoisin et al., 1965, Gibb et al., 1987, Rail et al., 1981, Vilensky et al., 2011). 
Some of the first described cases of PSP were also erroneously attributed as PEP 
(Brusa et al., 2004, Steele, 1994) and it was speculated that parkinsonism-dementia 
complex of Guam might be a PEP variant (Kurland et al., 1954). Cases coming to 
autopsy with the classical pathological findings associated with PEP were also often 
considered to have had the disorder even when the clinical picture differed markedly 
from the recognised presentation (Geddes et al., 1993, Gibb et al., 1987). By the end 
of the twentieth century, virtually all the survivors of von Economo’s disease had died 
but sporadic PEP cases presenting with a clinical picture identical to that reported 
during the pandemic have continued to be reported (Duvoisin et al., 1965, Eadie et al., 
1965, Ghaemi et al., 2000, Hu et al., 2012, Rail et al., 1981, Williams et al., 1979).  
Sporadic cases of Parkinson’s syndrome with NFT pathology without a history of 
encephalitis were first highlighted by Stadlan, Duvoisin and Yahr (Stadlan et al., 1965) 
and ten cases were subsequently described by Forno and Alvord (Forno et al., 1971). 
Morris and colleagues reviewed clinically atypical PSP cases in the QSBB and found 
further support for a separate entity of NFT-related parkinsonian disorder with the 
deposition of Alzheimer-type mixed 3R and 4R tau and clinically more closely 
resembling Parkinson’s disease than PSP (Morris et al., 2002). This study reviewed all 
the archival QSBB cases in which the final clinical diagnosis was either Parkinson’s 
disease or PEP without a history of encephalitis with severe nigral degeneration and 
NFT pathology that could not be ascribed to any recognised clinicopathological entity, 
and identified seven cases with clinicopathological findings that resembled the group 
of patients described by Forno and Alvord almost half a century earlier (Forno et al., 
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1971). This group of cases will be referred as ‘slowly progressive parkinsonism with 
neurofibrillary degeneration’ (PND) in the rest of this chapter.   
Materials and methods 
Written consent was obtained from all the included cases. The protocols used for brain 
donation in the QSBB have been approved by a London Multi-Centre Research Ethics 
Committee and tissue is stored under a license from the Human Tissue Authority. This 
study has been approved by the Tissue Request Committee of the QSBB.  
Case selection  
Cases were selected from the QSBB archival collection on the basis of the following 
criteria: (i) they had a final clinical diagnosis of Parkinson’s disease or PEP, (ii) an 
absence of a history of definite encephalitis despite full clinical documentation, (iii) 
slowly progressive disease course of ten years or more and (iv) neuropathological 
findings of nigral cell loss, the absence of Lewy body pathology and predominant NFT 
pathology that did not readily fulfil pathological criteria for any known primary 
tauopathy.   
Another five archival PEP cases were included in this study as comparative controls. 
These PEP cases fulfilled the diagnostic criteria of definite PEP with a history of EL 
which was followed by the development of progressive parkinsonism (Duvoisin et al., 
1972, Duvoisin et al., 1965, Geddes et al., 1993, Jellinger, 2011). All of these cases 
had been previously published in a previous QSBB PEP series (Geddes et al., 1993). 
Only two of the PEP cases had frozen tissue available for genetic analysis. 
Retrospective review of the medical records was carried out. All patients were assessed 
by at least one neurologist during life. Symptoms and signs were recorded as being 
absent if they were not reported in the case notes.  
Neuropathological methods 
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Following the QSBB protocols, the brains were divided mid-sagittally post-mortem. 
One-half of the brain was immediately frozen and stored at -80ºC, and the other half 
was immersed and fixed in 10% neutral formalin for 3 weeks. After slicing and 
sampling the brain, tissue blocks were processed using standard protocols. Using on 8-
μm thick sections histological slides were stained with haematoxylin and eosin method 
and modified Bielschowsky and Gallyas silver impregnations. Immunohistochemistry 
with antibodies to phospho-tau (AT8 clone recognizing Ser202/Thr205; BioScience 
Life Sciences; 1:600 and AT100 recognising Thr212/Ser214; BioScience Life 
Sciences; 1:200), 3R and 4R tau isoforms (3R tau: RD3; 1:2000; 4R tau: RD4; 
1:200)(de Silva et al., 2003), α B-crystallin (Novocastra; G2JF; 1:3000), Aβ (Dako; 
6F/3D; 1:100), p62 (BD Transduction Laboratories; 1:200), TAR DNA-binding 
protein-43 (TDP-43, monoclonal; clone 2E2-D3; 1:3000), and α-synuclein (Vector 
Laboratories; KM51; 1:50) was carried out using a standard avidin-biotin method. 
Double immunofluorescence for AT8 with GFAP (Dako; Z0334 1:1000) was detected 
using isotype specific anti-rabbit IgG or anti-mouse IgG secondary antibodies 
conjugated with either Alexa 488 or 594 fluorescent dyes (Life technologies, Paisley, 
UK; 1:400) followed by mounting with glass coverslips using VECTA shield 
mounting media with  4',6-diamidino-2-phenylindole (DAPI) nuclear stain (Vector 
laboratories, Peterborough, UK). Images were visualised using confocal fluorescence 
microscopy (Leica DM5500 B). 
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Neuropathological analysis 
A systematic neuropathological evaluation was carried out. Neuronal loss in the 
substantia nigra, subthalamic nucleus, locus coeruleus, caudate, putamen, globus 
pallidus and dentate nucleus were determined using a four-tiered semi-quantitative 
grading system (0-3, with grade 0=no neuronal loss to grade 3=most severe neuronal 
loss). The substantia nigra was divided into five regions for the grading (medial, 
dorsomedial, dorsolateral, ventrolateral and lateral). The different tau-positive cellular 
lesions, NFTs, PreTs, NTs, CBs and astrocytic lesions were quantified using a four-
tiered semi-quantitative grading scale (0-3, with grade 0=absence to grade 3=frequent).  
Additional pathologies were documented. Argyrophilic grain disease was identified by 
AT8, α B-crystallin and p62 immunohistochemistry (Saito et al., 2004). Aβ cortical 
plaque pathology was characterised using the CERAD criteria (Mirra et al., 1991). 
Alzheimer’s type NFT pathology was determined using AT8 immunohistochemistry 
for Braak and Braak staging (Braak et al., 2006). Alzheimer’s type Aβ-deposition was 
assessed for a Thal phase score (Thal et al., 2002). The ABC score according to the 
National Institute on Aging-Alzheimer’s Association (NIA-AA) guidelines 
representing the level of Alzheimer’s disease pathologic change was applied (Montine 
et al., 2012). The presence of cerebrovascular disease and CAA were recorded (Revesz 
et al., 2003). 
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Tau biochemistry 
Isolation and guanidine solubilisation of sarkosyl-insoluble tau was performed in seven 
PND cases and two PEP cases with frozen brain tissue available using a standard 
protocol as described in Chapter 3 (Goedert et al., 1992). Guanidine solubilized tau 
was then dephosphorylated using lambda protein phosphatase (New England Biolabs, 
Hitchin, UK) as previously described (Hanger et al., 2002) and separated by standard 
SDS-polyacrylamide gel electrophoresis (Laemmli, 1970) on a 10% gel followed by 
Western blot detection with a rabbit polyclonal anti-tau antibody (1;60,000; rPeptide, 
Bogart, GA). Cases with the pathological diagnosis of Alzheimer’s disease, PSP, CBD 
and Pick’s disease were included on the blot as comparative controls. Brain samples 
were obtained from the frontal cortex, caudate, pontine tegmentum and cerebellar 
dentate nucleus. However, not all regional samples yielded sufficient tau for analysis. 
Genetic analysis 
Genomic DNA was extracted from the frozen brain tissue of 12 included cases. Exons 
and exon-intron boundaries for all exons of parkin and MAPT, and for exons 24, 25, 
27, 29, 35, 36, 41, and 48 of LRRK2 were screened through Sanger sequencing of 
transcripts with accession numbers NM_004562.2/ NP_004553.2, 
NM_005910.5/NP_005901.2 and NM_198578.3/NP_940980.3 respectively. These 
genes were chosen because they may cause a Parkinson’s syndrome with absence of 
Lewy body pathology (Doherty et al., 2013, Hoglinger et al., 2011, Hutton et al., 
1998, Wszolek et al., 2004, Zimprich et al., 2004). PINK1 and DJ1 were sequenced in 
two cases, where heterozygous parkin mutations (c.1310C>T, p.P437E (rs149953814), 
c.823C>T, p.R275W (rs34424986))(Kay et al., 2007, Lesage et al., 2008) were 
identified, to exclude digenic mutations (Funayama et al., 2008). All cases were also 
assessed for whole exon deletions or multiplications in the Parkinson’s disease-related 
genes parkin, SNCA, PINK1, PARK7, UCHL1, GCH1 and LRRK2 through the 
Multiplex Ligation-dependent Probe Amplification kits P051 and P052 (MRC 
Holland). MAPT haplotypes (Hayesmoore et al., 2009) and APOE genotype (Rail et 
al., 1981) were determined through the H1/H2-tagging SNP rs1052553 and through 
sanger sequencing of exon 4 (Ghebranious et al., 2005), respectively.   
116 
 
Results 
Between 1989 and 2012, 750 cases were donated to the QSBB with a final clinical 
diagnosis of Parkinson’s disease. Of these, 70 cases (9.3%) showed no evidence of 
Lewy body pathology, with 14 cases fulfilling the inclusion criteria of this study. Two 
cases were later excluded due to the lack of frozen brain tissue which was required for 
tau immunoblotting and DNA extraction for genetic analysis. The two excluded cases 
were previously reported as case 6 in a PEP series (Geddes et al., 1993) and case 1 in a 
report of non-demented parkinsonian patients with Alzheimer-type pathology (Daniel 
et al., 1991). Seven of the 12 included cases were classified as PND. The remaining 
five had other confirmed genetic and neuropathological findings which distinguished 
them from the PND group (Figure 18):  
Two cases carried a rare p.A152T variant in exon 7 of the MAPT gene which was a 
risk factor for atypical neurodegeneration and may present with parkinsonism or 
dementia and abnormal tau accumulation in post-mortem (Coppola et al., 2012, 
Kovacs et al., 2011)(Chapter 5.2). One case carried the G2019S LRRK2 mutation and 
a novel heterozygous p.Q124E variant in exon 4 of the MAPT gene and had nigral 
degeneration, Alzheimer-type tau, occasional TDP-43 pathology and absence of Lewy 
bodies (Chapter 5.3). One case, who had a ten-year history of parkinsonism with gait 
freezing, normal cognition, bilateral extensor plantar responses and transient levodopa 
response, came to post-mortem at the age of 76 in 1989, and was initially reported to 
have Alzheimer-type pathology (Daniel et al., 1991). Re-evaluation using modern 
immunohistochemistry with AT8, 3R and 4R antibodies showed unequivocal 4R PSP-
tau pathology, including tufted astrocytes and CBs in the caudate nucleus and globus 
pallidus. Concomitant extensive Alzheimer-type tau pathology was also observed 
(Braak and Braak IV and ‘frequent’ CERAD neuritic plaque score). The relatively 
restricted and sparse tau pathology was compatible with PSP-P (Williams et al., 2007). 
Another case had early fall and subsequently developed progressive parkinsonism with 
moderate levodopa response, came to post-mortem in 1992. Re-evaluation confirmed 
the pathological diagnosis of PSP-P and the patient also carried a heterozygous 
p.P437E parkin mutation. However, the direct causative role of a single heterozygous 
parkin mutation in parkinsonism remains unclear (Klein et al., 2007).  
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Figure 18. Overview of 12 included cases with parkinsonism associated with 
neurofibrillary tangle pathology. 
14 cases were selected from the QSBB archive (1989-2012) 
Inclusion criteria: 
1. Final clinical diagnosis at death: PD or PEP 
2. No history of encephalitis 
3. Disease duration: ≥ 10 years 
4. Post-mortem findings: NFT pathology, no Lewy bodies 
12 cases were studied 
Protocol: 
1. Review of medical records 
2. Immunohistochemistry with modern antibodies  
3. Re-evaluation of neuropathological features 
4. Genetic analysis (LRRK2, PARK2, MAPT) 
2 cases were excluded due 
to lack of frozen brain tissue 
for DNA extraction 
2 cases carried MAPT 
p.A152T variant 
1 case carried G2019S 
LRRK2 mutation 
1 case had concomitant PSP & 
AD pathologies 
7 cases were classified as  
Parkinsonism with Neurofibrillary Degeneration (PND) 
Clinical features: 
1. Slowly progressive Parkinson’s syndrome 
2. Intact cognition 
3. Good and sustained therapeutic response 
Neuropathological features: 
1. Severe cell loss in substantia nigra 
2. No Lewy body pathology 
3. Characteristic distribution of NFT pathology 
4. Distinctive astrogliopathy 
5. Frequent argyrophilic grains & TDP-43 pathology 
Biochemical features: 
1. Mixed 3R and 4R tau isoforms  
1 case had concomitant PSP & 
heterozygous PARKIN mutation 
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Parkinsonism with neurofibrillary degeneration 
Seven cases with distinct clinicopathological features were identified and collectively 
referred as PND. All patients had a slowly progressive levodopa-responsive 
Parkinson’s syndrome with intact cognition and histopathological findings of severe 
nigral degeneration, Alzheimer-type NFT pathology in a characteristic distribution, 
distinctive astrogliopathy and high prevalence of argyrophilic grains and TDP-43 
pathology (Tables 16-17).  
Demographic and clinical features 
All patients were born between 1910 and 1929 and came to post-mortem between 1989 
and 2001. Cases 6 and 7 were previously reported (Geddes et al., 1993). Three cases 
(cases 1, 5 and 6) had received a differential diagnosis of PEP because of their history 
of oculogyric crises (cases 5 and 6), young age of onset of parkinsonism in the early 
30’s (cases 1 and 5) and a history of Spanish flu during the epidemic in 1919 (case 1). 
None of the cases had a history of encephalitis, but one patient (case 7),  at the age of 8 
in 1927, spent two months in bed with what was labelled as ‘nerves’ and, at age 24, 
developed parkinsonism with good levodopa response and was clinically diagnosed as 
Parkinson’s disease. One patient had influenza during the epidemic in 1919. There was 
no history of significant head injury, family history of movement disorders or 
dementing illnesses.  
The mean age of onset of parkinsonism was 42.6 years (range: 24-63 years), mean 
disease duration was 36.4 years (range: 19-50 years) and mean age of death was 78.9 
years (range: 67-87 years). Four patients were reported to have sustained asymmetry in 
their motor disability throughout the disease course (cases 1, 2, 6, 7). Four had a 
resting limb tremor (cases 1, 4, 6 and 7) and two underwent unilateral thalamotomy 
with complete resolution of tremor (cases 6 and 7). Six patients had received levodopa 
therapy with sustained good to excellent benefit and one patient (case 6) was never 
prescribed anti-parkinsonian medications because his parkinsonian features 
significantly improved after unilateral thalamotomy. Three developed levodopa-
induced chorea. No patients had dementia and only one patient (case 4) reported mild 
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impairment in short term memory. Psychiatric symptoms were noted in three patients 
(cases 1, 2 and 7), including nervous breakdown after a stressful life event (N=1), 
depression (N=1) and anxiety (N=2). Two patients had a history of oculogyric crises 
(cases 5 and 6), two had restricted upgaze (case 2 at age 77, case 5 at age 67) and one 
had blepharospasm (case 2).  
Case vignette (case 5) 
In 1947, aged 32, this woman developed weekly episodes of tonic oculogyric spasms 
lasting for 30 minutes but their frequency gradually waned after a few years. She then 
developed a very slowly progressive akinetic rigid syndrome. In 1975, levodopa was 
administered with good response. Mild levodopa-induced chorea was noted. At age 73, 
examination revealed hypomimia, intermittent hand tremor and bilateral limb rigidity, 
corresponding to H&Y stage II. An Apomorphine challenge test was positive which 
confirmed a beneficial response to dopaminergic replacement therapy. Two years later, 
she had increasing gait and balance difficulties and started to fall. At age 77, her 
UPDRS motor score was 27 and H&Y stage was IV. She had restriction of upgaze, 
occasional jaw tremor, marked bilateral bradykinesia with minimal limb rigidity, 
festinant parkinsonian gait and poor postural stability. She suffered two hip fractures 
as a result of frequent falls. Her speech and swallowing deteriorated relentlessly 
necessitating tube feeding in the last year of life. She was taking 300mg/day of 
levodopa and 5mg/day of selegiline. She died of pneumonia at age 82. The final 
clinical diagnosis was Parkinson’s disease but the diagnosis of PEP had also been 
suggested earlier in the course of the illness. The lack of Lewy body pathology in post-
mortem prompted genetic analysis which identified a heterozygous p.R275W mutation 
in the parkin gene. 
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Features Case 1 Case 2 Case 3 Case 4 
Year of birth 
Gender 
Acute Illnesses (year) 
Oculogyric crises 
Onset of parkinsonism 
Levodopa response 
Dyskinesia 
Duration of parkinsonism,year 
Age at death  
Year of post-mortem 
1910 
F 
Flu (1919) 
- 
34 (1944) 
Excellent 
+ 
48 
82 
1993 
1929 
M 
- 
- 
48 (1977) 
Good 
- 
19 
67 
1997 
1913 
M 
- 
- 
63 (1976) 
Good 
- 
25 
87 
2001 
1917 
M 
- 
- 
46 (1963) 
Good 
+ 
35 
81 
1998 
Neurofibrillary tangles 
  Frontal cortex 
  Temporal cortex 
  CA1 hippocampal subregion 
  GCL hippocampal subregion 
  Amygdala 
  Caudate 
  Putamen 
  Globus pallidus 
  Subthalamic nucleus 
  Substantia nigra 
  Oculomotor nucleus 
  Pontine tegmentum 
  Pontine base 
  Locus coeruleus 
  Dentate nucleus  
 
+ 
+ 
+++ 
+++ 
+++ 
++ 
+ 
++ 
+ 
+ 
NA 
+ 
- 
+ 
+ 
 
- 
+ 
- 
- 
+ 
+ 
+ 
+ 
+ 
++ 
- 
+ 
- 
+ 
+/- 
 
+ 
+ 
+ 
- 
+++ 
+ 
+ 
- 
+ 
+ 
+ 
+ 
- 
+ 
- 
 
+ 
+++ 
+++ 
+++ 
+++ 
++ 
++ 
++ 
+ 
+ 
+ 
+ 
+/- 
+ 
+ 
Astrocytic lesions  
  Frontal cortex 
  Temporal cortex 
  Caudate 
  Putamen 
  Subthalamic nucleus 
  Midbrain tegmentum 
  Substantia nigra 
  Pontine tegmentum 
 
++ B 
++ B 
++ G 
++ G 
+ G 
++ F,G 
- 
++ F,G 
 
- 
- 
- 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
- 
- 
+ G 
 
+ G 
- 
+ G 
+ G 
- 
+ F 
+ F 
+ G 
Substantia nigra cell loss 
 
Locus coeruleus cell loss 
Subthalamic nucleus cell loss 
Ghost tangles 
Braak and Braak stage  
CERAD 
Thal Aβ phase score 
Alzheimer-related ABC score: 
likelihood of AD change 
Hippocampal sclerosis 
Argyrophilic grain disease 
TDP-43 pathology 
Cerebral amyloid angiopathy 
Cerebrovascular disease 
3 (except 
DM-2, M-2) 
0 
0 
- 
II 
None 
3 
A2B1C0: 
low 
- 
+ (stage 3) 
- 
- 
+ (mild 
SVD) 
3 (except M-
2) 
3 
0 
- 
I 
Few 
1 
A1B1C1: 
low 
- 
- 
- 
- 
- 
3 (except M-
2) 
1 
0 
- 
III 
Few 
5 
A3B2C1:  
intermediate 
- 
+ (stage 1) 
+ 
+ (mild) 
+ (mild 
SVD) 
3-all 
 
3 
0 
+ 
IV 
Moderate 
4 
A3B2C2: 
intermediate 
+ 
1 (stage 2) 
+ 
+ (moderate) 
- 
Genetic findings (MAPT, 
PARK2, LRRK2)  
MAPT genotype 
APOE 
 
- 
H1/H1 
E2/E3 
 
MAPT* 
H1/H1 
E3/E3 
 
- 
H1/H2 
E3/E3 
 
- 
H1/H2 
E3/E4 
Table 16. Features of PND (cases 1 - 4). 
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Tau immunoreactive neurofibrillary tangles and astrocytic lesions were determined 
using a four-tiered semi-quantitative grading system; -: absent, (-/+: very sparse), +: 
few, ++: moderate, +++: frequent. 
B=bush-like, F=filamentous, G=granular, NA=not applicable as the oculomotor 
nucleus was not included in tissue section; GCL=granule cell layer; CERAD= 
Consortium to Establish a Registry for Alzheimer’s disease 
+: present; -: absent; Substantia nigra was divided into five regions for the grading; 
M=medial, DM=dorsomedial, DL=dorsolateral, VL=ventrolateral and L=lateral. 
*=MAPT intron 4A-5 was identified in case 2 (rs138482356) which is probably non-
pathogenic. 
Cell loss of the substantia nigra, locus coeruleus and subthalamic nucleus were 
determined using a four-tiered semi-quantitative grading system; 0-3; grade 0=no 
neuronal loss to grade 3=most severe neuronal loss. 
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Features Case 5 Case 6* Case 7* 
Year of birth 
Gender 
Acute Illnesses (year) 
Oculogyric crises 
Onset of parkinsonism 
Levodopa response 
Dyskinesia 
Duration of parkinsonism, years 
Age at death  
Year of post-mortem 
1915 
F 
- 
+ (32) 
32 (1947) 
Good 
+ 
50 
82 
1998 
1904 
M 
- 
+ (26) 
51 (1955) 
NA# 
NA 
33 
84 
1989 
1919 
F 
‘nerves’ (1927) 
- 
24 (1933) 
Good 
- 
45 
69 
1989 
Neurofibrillary tangles 
  Frontal cortex 
  Temporal cortex 
  CA1 hippocampal subregion 
  GCL hippocampal subregion 
  Amygdala 
  Caudate 
  Putamen 
  Globus pallidus 
  Subthalamic nucleus 
  Substantia nigra 
  Oculomotor nucleus 
  Pontine tegmentum 
  Pontine base 
  Locus coeruleus 
  Dentate nucleus  
 
++ 
+ 
+++ 
- 
+++ 
+ 
+ 
- 
+ 
++ 
NA 
+ 
- 
++ 
+/- 
 
+ 
+ 
+ 
- 
+++ 
+ 
+ 
+ 
+ 
+ 
+ 
++ 
+/- 
+ 
+ 
 
+ 
+ 
+++ 
+ 
+++ 
+++ 
+ 
+ 
+ 
+ 
NA 
+ 
+ 
+ 
+ 
Astrocytic lesions  
  Frontal cortex 
  Temporal cortex 
  Caudate 
  Putamen 
  Subthalamic nucleus 
  Midbrain tegmentum 
  Substantia nigra 
  Pontine tegmentum 
 
+ G 
- 
- 
+ G 
- 
+ F, G 
+ G 
- 
 
- 
- 
++ B, G 
- 
- 
++  G 
- 
++ G 
 
+ B 
- 
+ B, G 
- 
- 
+ F, G 
++ G 
+ F 
Substantia nigra cell loss 
Locus coeruleus cell loss 
Subthalamic nucleus cell loss 
Ghost tangles 
Braak and Braak stage  
CERAD 
Thal Aβ phase score 
Alzheimer-related ABC score: 
likelihood of AD pathologic change 
Hippocampal sclerosis 
Argyrophilic grain disease 
TDP-43 pathology 
Cerebral amyloid angiopathy 
Cerebrovascular disease 
3 (except M-1) 
0 
0 
- 
IV 
Few 
4 
A3B2C1:      
low 
- 
- 
+ 
- 
+ (mild SVD) 
3-all 
0 
0 
- 
III 
None 
1 
A1B2C0:      
low 
- 
- 
+ 
- 
- 
3-all 
2 
0 
+ 
III 
None 
1 
A1B2C0:      
low 
- 
1 (stage 1) 
+ 
- 
+ (lacunes) 
Genetic findings (MAPT, PARK2, 
LRRK2)  
MAPT genotype 
APOE 
Heterozygous 
parkin** 
H1/H2 
E3/E3 
- 
 
H1/H1 
E3/E3 
- 
 
H1/2 
E2/E3 
Table 17. Features of PND (cases 5 - 7). 
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Tau immunoreactive neurofibrillary tangles and astrocytic lesions were determined 
using a four-tiered semi-quantitative grading system; -: absent, (-/+: very sparse), +: 
few, ++: moderate, +++: frequent. 
B=bush-like, F=filamentous, G=granular, NA=not applicable as the oculomotor 
nucleus was not included in tissue section; GCL=granule cell layer; CERAD= 
Consortium to Establish a Registry for Alzheimer’s disease 
+: present; -: absent; Substantia nigra was divided into five regions for the grading; 
M=medial, DM=dorsomedial, DL=dorsolateral, VL=ventrolateral and L=lateral; 
#Tremor and parkinsonian features were significantly improved following 
thalamotomy in 1960 and anti-parkinsonian medications were never prescribed. 
*case 6 was reported as case 5 in Geddes et al, 1993; *case 7 was reported as case 7 
in Geddes et al, 1993; **=A heterozygous p.R275W parkin mutation was identified in 
case 5 and additional sequencing of the PINK1 and DJ1 genes were negative. 
Cell loss of the substantia nigra, locus coeruleus and subthalamic nucleus were 
determined using a four-tiered semi-quantitative grading system; 0-3; grade 0=no 
neuronal loss to grade 3=most severe neuronal loss. 
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Neuropathological findings 
Neuronal loss 
Histological examination demonstrated severe neuronal loss, atrophy and gliosis in the 
substantia nigra with relative preservation in the medial region in some cases (cases 1-
3 and 5; Figure 19). Neuronal loss in the locus coeruleus was observed in some cases, 
ranging from mild to severe (cases 2-4 and 7). The subthalamic nucleus was preserved 
without evidence of neuronal loss or atrophy. No cell loss was observed in the striatum 
and globus pallidus apart from occasional enlarged perivascular space noted in some 
cases (cases 1 and 3).  
α-synuclein, AT8 and Aβ immunohistochemistry 
There were no Lewy bodies, Lewy neurites or other abnormal structures labelled with 
the anti-α-synuclein antibody. AT8 immunohistochemistry demonstrated NFTs and 
NTs in variable amount and the severity of the tau pathology ranged from mild to 
severe in the frontal and temporal cortices. In some cases, neuritic plaques were also 
seen (cases 2-5; Figure 20). Only few NFTs and NTs were observed in the parietal 
cortex. Aβ-immunoreactive diffuse and mature parenchymal plaques were sometimes, 
but not always found in the frontal and temporal cortices. The amygdala was similarly 
affected by tau and Aβ pathologies. The severity of NFTs, PreTs, NTs ranged from 
moderate to severe in all hippocampal subregions; except in case 2, where tau 
pathology was very sparse. Aβ-positive diffuse and mature plaques were observed in 
the hippocampal subregions in some cases only (cases 1, 3-5). NFTs, PreTs, and NTs 
were invariably observed in the striatum, subthalamic nucleus, substantia nigra, 
pontine tegmentum, locus coeruleus and, in most cases, globus pallidus. Tau 
pathologies were sometimes seen in motor neurons of the oculomotor nucleus, but 
were rare in the pontine base and dentate nucleus. The tau lesions were both 3R- and 
4R-tau positive. 
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Figure 19. Neuronal loss of substantia nigra in PND, PEP and PD. 
Neuronal loss in substantia nigra of cases with PD (A), PEP (B) and PND (C & D). 
Predominant neuronal loss in the ventral tier with remaining pigmented neurons in the 
dorsal tier in PD (A, arrows). Neuronal loss and gliosis in PEP (B=PEP-5) and PND 
(C=case 6, D=case 2) are more severe than in PD, with involvement of all parts of the 
pigmented pars compacta but sparing of the non-pigmented pars reticulata. 
Preservation of the medial tier of the pars compacta is occasionally observed in PND 
(C, arrows). H&E; scale bar in A=250μm in A & B, =100 μm in C and =20μm in D. 
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Figure 20. Distribution of tau-positive lesions in different brain regions of PND. 
Tau immunoreactivity in different regions in parkinsonism with neurofibrillary 
degeneration (case 4). Neurofibrillary tangles, pretangles, neuropil threads and 
occasional astrocytic lesions, are observed. AT8; scale bar=50μm.  
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AT8 immunoreactive astrogliopathy 
Astrocytic lesions characterised by bush-like, filamentous or granular tau 
immunoreactivity along with astrocytic processes were variably observed in the frontal 
and temporal cortices, striatum, subthalamic nucleus, midbrain tegmentum, substantia 
nigra and pontine tegmentum; except in case 2, where tau pathology was mild in all 
regions (Tables 16-17, Figure 22). The presence of an astroglial nucleus with 
perinuclear enhancement of tau immunopositivity in the centre of a meshwork of 
labelled processes was observed allowed these structures to be distinguished from the 
patchy and more widely dispersed NTs. The majority of the astrocytic lesions were 
AT100-positive and Gallyas-negative, with some resembling those in argyrophilic 
grain disease. Rarely, astrocytic processes of the filamentous type were both AT100- 
and Gallyas-positive (case 5). Analysis of double label immunofluorescence 
microscopy revealed co-localisation of AT8 immunoreactive inclusions with GFAP 
positive astrocytes, shown in the pontine tegmentum of case 1 (Figure 21). 
 
 
 
Figure 21. Co-localisation of AT8 with GFAP-positive astrocytes. 
Representative double immunofluorescence images, from the pontine tegmentum of 
case 1, probed for AT8 (A, green; phospho-tau; Ser202/Thr205) and GFAP (B, red) 
show strong co-localisation in a subset of inclusions including fine neurites (C, 
yellow). DAPI (C, blue) stains the nuclei of surrounding neuronal and glial cells; scale 
bar=50μm. 
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Figure 22. Astrocytic lesions in PND. 
Characteristic astrocytic immunoreactivities in PND; granular lesion in the caudate 
(A=case 6), filamentous lesion adjacent to bush-like processes (B=case 7, midbrain), 
granular perinuclear accentuation and diffuse bush-like processes (C=case 1, 
midbrain). Bush-like astrocyte with perinuclear accentuation and thin process, most 
likely related to argyrophilic grain disease, in the temporal cortex (D=case 1). Most 
astrocytic lesions are AT100-positive (E=case 1; putamen) and Gallyas-negative. A 
rare Gallyas-positive filamentous astrocytic lesion in the midbrain tegmentum of case 
5 (F). AT8: A-D; AT100: E; Gallyas: F; scale bar in A=25μm. 
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Ghost tangles 
Ghost tangles, representing residual NFTs lying in the neuropil following neuronal 
death, were abundant in the CA1 hippocampal subregion, observed occasionally in the 
entorhinal and temporal cortices in two cases (cases 4 and 7), and were visible in H&E 
stained sections, Bielschowsky’s silver impregnation and tau immunohistochemistry 
(Figure 23). Some of them were decorated with anti-Aβ antibody, indicating secondary 
Aβ deposition on extracellular tau filaments. 
Additional pathologies 
Alzheimer’s disease related neuropathologic changes were identified as ‘low’ in five 
cases (cases 1, 2, 5-7) and ‘intermediate’ in two cases (cases 3 and 4) according to the 
NIA-AA guidelines (Tables 16-17)(Montine et al., 2012). Argyrophilic grains were 
commonly observed (cases 1, 3, 4 and 7; Figure 23)(Saito et al., 2004). Occasional 
TDP-43 immunoreactive neuronal cytoplasmic inclusions (NCIs) and threads (cases 3-
7) and, rarely, neuronal intranuclear inclusions (NIIs) were identified (case 6; Figure 
23). CAA, hippocampal sclerosis and cerebrovascular disease were occasionally seen 
(Tables 16-17). There were no p62-positive ‘star-shaped’ inclusions in the 
hippocampus or small ‘dot-like’ structures in the cerebellar granule cells of the type 
associated with C9orf72 repeat expansion. 
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Figure 23. Ghost tangles, argyrophilic grains and TDP-43 pathologies in PND. 
Extracellular ghost tangles (A-D, arrows) are visible in H&E (A=case 4, CA1 
hippocampal subregion) and some are Aβ (B=case 4, CA1), representing extracellular 
protein aggregates and tau (C=case 4, CA1; D=case 7, CA1) immunoreactive. 
Pretangles and a neurofibrillary tangle are also seen in D. Tau immunoreactive 
argyrophilic grains (arrowheads) from the entorhinal cortex (E=case 1) and granule 
cell layer of the hippocampus (F=case 1) are observed. There are several pretangles 
(arrowheads) and neurofibrillary tangles (arrow) next to the grains. TDP-43 
immunoreactive neuronal cytoplasmic inclusions (NCIs) in the granule cell layer of 
the hippocampus (G=case 3, arrows) and a rare neuronal intranuclear inclusion (NII; 
F=case 6, arrow) are identified. H&E: A, Aβ: B, AT8: C & D, TDP-43: G & H; scale 
bar in A=25μm in A, C, D, G & H, =50μm in B, E & F. 
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Tau biochemistry 
Western blots of the non-dephosphorylated sarkosyl-insoluble tau fractions from the 
homogenates showed the characteristic triplet electrophoretic migration pattern in the 
PND, PEP and Alzheimer’s disease cases indicating presence of paired helical 
filament-tau composed of both 3R and 4R-tau isoforms (not shown). This was 
confirmed after dephosphorylation of the sarkosyl-insoluble tau, where tau isoform 
profiles were comparable to that of Alzheimer’s disease with similar levels 0N and 1N 
variants of 3R and 4R-tau. PSP and CBD controls showed the expected dominance of 
4R-tau, mostly 0N4R and 1N4R, whereas Pick’s disease showed almost exclusively 
3R-tau (Figure 24). 
 
 
 
Figure 24. Tau immunoblot of cases with PND, PDP and controls. 
Dephosphorylated sarkosyl-insoluble tau was analysed by Western blotting with 
detection by a rabbit anti-tau antibody. All six tau isoforms are observed in cases with 
parkinsonism with neurofibrillary degeneration (PND), postencephalitic parkinsonism 
(PEP) and Alzheimer’s disease (AD). Progressive supranuclear palsy (PSP) and 
corticobasal degeneration (CBD) are 4R- tau predominant, mostly 0N4R and 1N4R. 
Pick’s disease (PiD) showed almost exclusively 3R-tau. L-tau ladder (the relative 
positions of the six isoforms are indicated on the left); PND: case 1 (frontal cortex), 
case 2 (cerebellar dentate nucleus) and case 3 (frontal cortex). 
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Genetic analysis 
Sanger sequencing of LRRK2, parkin and MAPT genes and dosage analysis of 
Parkinson’s disease-related genes were negative in five of the seven cases with PND. 
A heterozygous p.R275W parkin mutation was identified in case 5; secondary 
sequencing of the PINK1 and DJ1 genes in this case was negative. A heterozygous rare 
variant in the MAPT intron 4A-5 was identified in case 2 (rs138482356). This mutation 
locates deeply within the intron (37 base pairs away from the end of exon 4A) and 
leads to a deletion of nine nucleotides (CCTCCCAGG) and is probably non-
pathogenic. Four cases had H1/H2 and three cases had H1/H1 MAPT genotypes. The 
APOE genotype frequencies in the PND group were similar to those reported in the 
general population (Singh et al., 2006) and in other tauopathies, where they probably 
do not confer to disease risk (Cairns et al., 2007).  
 
  
133 
 
Postencephalitic parkinsonism 
Five cases with a definitive clinical diagnosis of PEP were included in this study as 
comparative controls (Table 18). Four cases had a clear history of classical EL during 
the epidemic and one case (PEP-2) developed an EL-like illness in 1944. Two cases 
had a history of oculogyric crises.  
The key neuropathological findings of our PEP control cases were consistent with 
those described in the literature (Geddes et al., 1993, Haraguchi et al., 2000, Jellinger, 
2009, Jellinger, 2011, Torvik et al., 1966, Wenning et al., 1997). All subregions of the 
substantia nigra pars compacta was almost entirely devoid of pigmented neurons with 
atrophy and gliosis, but there was relative preservation of the non-pigmented pars 
reticulata (Gibb et al., 1987). Moderate cell loss in the locus coeruleus was observed in 
most cases. The subthalamic nucleus was preserved. 
Tau-immunoreactive NFTs, PreTs and NTs were found in the frontal and temporal 
cortices, hippocampus, amygdala, subthalamic nucleus, substantia nigra and, to a lesser 
extent, in the parietal cortex, striatum, globus pallidus, pontine tegmentum and locus 
coeruleus. Only minimal tau pathologies, if any, were observed in the pontine base and 
dentate nucleus in the cerebellum. Globose NFTs were identified in the residual 
neurons of the substantia nigra and locus coeruleus. These tau lesions were 3R- and 
4R-tau positive. Bush-like and granular astrocytic tau immunoreactive lesions were 
common features (Haraguchi et al., 2000, Ikeda et al., 1993), some of which resembled 
the astrogliopathy in argyrophilic grain disease (Saito et al., 2004). However, 
argyrophilic grains, frequently seen in PSP, were not found in these PEP cases (Togo 
et al., 2002). Ghost tangles were abundant in three cases. 
Few incidental α-synuclein-positive Lewy bodies were observed in the upper brain 
stem in one case (PEP-1) but α-synuclein pathology was absent in all other cases. 
Alzheimer-related Aβ parenchymal plaques and neuritic plaques with tau-positive 
abnormal neurites were sometimes observed in these elderly individuals (Table 18). 
Hippocampal sclerosis, CAA and TDP-43, were occasional features. Sequencing of the 
LRRK2, parkin and MAPT genes performed in two cases (PEP-4, PEP-5) was negative.   
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Features PEP-1* PEP-2 PEP-3 PEP-4 PEP-5 
Year of birth 
Gender 
Onset of EL: Age (year) 
OGC (age of onset) 
Latency to parkinsonism
#
 
Onset of parkinsonism  
Levodopa response 
Dyskinesia 
Duration of parkinsonism 
Age at death  
Year of post-mortem 
1907 
F 
10 (1927) 
- 
<15 
<35(1942) 
Good 
- 
>44 
79 
1987 
1909 
M 
35 (1944) 
- 
3 
38 (1947) 
Good 
- 
41 
79 
1989 
1912 
M 
10 (1922) 
+ (27) 
47 
57 (1969) 
NA 
NA 
17 
74 
1986 
1917 
F 
10 (1927) 
- 
51 
61 (1978) 
NA 
NA 
20 
81 
1999 
1922 
M 
1 (1923) 
+ (38) 
37 
38 (1960) 
Good 
+ 
41 
79 
2001 
Neurofibrillary tangles 
  Frontal cortex 
  Temporal cortex 
  CA1 subregion  
  Amygdala 
  Caudate 
  Putamen 
  Globus pallidus 
  Subthalamic nucleus 
  Substantia nigra 
  Oculomotor nucleus 
  Pontine tegmentum 
  Pontine base 
  Locus coeruleus 
  Dentate nucleus  
 
- 
+/- 
+++ 
++ 
+ 
- 
- 
+/- 
+ 
NA 
- 
- 
- 
+ 
 
++ 
++ 
+++ 
+++ 
+ 
+ 
+ 
+ 
+++ 
NA 
+ 
+ 
+ 
+ 
 
+ 
+ 
++ 
+++ 
+ 
+ 
+ 
+ 
++ 
NA 
+ 
+ 
+ 
- 
 
+ 
++ 
+++ 
+++ 
+ 
+ 
++ 
++ 
+ 
NA 
+ 
- 
+ 
- 
 
+ 
+ 
+++ 
+++ 
++ 
- 
+ 
+ 
+++ 
- 
+ 
- 
- 
+ 
Astrocytic lesions  
  Frontal cortex 
  Temporal cortex 
  Caudate 
  Putamen 
  Subthalamic nucleus 
  Midbrain tegmentum 
  Substantia nigra 
  Pontine tegmentum 
 
- 
- 
- 
- 
- 
- 
- 
- 
 
- 
- 
+ B 
- 
+ G 
+ G 
+ G 
+ B 
 
- 
- 
- 
- 
- 
+ G 
- 
+ G 
 
- 
- 
+ G 
- 
- 
+ B 
- 
- 
 
- 
- 
- 
- 
- 
+ G 
+ G 
- 
Substantia nigra cell loss 
Locus coeruleus cell loss 
STN cell loss 
Ghost tangles 
Braak and Braak stage  
CERAD 
Thal Aβ phase score 
Alzheimer-related ABC 
score: likelihood of AD  
Hippocampal sclerosis 
Argyrophilic grain 
disease 
TDP-43 pathology 
CAA 
Cerebrovascular disease 
3-all 
0 
0 
+ 
II 
None 
0 
A0B1C0: 
not 
- 
- 
 
- 
- 
- 
3-all 
2 
0 
+ 
IV 
Moderate 
3 
A2B2C2: 
moderate 
+ 
- 
 
+ 
+ (mild) 
+ (mild) 
3-all 
2 
0 
- 
II 
None 
0 
A0B1C0: 
not 
- 
- 
 
- 
- 
+ (multiple 
infarcts) 
3-all 
2 
0 
- 
IV 
Moderate 
5 
A3B2C2: 
moderate 
+ 
- 
 
- 
+ (mod) 
- 
3-all 
2 
0 
+ 
III 
None 
2 
A1B2C0: 
low 
+ 
- 
 
+ 
- 
- 
Genetic findings (MAPT, 
PARK2, LRRK2)  
MAPT genotype 
APOE 
 
NK 
NK 
NK 
 
NK 
NK 
NK 
 
NK 
NK 
NK 
 
- 
H1/H2 
E3/4 
 
- 
H1/H2 
E3/3 
Table 18. Features of five PEP control cases. 
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Tau immunoreactive neurofibrillary tangles and astrocytic lesions were determined 
using a four-tiered semi-quantitative grading system (-: absent, +: few, ++: moderate, 
+++: frequent) 
B=bush-like, F=filamentous, G=granular, NA=not applicable (as the oculomotor 
nucleus was not included in tissue section) 
CERAD=Consortium to Establish a Registry for Alzheimer’s disease, EL=encephalitis 
lethargica, Int=intermediate, NK=not known (no frozen brain tissue available for 
frozen tissue extraction), OGC=oculogyric crises, SVD=small vessel disease, +: 
present, -: absent 
*These PEP cases were published in Geddes et al 1993: PEP-1 was reported as case 
2, PEP-2 was reported as case 3, PEP-3 was reported as case 4. PEP-4 was reported 
as case 6, PEP-5 was reported as case 7 
#Latency from encephalitis lethargica to onset of parkinsonism 
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Figure 25. Neuropathological features of PEP. 
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Severe neuronal loss and gliosis in the ventral (arrows) and dorsal tier of the 
substantia nigra (SN) pars compacta with relatively sparing of the neurons in pars 
reticulala (A). Tau immunoreactive neurofibrillary tangle (NFT) and neuropil threads 
(NTs) in the SN (B). Many ghost tangles (arrows) are observed using H&E staining 
(C) and tau immunohistochemistry (D) in CA1 hippocampal subregion. TDP-43 
immunoreactive neuronal cytoplasmic inclusions (NCI) in the dentate fascia of the 
hippocampus (arrow, E), NCI in the amygdala (left inset, F), tangle-like NCI in the 
subiculum (right inset, G), 2 NCIs (left inset) and a tangle-like NCI (right inset) in the 
entorhinal cortex (G), and a NCI as well as few neurites (arrows) in the inferior 
temporal neocortex (H). 
A, C: H&E, B, D: tau immunohistochemistry and E-H: TDP-43 
immunohistochemistry. A- D, E (left inset): case 7; E (right inset), F, G: case 2; scale 
bar in A=250µm, in B=50µm, in C, D, F-H=25 µm and in E=17µm. 
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Distinguishing features between PEP and PSP 
Histopathological findings in PEP were thought to bear similarities to PSP (Geddes et 
al., 1993). However, our re-evaluation provided some helpful histopathological 
distinctions (Table 19). Key histological features that distinguish PSP from PEP are 
atrophy of the subthalamic nucleus, cell loss in the dentate nucleus, cell loss in both 
the pigmented substantia nigra pars compacta and non-pigmented pars reticulata, 
frequent tau pathologies in the pontine base and dentate and the absence of ghost 
tangles (Dickson et al., 2011, Hauw et al., 1994, Oyanagi et al., 2001). 4R-tau 
immunoreactive tufted astrocytes are frequently observed in the precentral gyrus, 
striatum and superior colliculus in PSP, and they differ from the mixed 3R and 4R-tau 
immunoreactive lesions in both PEP and PND in terms of morphology and distribution 
(Dickson et al., 2011). The tau pathology is overall more severe in PSP than in either 
of these other two conditions. The MAPT H1/H1 genotype is over-represented in PSP 
but only three out of the seven PND cases are H1 homozygous. The remaining four 
cases as well as the two PEP cases that were analysed are H1/H2 heterozygous (Baker 
et al., 1999, Houlden et al., 2001). 
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Features PND PEP AD PSP 
Substantia nigra cell loss 
Subthalamic nucleus cell loss 
Ghost tangles 
++ 
- 
-/+ 
++ 
- 
+ 
-/+ 
-/+ 
+ 
++ 
++ 
- 
Tau pathology 
  Frontal cortex 
  Temporal cortex 
  Hippocampus 
  Amygdala 
  Caudate 
  Putamen 
  Globus pallidus 
  Subthalamic nucleus 
  Substantia nigra 
  Oculomotor nucleus 
  Pontine tegmentum 
  Pontine base 
  Locus coeruleus 
  Dentate nucleus  
 
+ 
++ 
++ 
++ 
++ 
++ 
+ 
++ 
++ 
+ 
++ 
-/+ 
++ 
-/+ 
 
++ 
++ 
++ 
++ 
+ 
+ 
+ 
++ 
++ 
+ 
+ 
-/+ 
+ 
-/+ 
 
+ 
++ 
++ 
+ 
-/+ 
-/+ 
-/+ 
-/+ 
-/+ 
-/+ 
-/+ 
- 
+ 
- 
 
+ 
-/+ 
- 
- 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
Astrocytic lesions  
  Tufted astrocytes 
  Others 
 
- 
++ B,G,F 
 
- 
++ B,G 
 
- 
- 
 
++ 
- 
Tau isoforms 4R + 3R 4R + 3R 4R + 3R 4R>> 
Table 19. Neuropathological findings in PND, PEP, AD and PEP. 
Cell loss and tau immunoreactive lesions; -: not described, -/+: rare, +: commonly 
observed, ++: characteristic; B=bush-like, F=filamentous, G=granular, >> 
predominant. 
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Discussion 
Of the 12 cases included in this study, seven cases were identified as PND who had 
slowly deteriorating levodopa-responsive Parkinson’s syndrome and pathology 
compatible with that described in PEP with severe nigral degeneration and 
accumulation of Alzheimer-type tau pathology. The remaining five cases had other 
confirmed genetic and neuropathological findings, distinguishing them from the PND 
group, three of which are reported in Chapters 5.2 and 5.3. 
The clinical features of PND resembled Parkinson’s disease, but had a more benign 
course with normal longevity and a disease duration lasting up to 50 years. The 
deterioration in motor symptoms was very slow with preservation of cognition. Three 
patients (cases 3-5) had a more rapid worsening of gait, balance, speech and 
swallowing in the later stage. Another three patients (cases 1, 2 and 7), who died of 
cancer, had well controlled motor symptoms prior to death. Levodopa-induced 
dyskinesia observed in three PND cases was never a predominantly disabling feature 
as observed in patients with PEP or parkin disease. The mean age of onset was 
relatively young (42.6 years) and three patients developed their symptoms before the 
age of 40 (cases 1, 5, 7). A single heterozygous parkin mutation was identified in case 
5. Although heterozygous carriers of parkin mutation is thought to have an increased 
generic risk for nigrostriatal dysfunction, its role in causing symptomatic parkinsonism 
is still unclear (Pavese et al., 2009).  
All PND cases were born before or during the EL epidemic but none of them had a 
history consistent with EL. Nevertheless, one cannot exclude the possibility that a 
history of mild encephalitis with rapid recovery may have been overlooked or 
dismissed as inconsequential by the patients. The time convergence of the EL epidemic 
and the Spanish influenza initially led to the hypothesis of a common aetiological 
agent (Foley, 2009, Foley, 2009, Ravenholt et al., 1982), a hypothesis that was rejected 
by von Economo (Von Economo, 1931). Studies using polymerase chain reaction to 
successfully identify the H1N1 influenza virus responsible for the epidemic in 1918 
failed to detect influenza RNA in archival EL and PEP brain tissue (Lo et al., 2003, 
McCall et al., 2001, McCall et al., 2008). A recent study identified enterovirus in a 
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small number of EL and PEP brains (Dourmashkin et al., 2012). Sporadic viral 
mesencephalitis presenting with an EL-like illness and extrapyramidal sequalae is well 
recognised (Duvoisin et al., 1965). Viruses, such as the one responsible for Japanese B 
encephalitis, are identified in some cases of PEP (Casals et al., 1998).  There is some 
evidence to support an immunological role in the pathogenesis of EL (Dale et al., 
2009, Vincent, 2004). Studies on patients with  sporadic EL have identified 
antineuronal antibodies, oligoclonal bands in the cerebrospinal fluid and N-methyl-D-
aspartate (NMDA) receptor antibodies in some cases (Dale et al., 2004, Dale et al., 
2009, Howard et al., 1987). Furthermore, the findings of elevated anti-streptolysin-O 
titres and anti-basal ganglia antibodies have been described, suggesting a post-
streptococcal autoimmune phenomenon (Dale et al., 2004, Vincent, 2004).  
Classic EL was an acute or subacute encephalitic illness, commonly associated with 
other major clinical features including somnolence, sleep inversion, ophthalmoplegia, 
oculogyric crises, extrapyramidal symptoms, obsessive-compulsive behaviour, akinetic 
mutism and central respiratory irregularities (Howard et al., 1987). Nevertheless, the 
diagnostic label of ‘EL’ was sometimes retrospectively and erroneously applied in 
patients with parkinsonism who recalled a past history of a catarrh-like illness, 
headache or flu that had occurred between the late 1910’s and late 1920’s (Vilensky et 
al., 2011). About a third of ‘PEP’ cases in the literature never had any antecedent 
encephalitic illness (Duvoisin et al., 1965, Foley, 2009, Geddes et al., 1993, Rail et al., 
1981, Vilensky et al., 2011, Vilensky et al., 2010). These cases were reported as ‘post-
encephalitic disorder without acute phase’ (Foley, 2009) or ‘sequelae of epidemic 
encephalitis without any preceding acute illness’ (Burr, 1925) and were considered as 
forme fruste PEP. Whether neurological sequelae can occur following ‘asymptomatic’ 
EL remains unproven.  
Cases with PEP in which parkinsonism developed more than 15 years after apparent 
recovery from EL have occasionally been reported (Duvoisin et al., 1965). A long 
latent interval was also observed in two of the PEP control cases (PEP-4, PEP-5; Table 
18). Nevertheless, latencies of more than a decade between acute EL and onset of 
parkinsonism are considered exceptional. Large series reported that the latent interval 
was five years or less in about half of the cases and less than ten years in more than 
80% of patients (Duvoisin et al., 1965), therefore, most survivors would have 
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developed parkinsonism by the 1940’s. The onset of parkinsonism in three of the PND 
cases was in the 1960’s and 1970’s. If these PND cases did have indolent EL, which 
was missed clinically or in the history, the latent interval between the ‘asymptomatic’ 
EL and onset of parkinsonism would have to have been four decades or more.  
Oculogyric crises was historically considered as pathognomonic for PEP and occurred 
in 30 to 60% of patients with PEP (Duvoisin et al., 1965, Howard et al., 1987). This 
phenomenon was observed in two PND patients and neither had a history of 
neuroleptic exposure. The two cases with oculogyric spasms in the present study 
seemed to improve with levodopa and the phenomenon has also been reported to remit 
spontaneously over time (Duvoisin et al., 1972, Rail et al., 1981). Dystonic spasms of 
the extraocular muscles, have also been described in other conditions such as dopa-
responsive dystonia, parkin disease, tic disorders and brainstem encephalitis (Della 
Marca et al., 2011). The phenomenon is associated with a dopaminergic deficient state 
and pathologies in the mesencephalic locomotor region of the dorsal midbrain (Clot et 
al., 2009, Della Marca et al., 2011, Wenning et al., 1997). Other associated features 
historically served to distinguish PEP from Parkinson’s disease were not observed in 
the PND group, notably behavioural change, psychosis, bulbar palsy, torticollis, facial 
tics, pallilalia, scoliosis, pyramidal signs and respiratory disturbances (Duvoisin et al., 
1965, Litvan et al., 1998, Vilensky et al., 2011). Ophthalmoplegia was common in 
PEP (Wenning et al., 1997), but the restricted upgaze noted in the two PND patients 
were most likely age-related. Severe dyskinesias or neuropsychiatric sequelae  from 
levodopa were not observed in the PND group (Duvoisin et al., 1972). The gradual 
disease progression of the PND cases also differed from the rapid initial deterioration 
followed by a static disease for decades and late motor deterioration in old age 
described in PEP (Calne et al., 1988, Duncan, 1924). 
The pathological findings of PND are very similar to PEP (Geddes et al., 1993, 
Haraguchi et al., 2000, Jellinger, 2011, Torvik et al., 1966, Wenning et al., 
1997)(Table 19), but differ considerably from PSP. Severe depletion of pigmented 
neuron in the substantia nigra pars compacta is characteristic in both PND and PEP 
cases, and was much more extensive than in Parkinson’s disease (Gibb et al., 
1987)(Figure 19). Relative preservation in the medial region of the nigra is noted in 
some PND cases, whereas the damage affects all parts of the pars compacta in PEP 
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(Geddes et al., 1993, Gibb et al., 1987, Jellinger, 2011). There is no evidence of active 
cell breakdown or extraneuronal melanin as seen in Parkinson’s disease (Gibb et al., 
1987), indicating a protracted degenerative process. The distribution of tau-
immunoreactive NFTs, PreTs and NTs is similar in PND and PEP, predominantly 
affecting the frontal and temporal cortices, hippocampus, amygdala, striatum, 
subthalamic nucleus, remaining neurons of the substantia nigra, locus coeruleus and 
pontine tegmentum. Other similarities between PND and PEP are the preservation of 
the subthalamic nucleus and cerebellar dentate nucleus, the presence of ghost tangles 
and the frequent concomitant TDP-43 pathology. The findings of severe and extensive 
nigral atrophy and ghost tangles also underpin the prolonged disease duration in these 
cases. The acute markers of disease activity observed in active EL brains, such as 
leptomeningeal and parenchymal perivascular lymphoplasmocytic infiltrates with 
scattered foci of acute neuronal injury, are absent in both PND and PEP. However, the 
consistent findings of granular PreTs, a precursor of the final filamentous NFTs, 
support a continuing neuronal degenerative process. The tau lesions in both PND and 
PEP are immunoreactive to both 3R- and 4R-tau antibodies and immunoblotting 
confirms a tau-triplet pattern, which is identical to that observed in Alzheimer’s 
disease, PDC of Guam and CTE, but it differs from the predominant 4R-tau lesions 
and tau-doublet pattern in PSP and CBD (Buee-Scherrer et al., 1997). 
Astrocytic lesions are a distinctive feature in PND. Most of these lesions are granular 
and are clearly different from the characteristic tufted astrocytes in PSP. Some can be 
bush-like with very fine processes or, rarely, filamentous. The fine bush-like lesions 
resemble those observed in argyrophilic grain disease (Saito et al., 2004), however, the 
lesions in PND are more widely distributed and are also detected in cases without 
grains. Similar astrocytic lesions are also noted in the PEP controls and in other PEP 
series (Ikeda et al., 1993), but have a more restricted distribution and are less abundant 
than those in PND. The astrogliopathy in both PND and PEP groups are predominantly 
AT100-positive and Gallyas-negative, unlike tufted astrocytes in PSP, which are 
Gallyas-positive. Tufted astrocytes, which were previously described in a single case 
of PEP, are not seen in the PEP controls in this series (Haraguchi et al., 2000). 
Oligodendroglial CBs and astrocytic plaques, as seen in CBD, are also absent.  
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Lewy bodies, the morphological hallmark in Parkinson’s disease, are absent in all PND 
cases. However, a few incidental Lewy bodies are found in one PEP case (PEP-1). 
Concomitant α-synuclein pathology, which can be observed in 12% of normal elderly, 
was reported to be characteristically absent in other PEP series (Jellinger, 2009, 
Josephs et al., 2002). The NFTs seen in PND and PEP are visibly no different from 
those in Alzheimer’s disease and tangle-predominant dementia (Jellinger et al., 2007). 
However, considering the most severe Braak and Braak stage being IV in our cases, 
their NFT distribution exceeds those expected in moderate Alzheimer-related 
pathology (Table 19). Aβ pathology, which was also reported to be rare in PEP 
(Jellinger, 2011), was found in all PND and three elderly PEP cases. Despite the co-
existence of amyloid plaques, dementia was not a feature in the PND and PEP groups, 
and the dissociation between pathology and dementia is now increasingly recognised 
in the elderly (Wharton et al., 2011).  
In 1971, Forno and Alvord referred to a group of parkinsonian cases without a history 
of EL but with NFTs as ‘idiopathic parkinsonism with Alzheimer neurofibrillary 
degeneration’ (Forno et al., 1971). In 1989, Rajput and colleagues reported four 
patients with benign levodopa-responsive parkinsonism. Unlike cases in the present 
series, their tau lesions were restricted to the substantia nigra and locus coeruleus and 
extraneuronal melanin in the substantia nigra was observed in two cases, indicating 
active breakdown of pigmented neurons (Rajput et al., 1989). Genetic analysis has not 
been performed on these cases (personal communication). Other case reports of 
unclassifiable neurofibrillary tangle parkinsonian disorders were all published more 
than two decades ago and all had some distinctive clinical or pathological differences 
to the PND cases (Daniel et al., 1991, Lidov et al., 1989, Mata et al., 1983, Renkawek 
et al., 1993). Some of these cases in the literature may belong to various genetic and 
neurodegenerative entities which are now better recognised, for instance, parkin 
disease (Mori et al., 1998), LRRK2 mutation (Zimprich et al., 2004) , FTDP-17 
(Hutton et al., 1998), PSP-P (Williams et al., 2007), PSP-PAGF (Williams et al., 
2007), cortical variants of PSP (Dickson et al., 2010), globular glial tauopathies 
(Ahmed et al., 2013), Niemann-Pick type C (Suzuki et al., 1995), Perry’s syndrome 
(Wider et al., 2010) and pantothenate kinase-associated neurodegeneration (Li et al., 
2012). Likewise, five of the 12 cases included in this study had a genetic or 
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neuropathological explanation after evaluation (Figure 18). Unclassifiable sporadic 
tauopathy with cognitive presentation has also been reported. Kovacs and colleagues 
studied the post-mortem findings of seven elderly patients, age ranged from 77 to 94, 
with dementia and, in three cases, associated parkinsonism (Kovacs et al., 2011). They 
all had a constellation of tau pathology and distinctive astrogliopathy, in a 
characteristic distribution, along with some Alzheimer-related changes, reminiscent of 
our PND cases. The authors referred them collectively as complex tauopathy which 
may have heterogeneous aetiologies.  
Guamanian PDC is a rapidly progressive parkinsonian and dementia syndrome, 
affecting the indigenous Chamorro population in the Western Pacific (Hirano et al., 
1961). The disorder, referred by the locals as ‘bodig’, begins in the fifth or sixth 
decade, resulting in death after five years. Oculomotor abnormalities are sometimes 
observed. Guamanian PDC, PEP and PND share many neuropathological similarities, 
including severe nigral cell loss, NFT accumulation in the hippocampus, temporal and 
frontal cortices and striatum, ghost tangles and concomitant TDP-43 pathology 
(Geddes et al., 1993, Hasegawa et al., 2007, Hirano et al., 1961). However, the typical 
Gallyas-positive hazy granular astrocytic lesions and tau-positive fine white matter 
granules described in PDC are notably absent in the PEP and PND cases in the present 
study (Oyanagi et al., 1997, Yamazaki et al., 2005). Like PEP, the cause of PDC 
remains enigmatic, although a combination of environmental and genetic factors is 
hypothesized (McGeer et al., 2011). Two sites in the MAPT gene conferring risk for 
PDC of Guam have been identified, indicating a role in genetic susceptibility (Sundar 
et al., 2007). Since 1965, the incidence of bodig has significantly decreased and, 
similarly, ‘lytico’ amyotrophic lateral sclerosis, which was once prevalent in Guam, 
has become much rarer (Plato et al., 2003). There are only a few new cases of PDC 
born after 1951 (McGeer et al., 2011). The intriguing change in epidemiology suggests 
a local exogenous insult, which most likely to have occurred in the first half of the 
twentieth century and has since declined significantly. A change in diet is proposed as 
the explanation but this remains controversial (McGeer et al., 2011). Mulder and 
Kurland initially speculated links with von Economo’s disease and the possibility of a 
viral pathogen was raised (Kurland et al., 1954). The absence of new PND cases born 
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after 1930’s in this series suggests that it may be an entity which is dying out 
spontaneously, in the same way as Guamanian PDC and PEP.  
It is plausible that PND and PEP share a common aetiology based on the evidence that 
all PND cases were born before or during the EL epidemic posing opportunities of 
exposure, and that there is a striking resemblance of the neuropathology between the 
two groups. The lack of a history of encephalitis in PND, however, is a fundamental 
anomaly that should serve as a stimulus to question the paradigm of PEP (Vilensky et 
al., 2010). A historical analysis has highlighted that EL and PEP had a complex rather 
than a direct relationship (Vilensky et al., 2010). Nevertheless, the limited knowledge 
of the cause of EL and of its pathophysiological links with PEP poses difficulties in 
speculating whether the patients with PND could have had EL without clinical 
evidence. In both PEP and PND, there are extensive neuronal loss and NFT 
pathologies in the brainstem where the brunt of pathology in acute EL is also observed, 
supporting some causal relations (Jellinger, 2011). If indeed PND is forme fruste PEP, 
patients with PND and PEP would have had the same early insult, which may be an 
infective agent or an immunological response to an external or internal antigen, leading 
to acute injury of the central nervous system. It is hypothesized that in PEP the acute 
neuronal injury subsequently triggers a neurodegenerative process which presents 
clinically some time later and progresses slowly over many years (Geddes et al., 
1993).  
Other examples of acute neuronal insult triggering progressive neuronal degeneration 
with NFT accumulation are subacute sclerosing panencephalitis (SSPE)(Cobb et al., 
1984, McQuaid et al., 1994) and CTE (McKee et al., 2013). Alzheimer-type NFT 
pathology occurs after a latent period in SSPE survivors and in individuals exposed to 
repetitive brain injury. The NFT pathology in these cases has a similar distribution as 
in PND and PEP. Nevertheless, the findings of neuronal measles viral genome in SSPE 
and subpial perivascular astrocytic tangles in CTE provide distinguishing markers for 
these conditions (Geddes et al., 1999, McKee et al., 2013, McQuaid et al., 1994). It is 
proposed that once tau aggregates are formed in discrete brain regions, they undergo 
intercellular transfer, promoting a self-propagating process, which leads to the spread 
of abnormal tau throughout the brain (Clavaguera et al., 2009, Hardy, 2005).  
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Genetic susceptibility as identified in other sporadic tauopathies, such as the H1 
haplotype in PSP and CBD (Houlden et al., 2001), may also exist for PND. The 
genome-wide association studies for Parkinson’s disease, a disorder characterised by 
α-synuclein pathology, revealed a surprising MAPT locus, suggesting cross-talk 
between molecular pathways of different protein aggregates (Simon-Sanchez et al., 
2009). A search of genetic loci outside the MAPT gene in these PND and PEP cases 
might in the future also reveal unexpected hotspots.  
This study identified a group of patients with NFT pathology resembling that found in 
PEP but with no history of encephalitis and a somewhat different clinical picture, 
leading to a reconsideration of the links between acute EL and presumed PEP and the 
mechanisms involved. 
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5.2: The MAPT p.A152T variant: a risk factor 
associated with atypical tauopathies 
Introduction 
Tau belongs to the family of the microtubule-binding proteins (Witman et al., 1976) 
and is encoded by the MAPT gene located on chromosome 17 (17q21)(Andreadis et 
al., 1992). MAPT mutations have been mainly linked to FTD (Hutton et al., 1998), as 
well as to a variety of neurodegenerative diseases with abnormal tau accumulation, 
including PSP, CBD and other rarer tauopathies (Conrad et al., 1997, Hoglinger et al., 
2011, Momeni et al., 2009). Recently, an A152T variation in MAPT exon 7 was 
identified in a patient who had dementia and unclassifiable tauopathy (Kovacs et al., 
2011). With this background, primary sequencing of the MAPT gene was performed as 
part of the evaluation of the 12 cases with slowly progressive levodopa-responsive 
parkinsonism and unclassifiable tau accumulation as detailed in Chapter 5.1 (Figure 
18). Of the 12 cases sequenced, two were found to carry the p.A152T variation. A 
secondary sequencing was subsequently carried out in a larger series of cases with 
PSP, CBD and Parkinson’s disease to determine the nature of the phenotype associated 
with this variant and two additional cases with this variant were identified.  
Materials and methods 
Primary sequencing 
Initial sequencing was performed on the entire MAPT gene open reading frame in 12 
cases fulfilling the inclusion criteria as described in Chapter 5.1 (Figure 18).  
Three of these cases have been previously reported (case 1 with the MAPT p.A152T 
variant=case 8 in Geddes’ series, PND-6=case 5 in Geddes’ series and PND-7=case 7 
in Geddes’ series (Geddes et al., 1993). 
149 
 
Initial post-mortem study reported case 1 as PEP despite the absence of a history of 
encephalitis. The original neuropathological examination did not reach a conclusive 
diagnosis in case 2, which had been categorized as ‘parkinsonism associated with 
unclassifiable neurofibrillary tangle pathology’. 
Genetic analysis 
Genomic DNA was extracted from brain tissue of the 12 included cases. After the 
p.A152T mutation was found in exon 7 in two cases, additional screening of this exon 
was carried out in blood derived DNA of the three siblings of case 1 (two suffering 
from dementing illnesses and one unaffected), and in 150 neuropathologically defined 
controls and 133 1958 Wellcome Trust blood donor controls. At this stage, the 
occurrence and frequency of this variant in public databases was also assessed. 
Statistical analysis 
Fisher exact tests were conducted using an online tool: 
http://research.microsoft.com/enus/um/redmond/projects/mscompbio/FisherExactTest/
P-value below 0.01 was considered statistically significant. 
Secondary sequencing 
After identifying the variant in two of the 12 included cases and failing to find the 
variant in control samples, secondary screening was performed in DNA derived from 
the brains of the QSBB archival collection, including pathologically confirmed cases 
with PSP (N=114)(Pittman et al., 2004), CBD (N=8)(Houlden et al., 2001) and 
Parkinson’s disease (N=48).  
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Results 
Primary sequencing 
Genetic analysis 
Among the 12 cases included in the primary genetic analysis, two cases were identified 
to carry a heterozygote non-synonymous variant in exon 7 (rs143624519, c.454G>A, 
p.A152T)(accession numbers NM_005910.5 and NP_005901.2 respectively)(Figure 
26). This variant was also found in the two living sisters of case 2, who were both 
developing progressive cognitive impairment, but this variant was absent in the third 
unaffected sister. All patients are Caucasian and of northern European descent. This 
variant is present with a frequency of 19 in 3510 (0.54%) individuals of European 
American origin (19 in 7020 alleles) in the publicly available database from the 
National Heart Lung Blood Institute (NHLBI) GO-Exome Sequencing Project (Exome 
Variant Server, NHLBI GO-ESP, Seattle, WA; http://evs.gs.washington.edu/EVS/, 
accessed on January 2012). Additional screening was performed on 283 control cases 
but this variant was not identified. The Fisher exact test used to compare both allele 
and genotype frequencies between the unclassifiable tauopathy and the ESP cohort 
gave a two-tailed p-value of < 0.01 for allele and genotype frequencies. A search 
through two publicly available databases: 1000 genomes and The National Institute of 
Environmental Health Sciences Environmental Genome Project (NIEHS, Seattle, WA; 
http://evs.gs.washington.edu/niehsExome/, accessed on March 2012) revealed 
similarly low frequencies of the A152T variant (1000 Genomes Project 
Consortium)(2010). This variant has been reported more frequently in Alzheimer’s 
disease than in controls (Cruchaga et al., 2012). 
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Figure 26. Sequencing chromatograms and family tree of cases carrying the MAPT 
p.A152T variant. 
A: c.454>A/p.A152T variant in case 1 (upper panel) and case 2 (lower panel); B:  
family tree of case 2 showing segregation of the variant with affected family   
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Case 1 
At the age of 26, this patient developed a slowly progressive levodopa-responsive 
Parkinson’s syndrome with intact cognition. There was a long history of levodopa-
induced orofacial dystonia. She never had any encephalitic illnesses prior to the onset 
of parkinsonism. The disease duration was 54 years and she died at the age of 80. A 
family history of dementia was noted, but not elaborated in her medical records. 
Neuropathological examination showed a significant degree of neuronal loss in the 
substantia nigra, which was most severe in the ventrolateral tier. There were tau-
immunoreactive NFTs and numerous NTs in the substantia nigra. Sparse NFTs and 
NTs were also seen in the midbrain tegmentum. Amyloid plaque-associated abnormal 
neurites were also observed in the midbrain tectum. Scattered NFTs and NTs were 
identified in the striatum, globus pallidus and subthalamic nucleus. There was a single 
NFT with sparse NTs in the cerebellar dentate nucleus. Aβ-positive diffuse and mature 
plaques in the frontal, parietal and temporal cortices were noted. Severe NFTs, NTs 
and plaque-associated neurites in the CA1 hippocampal subregion, entorhinal cortex 
and fusiform gyrus corresponded to Braak and Braak stage IV (Figure 27). The tau 
inclusions were both 3R and 4R-tau positive. Neither TDP-43-related pathology nor 
argyrophilic grain disease was observed. The tau-positive lesions observed in this case 
were consistent with age-related changes. However, the severe neuronal loss in the 
substantia nigra was as extensive as those in PEP and PND (Chapter 5.1). The 
neuropathological findings of this case were not compatible with any known entity.  
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Figure 27. Neuropathological features of a case carrying the MAPT p.A152T variant. 
A: Severe loss of pigmented neurons in ventral tier of substantia nigra (white 
asterisks) with gliosis and free pigment (arrow head). Non-pigmented neurons are still 
present in this region of the substantia nigra (arrows); B: A tau-positive 
neurofibrillary tangle in a nigra neuron; C: neurofibrillary tangles, neuropil threads 
and neuritic plaques in the CA1 hippocampal sub-region. 
A: H&E; B & C: AT8 immunohistochemistry; scale bar on A=80microns on A, 
=20microns on B, =40microns on C. 
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Case 2 
At the age of 57, this English woman began to develop a symmetrical akinetic rigid 
syndrome. Two years later, examination revealed hypomimia, drooling, predominant 
axial rigidity with mild symmetrical limb rigidity, brisk deep tendon reflexes and 
flexor plantar response. A diagnosis of Parkinson’s disease was made, but she only had 
transient benefit from levodopa therapy. Her symptoms gradually deteriorated and 
seven years later, she developed dysarthria and dysphagia. In her mid-60’s, she started 
to experience daily episodic dystonic spasms with an opisthotonus posture and 
oculogyric crises. Examination in-between these episodes revealed normal pursuit and 
saccadic eye movements, fixed retrocollis, slow tongue movement, anarthria and 
severe axial and limb rigidity and dystonic posturing of the feet. Her cognitive function 
remained intact. The presence of oculogyric spasms prompted the neurologist to revise 
the diagnosis to PEP in the last year of her life. She died after a disease duration of ten 
years.  
This patient had three younger sisters (Figure 26). The second sister, now in her mid-
80s, has developed dementia with short term memory impairment, executive 
dysfunction, disorientation to time and required assistance with dressing and 
housework. Her youngest sister, in her mid-70s, has experienced symptoms of 
forgetfulness but remains independent. These sisters were assessed in person and over 
the telephone. Her third sister remains well. Both affected sisters carried the mutation 
but the healthy sister did not.  
Neuropathological re-evaluation using modern immunohistochemistry staining 
indicated that the findings were consistent with the pallido-nigro-luysial atrophy 
(PNLA) variant of PSP (Ahmed et al., 2008). There were moderate numbers of AT8 
and 4R-positive and 3R-negative tufted astrocytes, NFTs, NTs and CBs in the caudate 
and, to a lesser severity, in the putamen. Severe gliosis and neuronal loss was noted in 
the substantia nigra. Significant reduction in size, cell loss and gliosis was observed in 
the globus pallidus and subthalamic nucleus. However, the cerebellar dentate nucleus 
and superior cerebellar peduncle were relatively well preserved, which differs from the 
typical findings in classic PSP-RS. Together with both neuronal and glial tau 
pathology in the basal ganglia, brainstem and cerebellar nuclei and the relatively mild 
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tau pathology in the cerebral cortex, pontine base and cerebellar dentate nucleus, these 
histopathological findings were in favour of the diagnosis of the PNLA variant PSP. 
The age-related tau pathology corresponded to Braak and Braak stage II. There was no 
evidence of argyrophilic grains. 
Secondary sequencing 
The secondary screening of exon 7 of the MAPT gene was subsequently carried out in 
114 PSP, 8 CBD and 48 Parkinson’s disease cases from the QSBB archival collection. 
The mutation was identified in one case with CBD. More surprisingly, it was also 
found in one case with Parkinson’s disease. 
Case 3 
In the mid-60s, this patient developed word-finding difficulties, right-sided rigidity 
followed by difficulties in walking. His predominant symptoms evolved from non-
fluent aphasia to mutism, increasing dependency and then death within 11 years. There 
was no documented family history of dementing illness.  
Neuropathological findings were consistent with CBD, including achromatic, swollen 
neurons in the neocortex and limbic areas, numerous PreTs and NFTs, dense 
meshwork of tau-positive threads, astrocytic plaques in the frontal, temporal and 
parietal cortices and tau-positive threads and some CBs in subcortical white matter. 
Additionally, there were numerous TDP-43 positive NCIs and occasional NIIs in the 
globus pallidus, caudate and putamen. Severe neuronal loss in the substantia nigra was 
noted. 
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Case 4 
In his late 40s, this patient developed an anxiety disorder and poor concentration which 
resulted in him getting dismissed from his job. In the following year, he started to 
stutter and was diagnosed with depression. Two years later, he had memory loss, 
executive impairment, slowness in movement. Following the subsequent findings of 
markedly reduced tracer reuptake in the basal ganglia on DAT-SPECT, a diagnosis of 
Parkinson’s disease with dementia was made when he was in his early 50’s. He was 
commenced on levodopa therapy with moderate response. His cognitive function 
deteriorated markedly in the following year with fluctuating consciousness, 
disorientation, urinary incontinent, severe dementia, visual hallucination, myoclonus 
and asymmetrical akinetic rigidity. He died seven years after the onset of his first 
symptoms.  
Neuropathological findings were consistent with the diagnoses of Parkinson’s disease 
with dementia and pathological ageing. Histopathological examination revealed 
moderate to severe cell loss in the substantia nigra in association with α-synuclein-
positive Lewy bodies and Lewy neurites. Frequent cortical Lewy bodies were observed 
in the frontal, temporal, parietal, cingulate gyrus and transentorhinal cortices, 
corresponding to Braak stage 6 (Braak et al., 2003) and diffuse neocortical Lewy body 
type pathology according to consensus criteria (McKeith et al., 2005). NFTs were 
found in the hippocampus, entorhinal and transentorhinal cortices which were 
consistent with Braak and Braak II. There were few tau-positive NTs in the caudate 
nucleus, midbrain tegmentum and periaqueductal grey. A single NFT was noted in the 
locus coeruleus. A ‘low’ level of Alzheimer Disease pathologic change (A1, B1, C0) 
was identified according to the NIA-AA guideline (Montine et al., 2012).  
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Discussion 
Four cases were identified in this study to carry the p.A152T MAPT mutation in 
primary and secondary sequencing. This rare variant has only been reported in few 
cases in the literature, including one case with dementia and unclassifiable tauopathy 
(Kovacs et al., 2011), one with a clinical picture of PSP (Coppola et al., 2012), one 
with PNLA variant of PSP, akin to case 2 in this report (Graff-Radford et al., 2013) as 
well as in few Alzheimer’s disease cases (Cruchaga et al., 2012, Jin et al., 2012). 
These case reports, along with the segregation with affected family members in case 2, 
its absence in the 283 control samples and its rarity in the public databases all support 
the notion that the p.A152T variant contributes to disease risk. The finding that the 
mutation occurs in one of eight CBD cases sequenced may also be adduced to support 
this view.  
The identification of the variant in a case of Parkinson’s disease was a surprise. 
However, this case was unusual in view of the rapid disease course and the 
considerable burden of tau pathology exceeded the amount of age-related change 
which would have been expected in a case of a relatively young age. Additionally, the 
clinical and pathological findings vary in all four reported cases in this series. Despite 
some evidence for segregation in the single family of case 2, in which this analysis was 
possible, and a positive family history in case 1, there was no family history of 
dementia or movement disorders in cases 3 and 4. Unlike in classic cases with MAPT 
mutations, the tau pathology was variable, both in morphology and distribution; being 
4R in cases 2 and 3 and a classic mixture of 3R and 4R in cases 1 and 4.  
The position of the variant is interesting in that it creates an additional phosphorylation 
in the tau protein and tau hyperphosphorylation has been repeatedly suggested to 
contribute to NFT formation and cell death (Rademakers et al., 2004). One plausible 
suggestion is that this mutation contributes to disease pathogenesis through the 
creation of an additional phosphorylation site but that this is not sufficient, of itself, to 
cause disease in the way that the MAPT splice and P301L mutations do. The mutated 
residue is next to Thr153 (T153), a phosphorylation site, which is a target for proline-
directed kinases MAPK, cdk5 and GSK3α. Using an antibody against the 
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phosphorylated T153 (pT153), a study showed that although intra-neuronal and extra-
neuronal tangles were labelled, the dominant staining was punctate and of PreTs within 
morphologically intact neurons, with normal cellular integrity and well preserved 
dendrites (Augustinack et al., 2002). A similar staining pattern of PreTs was observed 
with the conformation-specific TG3 antibody (Jicha et al., 1997) and a phospho-tau 
specific pS262 antibody, suggesting that these antibodies label an early stage of tangle 
formation characterised by punctate inclusions that precede fully-fledged fibrillar 
tangles (Augustinack et al., 2002). It is possible that the additional Thr152 increases 
phosphorylation and, thus, further contributes to the early stages of the fibrillogenic 
pathway. A recent functional study has shown that the p.A152T MAPT variant plays a 
role in reducing tau binding to the microtubule and increases tau oligomer formation 
(Coppola et al., 2012). 
LRRK2 mutations offer a precedent for this complex relationship between mutations 
and disease. Some mutations (e.g. p.G2019S) cause disease in an almost fully 
penetrant autosomal dominant fashion (Paisan-Ruiz et al., 2004), whereas others (e.g. 
p.G2385R) increase disease risk by a modest amount (Tan et al., 2010). In the same 
way as in the p.A152T MAPT variant, LRRK2 mutations also cause variable 
pathologies, with the majority having Lewy body pathology, but, tau, ubiquitin and 
TDP-43 pathologies have also been reported (Zimprich et al., 2004). For the true role 
of this variant in neurological disease to be determined, very large number (in the 
thousands) of cases with various tauopathies and controls will need to be sequenced. 
Certainly until that time, the present data would not support this mutation becoming 
part of the clinical test in the way that the penetrant mutations are.  
In conclusion, the rare MAPT p.A152T variant is likely to increase the susceptibility to 
the development of relatively common or atypical neurodegenerative diseases, 
associated with abnormal tau accumulation and with clinical presentation of either 
dementia or movement disorder. Further functional studies are necessary in order to 
fully dissect the functional consequences and precise pathogenic mechanisms 
associated with this mutation.  
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5.3:  LRRK2 G2019S mutation with tau and 
TDP-43 pathologies 
Introduction 
Among the five identified pathogenic leucine-rich repeat kinase 2 (LRRK2) mutations, 
G2019S is the most common and accounts for 1% of sporadic Parkinson’s disease and 
4% of hereditary parkinsonism worldwide (Healy et al., 2008). Clinical presentation of 
LRRK2 mutation resembles idiopathic Parkinson’s disease but may be associated with 
a more benign disease course (Healy et al., 2008). Most cases with LRRK2 mutation 
exhibit neuropathological features consistent with typical Lewy body Parkinson’s 
disease (Gilks et al., 2005, Khan et al., 2005, Zimprich et al., 2004), but ‘pure’ nigral 
degeneration, tau, α-synuclein or ubiquitin pathologies, resembling PSP, multiple 
system atorphy (Hasegawa et al., 2009), and frontotemporal lobar degeneration with 
ubiquitin-positive inclusions (FTLD-U) have also been reported (Dachsel et al., 2007, 
Gaig et al., 2008, Giasson et al., 2006, Rajput et al., 2006, Zimprich et al., 2004). 
Ubiquitinated TAR DNA-binding protein-43 (TDP-43) is a major disease protein in 
FTLD and amyotrophic lateral sclerosis (ALS) and can occasionally be observed in 
Lewy body disorders and tauopathies (Mackenzie et al., 2010, Neumann et al., 2006, 
Sreedharan et al., 2008). Recently, TDP-43 related pathology was reported in three 
cases carrying LRRK2 mutations (p.R1441C, p.R793M and L1165P)(Covy et al., 
2009, Zimprich et al., 2004).  
As part of the evaluation of cases presenting with parkinsonism and unclassifiable tau 
accumulation in post-mortem (Chapter 5.1), sequencing of the LRRK2, MAPT and 
parkin genes was performed. Of the 12 cases included in the study, one case was found 
to carry the LRRK2 G2019S mutation as well as a novel heterozygous variant 
c.370C>G, p.Q124E in exon 4 of the MAPT gene. This patient was clinically 
diagnosed with Parkinson’s disease and had neuropathological findings of nigral 
degeneration with absence of Lewy body pathology.   
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Materials and methods 
Case selection and genetic analysis  
In addition to the methods described in Chapter 5.1, sequencing of the TDP-43 gene 
was performed in this case with LRRK2 G2019S mutation. In four other cases with 
proven LRRK2 G2019S mutations and Lewy body pathology available in the QSBB 
archival collection (Gilks et al., 2005), sequencing of the MAPT gene was performed.  
Neuropathology 
In addition to the neuropathological methods described in Chapter 5.1, a semi-
quantitative assessment of nigral cell loss was performed in 12 randomly selected 
cases with confirmed pathological diagnosis of Alzheimer’s disease. The aim of the 
assessment was to evaluate if the neuronal loss in the substantia nigra pars compacta 
identified in the LRRK2 case was related to the genetic mutation or to its Alzheimer-
related pathology. 
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Results 
Genetic analysis  
Of the 12 included cases, one was identified to carry both the LRRK2 G2019S 
mutation and a heterozygous variant in MAPT exon 4 (c.370C>G, p.Q124E, Figure 
28). The MAPT p.Q124E variant is absent in all control subjects in the public 
databases (N=6568, of which 3913 are Caucasians), including ENSEMBL 
(http://useast.ensembl.org/index.html), Exome Variant Server (NHLBI GO-ESP, 
Seattle, WA; http://evs.gs.washington.edu/EVS/, accessed in January, 2013)(Table 20). 
The pathogenicity is predicted to be ‘possibly damaging’ based on a web-based 
assessment on Polyphen2 (http://genetics.bwh.harvard.edu/pph2/ ). This variant is 
absent in the four archival LRRK2 cases with Lewy body pathology. The MAPT 
genotype of this patient was H1/H2. Sequencing of the parkin and TDP-43 genes in 
this case was negative. Dosage study using MLPA was negative for all analysed genes 
including parkin and LRRK2. 
 
 
 
Figure 28. Diagram of the MAPT gene and locations of three rare risk variants 
associated with tau pathology. 
The novel c.370C>G variant is indicated with a black arrow on the chromatogram 
above the p.Q124E variant.  
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Database Ethnicity of 
subjects 
No. of 
subjects 
included  
Genotype 
frequency of the 
p.Q124E MAPT 
variant 
Allele frequency 
of the p.Q124E 
variant 
NHLBI GO-ESP European 
American 
3510 0/3510 (0%) 0/7020 
NHLBI GO-ESP African 
American 
1869 0/1869 (0%) 0/3738 
1000 genomes Mixed 
American 
181 0/181 (0%) 0/362 
1000 genomes European 381 0/381 (0%) 0/762 
1000 genomes African 
  East Asian 
South Asian 
532 0/532 (0%) 0/1064 
NIEHS Caucasian 22 0/22 (0%) 0/44 
NIEHS African 
American 
14 0/14 (0%) 0/28 
NIEHS Asian 24 0/24 (0%) 0/48 
NIEHS Hispanic 22 0/22 (0%) 0/44 
NIEHS Yoruban 13 0/13 (0%) 0/26 
Table 20. Genotype frequency of the MAPT p.Q124E variant in public databases. 
The MAPT p.Q124E variant is not identified in any control subject. ESP=Exome 
Sequencing Project; NHLBI=National Heart Lung Blood Institute; NIEHS=The 
National Institute of Environmental Health Sciences 
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Case report  
This British Caucasian woman, who carried the LRRK2 G2019S mutation and the 
heterozygous p.Q124E MAPT variant, developed right hand tremor at the age of 73. 
She had mild bradykinesia and rigidity and had received a clinical diagnosis of 
Parkinson’s disease. She was initially started on an anticholinergic medication and five 
years later, levodopa therapy was administered and titrated to 1000mg/day with good 
response. Her motor symptoms gradually deteriorated over the years. She reported 
wearing-off symptoms but she never had any dyskinesia. She had intact cognition 
throughout the disease course. In the last year of life, she had balance difficulty, 
multiple falls and required a rollator to mobilize. She died at the age of 85. There was 
no family history of any neurological disorders. 
Neuropathological analysis confirmed a moderate degree of neuronal loss in the 
substantia nigra, except in the ventrolateral tier where severe neuronal loss was found 
(Figure 29). There were no Lewy bodies on α-synuclein or phospho-α-synuclein 
immunohistochemistry. There were sparse tau-positive NTs in the frontal and parietal 
cortices; sparse NTs, NFTs and PreTs in the CA1 and CA4 hippocampal subregions; 
mild PreTs, moderate numbers of neuritic plaques, NFTs and NTs in the subiculum; 
severe NFTs, NTs and PreTs in the entorhinal cortex and very sparse NTs in the 
striatum. All tau inclusions were both 3R and 4R-tau positive. The subthalamic 
nucleus was preserved and no tau pathology was noted.  
Aβ immunohistochemistry demonstrated parenchymal deposition in the cerebral 
cortex, hippocampus and striatum, corresponding to a Thal phase score ‘3’ (Thal et al., 
2002) and the distribution of tau pathology corresponded to Braak and Braak stage III 
(Braak et al., 2006). Using the CERAD criteria (Mirra et al., 1991), the neuritic plaque 
score was ‘sparse’ in the temporal cortex, ‘moderate’ in the frontal cortex and ‘sparse’ 
in the parietal cortex. These results gave a ‘low’ likelihood of Alzheimer’s disease 
according to the NIA-Reagan criteria (Hyman et al., 1997) and ‘intermediate’ level of 
Alzheimer-pathologic change (A2, C2, B2) according to the NIA-AA criteria (Montine 
et al., 2012).  
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TDP-43 immunohistochemistry showed numerous fine thread-like processes and few 
coarser neurites in the CA1 hippocampal subregion and subiculum. In the amygdala, 
temporal and frontal cortices, there were occasional NCIs and few threads. Occasional 
NCIs, threads and NIIs were observed in the subiculum, striatum and substantia nigra. 
Skein-like NCIs were also found in the substantia nigra. 
No hippocampal sclerosis, α-synuclein immunoreactive inclusions, argyrophilic grains, 
CAA or vascular pathology was observed. There were no p62-positive ‘star-shaped’ 
inclusions in the hippocampus or small ‘dot-like’ structures in the cerebellar granule 
cells of the type associated with C9orf72 repeat expansion. 
Findings in other LRRK2 G2019S cases 
In the other four archival cases with proven LRRK2 G2019S mutation, no TDP-43 
related pathology was observed in the hippocampus or amygdala. Sequencing of the 
MAPT gene was negative.  
Substantia nigra in Alzheimer’s disease  
In the 12 randomly selected control cases with confirmed pathological diagnosis of 
Alzheimer’s disease (NIA/Reagan ‘high’ likelihood of Alzheimer’s disease), cell loss 
of the substantia nigra was at most mild as evidenced by regional pigment 
incontinence in the pars compacta.  
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Figure 29. Neuropathological findings of the LRRK2 G2019S case. 
A: Severe loss of neuromelanin-containing neurons in the ventrolateral tier of the 
substantia nigra (arrows) as well as gliosis and free pigment (arrowheads); B: 
abundant tau-positive neurofibrillary tangles, neuropil threads and pre-tangles in the 
entorhinal cortex; C: phospho-TDP-43 (p-TDP) -immunoreactive neuronal 
cytoplasmic inclusions (NCIs), neurites and a skein-like structure (inset) in the 
substantia nigra; D: numerous p-TDP-positive fine thread-like processes, few coarser 
neurites, round, dot-like structures and a ‘cat-eye’ neuronal intranuclear inclusion 
(NII, inset) in the subiculum. 
A: H&E, B: AT8, C&D: Phospho-TDP-43 immunostaining. 
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Discussion 
LRRK2 G2019S mutation is commonly associated with Lewy body pathology. Of the 
22 published post-mortem cases with this mutation, only four cases had absence of 
Lewy bodies. Rajput et al reported a case with slowly progressive non-levodopa-
responsive parkinsonism and tau-positive NFTs, resembling the neuropathology of 
PSP (Rajput et al., 2006), Gaisson et al and Gaig et al each reported a case with classic 
tremor-dominant parkinsonism and pure nigral degeneration (Gaig et al., 2008, 
Giasson et al., 2006) and Dachsel et al reported a case with dementia and tremor and 
neuropathology consisted of FTLD with ubiquitinated neuronal inclusions (FTLD-
U)(Dachsel et al., 2007). On the other hand, pleomorphic pathologies, including α-
synuclein, tau and ubiquitin, seem to be more commonly associated with other 
pathogenic LRRK2 mutations (Hasegawa et al., 1997, Hasegawa et al., 2009, Santpere 
et al., 2009, Wszolek et al., 2004, Wszolek et al., 1997, Zimprich et al., 2004).  
The present case, with LRRK2 G2019S mutation, was clinically diagnosed as 
Parkinson’s disease and had good levodopa response. Neuropathological analysis 
revealed nigral degeneration with Alzheimer-type tau and TDP-43 proteinopathy and 
absence of Lewy body pathology. Interestingly, this patient was also found to carry a 
novel p.Q124E MAPT variant. Prompted by the TDP-43 pathology, screening for 
TDP-43 mutations was carried out and was negative. A survey for TDP-43 pathology 
in another four archival QSBB cases with LRRK2 G2019S mutation and Lewy body 
pathology did not identify any TDP-43-immunoreactive lesions and MAPT sequencing 
of these cases were also negative.  
To date, only three cases with LRRK2 mutation have been reported to have TDP-43 
related pathology (p.R1441C, p.R793M and L1165P)(Covy et al., 2009, Zimprich et 
al., 2004), and none of which carried the G2019S mutation. Only three other published 
cases carrying the LRRK2 G2019S mutation were evaluated for TDP-43 pathology 
(Giasson et al., 2006), but no TDP-43-positive inclusions were observed (Covy et al., 
2009).  
The discovery of TDP-43 in 2006 as a major disease protein in FTLD and ALS led to 
the introduction of TDP-43 immunohistochemistry into the routine diagnostic 
167 
 
protocols of brain banks. It is, therefore, likely that other reported LRRK2 cases with 
ubiquitin pathology may also have TDP-43 inclusions (Dachsel et al., 2007, Wszolek 
et al., 2004, Wszolek et al., 1997, Zimprich et al., 2004) and will warrant 
comprehensive assessment. In addition to FTLD-TDP and ALS, TDP-43 inclusions 
can sometimes be detected in other neurodegenerative diseases, including Alzheimer’s 
disease, Lewy body disorders, CBD, PSP, Guamanian PDC, and CTE (Arai et al., 
2009, Hasegawa et al., 2007, Higashi et al., 2007, King et al., 2010, Lashley et al., 
2011, Mackenzie et al., 2010, McKee et al., 2013, Uryu et al., 2008). The cause and 
mechanism of TDP-43 in tauopathies are not known but it has been postulated that tau 
aggregates may promote aggregation of TDP-43 through cross-seeding (Morales et al., 
2009, Uryu et al., 2008). TDP-43 immunoreactivity may modify clinical features in 
Alzheimer’s disease and other types of dementia (Josephs et al., 2008, Lashley et al., 
2011) and is also closely associated with hippocampal sclerosis (Amador-Ortiz et al., 
2007, Josephs et al., 2008). It remains to be determined if TDP-43 protein plays a role 
in influencing the clinical features in LRRK2 cases.  
As in Lewy-body Parkinson’s disease, degeneration of the substantia nigra is a typical 
finding in LRRK2 mutation and is considered the pathological substrate of clinical 
parkinsonism (Wider et al., 2010). Although previous studies have shown a correlation 
between nigral pathology and extrapyramidal symptoms in Alzheimer’s disease (Burns 
et al., 2005), the screening of 12 randomly selected Alzheimer’s disease controls in 
this present study did not reveal significant neuronal loss in the substantia nigra. It is, 
therefore, unlikely that the modest Alzheimer-type tau pathology in this case is directly 
contributory to the extent of the neuronal loss and atrophy of the substantia nigra. 
The pleomorphic pathologies in LRRK2 mutation supports the notion that LRRK2 acts 
upstream from the pathway of other proteins implicated in neuronal death. It is likely 
that genetic and environmental factors then influence the type of proteinopathy that 
eventually develops in the individual, whether it is α-synuclein, tau or ubiquitin 
pathology (Wider et al., 2010). The novel MAPT variant identified in this case is 
located in a region of the protein far from microtubule binding domains and does not 
have an obvious role in the molecule’s function. The p.A152T MAPT variant in exon 7 
described Chapter 5.2 and the p.A239T in exon 8 (NM_005910.5) found in a carrier of 
the C9orf72 repeat expansion (King et al., 2013) are another two rare variants recently 
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identified. Interestingly, these three variants all localize in an uncharacterised region of 
the MAPT protein in cases with unexpected tau pathology, suggesting that they may 
have a disease modifying role in predisposing the individual to tau pathology (Coppola 
et al., 2012). Nevertheless, when encountering LRRK2 cases with atypical clinical 
presentation or unusual pathologies, the possibility of a non-penetrant LRRK2 mutation 
and coincidental neurodegenerative disorder should also be considered (Goldwurm et 
al., 2011, Sierra et al., 2011, Xiromerisiou et al., 2012).  
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Summary of findings and future work 
Traditionally, neurodegenerative diseases have been classified based on the basis of 
their combined clinical and neuropathological findings. Clinicopathological studies on 
CBD and PSP have recently widened the spectrum of clinical phenotypes far beyond 
their classic presentations, and the classic clinical picture of CBD and PSP is now 
known to be associated with heterogeneous pathologies. It has also been determined 
that the clinical features of CBD and PSP are closely linked with the severity and the 
topographical distribution of the underlying tau pathology and neuronal loss.  
Advances in molecular genetics have further complicated the taxonomy of 
neurodegenerative diseases and it is now clear that the same gene mutation may have 
different clinical manifestations and diverse pathology while identical clinical 
presentations can be seen with different genetic disorders. Disease entities, which were 
once considered as ‘sporadic’ are now suspected as being due to genetic abnormalities. 
This thesis used a combination of clinical, neuropathological, and genetic approaches 
to re-evaluate a group of disorders in which parkinsonism is seen in association with 
abnormal tau accumulation.    
Review of archival cases in the QSBB over a 20-year period identified 19 cases with 
CBD; five had a CBS presentation and eight had a RS phenotype, all of whom had 
vertical supranuclear gaze palsy and seven had falls within the first 2 years.  Of 21 
cases who had a clinical diagnosis of CBS; only five had CBD pathology, giving a 
positive predictive value of 24%, six others had PSP pathology, five had Alzheimer’s 
disease and the remaining five had other non-tau pathologies. CBD can present very 
commonly with a clinical picture closely resembling the classic RS, and the term 
CBD-RS for this subgroup was proposed. Cases with CBD-RS have delayed onset of 
vertical supranuclear gaze palsy and infrequent occurrence of predominant downgaze 
abnormalities, both of which can be helpful pointers to their underlying CBD 
pathology. Forty-two per cent of CBD cases presented clinically with a RS phenotype 
and 29% of CBS had underlying PSP pathology. In contrast, CBS is a rare clinical 
presentation of PSP, occurring in 4% of all pathologically diagnosed PSP cases. These 
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results indicate that CBD is a discrete clinicopathological entity but has a broader 
clinical spectrum than was originally proposed. 
PSP-CBS was reported to have more tau pathology in the mid-frontal and inferior-
parietal cortices than in PSP-RS. However, it was uncertain if differences exist in the 
distribution of tau pathology in other brain regions or if the overall tau load was 
increased in the brains of PSP-CBS. The clinical and pathological features of 10 PSP-
CBS and 10 PSP-RS cases were compared and quantitative assessment of tau load in 
15 cortical, basal ganglia and cerebellar regions were carried out. In addition to the 
similar age of onset and disease duration, the study demonstrated that the total tau load 
was the same between PSP-CBS and PSP-RS. However, there was a shift of tau 
burden towards the cortical regions and away from the basal ganglia, supporting the 
notion that PSP-CBS is a ‘cortical’ PSP variant. PSP-CBS also had less severe 
neuronal loss in the dorsolateral and ventrolateral subregions of the substantia nigra 
and more severe microglial response in the corticospinal tract than in PSP-RS, but 
neuronal loss in the subthalamic nucleus was equally severe in both groups.  
Repetitive finger tapping is commonly used to assess bradykinesia in Parkinson’s 
disease. The QSBB diagnostic criterion of Parkinson’s disease defines bradykinesia as 
‘slowness of initiation with progressive reduction in speed and amplitude of repetitive 
action’. However, it is not known if patients with PSP have criteria-defined 
bradykinesia. Objective assessment of repetitive finger tap performance and 
handwriting in 15 patients with Parkinson’s disease, nine patients with PSP and 16 
healthy age- and gender-matched controls were carried out. The motion of the hand 
and digits was recorded in three-dimension during 15-second repetitive index finger-
to-thumb tapping trials. The main finding was ‘hypokinesia without decrement’ in 
patients with PSP, which differed from the finger tap pattern in Parkinson’s disease. 
Average finger separation amplitude in PSP was less than half of that in controls and 
Parkinson’s disease. Change in tap amplitude over consecutive taps was computed by 
linear regression. The average amplitude slope in PSP was nearly zero, indicating a 
lack of decrement, which differed from the negative slope in patients with PD-OFF. 
‘Hypokinesia’ and ‘absence of decrement’ were identified in 87% of finger tap trials in 
the PSP group and only 12% in the PD-OFF group. In Parkinson’s disease, finger tap 
pattern was compatible with criteria-defined bradykinesia characterised by slowness 
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with progressive reduction in amplitude and speed and increased variability in speed 
throughout the tap trial. Analyses of handwriting showed that ‘micrographia’ was 
present in 75% of PSP and 15% of Parkinson’s disease patients. Most scripts 
performed by patients with PSP did not exhibit decrements in script size. The distinct 
finger tap and handwriting pattern in PSP can be useful clinically to differentiate the 
PSP-P subgroup from Parkinson’s disease.  
A review of all the archival cases in the QSBB, who had a final clinical diagnosis of 
Parkinson’s disease and extensive neuronal loss in the substantia nigra and 
predominant NFT pathology at post-mortem, was performed. Cases with a definite 
history of encephalitis or the presence of Lewy bodies at autopsy were excluded. 
Twelve of the 750 cases with unclassifiable NFT pathology were included in the study. 
Within this subgroup, seven cases with ‘parkinsonism with neurofibrillary 
degeneration’ (PND) were identified and they had presented with levodopa-responsive 
Parkinson’s syndrome, normal cognition and a prolonged disease duration. In addition 
to severe cell loss in the substantia nigra and Alzheimer-type NFT, a distinctive 
astrogliopathy, with diffuse granular tau-immunoreactivity of astrocytic processes in a 
characteristic distribution, was identified. TDP-43 and argyrophilic grain pathologies 
were common associated pathologies. The other five cases were distinguished from the 
PND group because two carried the MAPT p.A152T risk variant, one carried the 
G2019S LRRK2 mutation and two had pathological findings consistent with the PSP-P 
variant. The identification of the PND cases with NFT pathology resembling that 
found in PEP but with no history of encephalitis and a somewhat different clinical 
picture has led to a reconsideration of the links between acute EL and presumed PEP 
and the mechanisms involved. 
In conclusion, despite the widening spectrum of clinical phenotypes of CBD and PSP,   
meticulous clinical observation continues to be of great importance if progress is to be 
made in understanding the diversity of the clinical and pathological presentation of 
these brutal diseases. It is hoped that new studies to analyse the spread of tau 
pathology in the brain will shed light on the mechanisms underlying the selective 
vulnerability of neurons in CBD and PSP. Future studies of the temporal progression 
of pathology in CBD and PSP and the identification of early molecular events 
preceding the spread of hyperphosphorylated tau will lead to new insights into the 
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disease biology. A search for genetic loci in sporadic CBD and PSP using genome 
wide association studies and exome sequencing will help to delineate the biochemical 
pathways involved in disease pathogenesis, which will underpin future therapeutic 
approaches. Prospective studies on patients with early PSP and PSP-P subtype will 
determine if the specific finger tap pattern of ‘hypokinesia without decrement’ can be 
used as a reliable early diagnostic sign to distinguish PSP-P from Parkinson’s disease. 
Studies on viral RNA, immunological antibodies and more extensive genetic studies 
may shed light on the aetiology of PND and PEP. 
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